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ABSTRACT 
Psychotic disorders are characterised by episodes consisting of delusions, hallucinations, and 
disordered thinking and behaviour. Psychotic symptoms have a long history; as a result, there is 
now a large knowledge base about the causes of the disorders, and how damaging they can be to 
an individual, their family, and society. The current diathesis-stress model suggests that psychosis 
occurs as a result of both genetic and environmental factors. While researchers and clinicians 
alike have attempted to provide effective and long-lasting treatments for psychosis, the most 
successful medications still need further development. In particular, a significant proportion of 
psychotic episodes do not respond to treatment, and a large number of individuals do not adhere 
to their medication. As researchers have been able to identify the cognitive components 
contributing to psychotic symptoms, they have explored the efficacy of Cognitive-Behavioural 
Therapy (CBT) for individuals in different stages of the illness. This previous body of research 
has demonstrated the positive results of different trials of CBT, over a number of locations, and 
with different populations. However, CBT for psychosis continues to be a relatively new and 
unexplored treatment area, particularly in relation to defining and examining social functioning 
and quality of life outcomes, and exploring caregivers’ views on these areas. Therefore, the 
current study aimed to explore the results of a trial of CBT for individuals experiencing ongoing 
psychotic symptoms despite receiving routine care and treatments. Psychotic symptoms, quality 
of life, and social functioning were examined using clinician-rated tools, questionnaires 
completed by participants and their caregivers, as well as information given in post-treatment 
interviews with participants and caregivers. It was predicted that there would be a significant 
decrease in psychotic symptoms over the course of the treatment. Furthermore, it was predicted 
that there would be significant increases in social functioning and quality of life over the course 
of the treatment. The quantitative and qualitative data provided mixed results. Statistical analyses 
suggested that participants experienced significant decreases in their delusions from pre-
treatment to post-treatment. These decreases were most apparent in participants’ pre-occupation 
with their delusions, distress associated with the delusions, and their conviction in their 
delusional beliefs. Participants rated themselves higher in interpersonal communication skills 
than caregivers rated participants. Changes in pro-social activities approached significance from 
baseline to post-treatment, although an examination of the data suggested that the greatest change 
occurred from baseline to pre-treatment. There were no statistically significant results for other 
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social functioning areas or quality of life. Implementing clinical significance criteria, results 
indicated that few participants experienced decreases in psychotic symptoms, and increases in 
their quality of life and social functioning as rated by themselves and their caregivers. These 
criteria also indicated that there was clinically significant worsening in participants’ social 
functioning and quality of life. Graphical representations of participants’ data from each 
assessment period, and at each session, suggested that several participants experienced reductions 
in their psychotic symptoms over the course of the therapy. Finally, a grounded theory 
methodology was implemented to examine information provided by participants and their 
caregivers regarding their experiences of the therapy, and any changes noticed in symptoms and 
functioning over time. The categories and sub-categories that emerged from this data indicated 
that participants and their caregivers noticed changes in the participants’ thoughts, feelings, and 
behaviours over the course of the treatment program. Additionally, changes were noticed in 
participants’ attitudes and self-esteem, social relationships, hygiene and self-care, activities and 
independence. Participants and their caregivers attributed these changes to several factors, 
including medication adherence, CBT, the mental health service, reduced substance use, the 
opportunity to talk, occupying activities, and motivation and coping strategies. Altogether, these 
results provide further support for the efficacy of CBT for psychosis, and add to the growing 
body of literature indicating that a number of areas of functioning are affected by the treatment.   
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Chapter 1. Introduction and Overview 
 
 
People with a range of disorders including schizophrenia, schizoaffective, delusional, mood, and 
substance use disorders may experience the effects of psychotic symptoms (APA, 2000). These 
symptoms can include delusions, hallucinations, disordered thoughts and behaviours, and lead to 
a range of negative psychological and social outcomes. Psychotic symptoms have been described 
throughout history, and various treatment interventions have been developed over time. A 
significant amount of research has been performed examining causes; results of these studies 
suggesting an interplay of genetic and environmental factors can produce psychotic symptoms 
(Zubin & Spring, 1977). While past conceptions of psychotic disorders were of chronic, 
unremitting symptoms and degeneration (Kraepelin, 2002), more recent research suggests that 
there is a great deal of variation in onset, course, and outcomes of the disorders, and that a 
number of factors can affect how the illnesses progress (Grossman, Harrow, Rosen, & Faull, 
2006; Haro et al., 2006; Pillman & Marneros, 2005; Usall, Ochoa, Araya, & Marquez, 2003). 
While the incidence of schizophrenia is relatively low (Jablensky et al., 2000), the burden of this 
illness includes a number of areas including hospital, legal, accommodation, mortality, and 
indirect costs, amounting to an expenditure of several billion dollars (Knapp, 2000). The most 
effective treatments for psychosis are antipsychotic medications, although these do not work for 
every individual every time (Kane, 1996), and many individuals struggle to adhere to their 
medication (Janssen et al., 2006). Therefore, a number of psychotherapeutic options have been 
explored, with mixed effects. Therapy options include psychoanalytic therapy (Margison, 2005), 
cognitive remediation (Bellucci, Glaberman, & Haslam, 2002), social skills training (Bustillo, 
Lauriello, Horan, & Keith, 2001), psychoeducation, and family interventions (Pekkala & 
Merinder, 2002). The most well-researched and effective treatment has been cognitive-
behavioural therapy (CBT) (Gould, Mueser, Bolton, Mays, & Goff, 2001; Tarrier, Sharpe et al., 
1993). CBT has been modified to treat a range of psychotic disorders and co-occurring problems, 
in various phases of the illness, and with very positive outcomes (Cather et al., 2005; Haddock et 
al., 2003; Jenner, Nienhuis, Wiersma, & van de Willige, 2004). While CBT for psychosis has 
been explored for over two decades, there are many areas that require further expansion and 
exploration. In particular, little information has been provided in terms of the social functioning 
and quality of life outcomes of this research. The current study aimed to provide a course of 
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cognitive behavioural therapy for individuals experiencing ongoing positive psychotic symptoms 
despite adequate medication adherence and routine care. A number of treatment outcomes were 
explored, including psychotic symptoms, medication adherence, and co-morbid mood and 
anxiety symptoms. The main variables of interest were the individuals’ social functioning and 
quality of life outcomes, explored through questionnaires given to participants and their 
caregivers, and qualitative interviews. 
1.1.1 Psychotic symptoms and disorders  
A psychotic episode is identified by the presence of three key indicators: delusions, 
hallucinations, and disorganised thoughts and behaviour (APA, 2000). A delusion is a fixed 
erroneous belief, usually involving a misunderstanding of experiences and perceptions. They are 
further categorised by their underlying theme, including mind reading, paranoid, reference, 
persecution, bizarre, grandiose, religious, infestation, somatic, Capgras (believing a loved one has 
been replaced by a doppelgänger), cotard (belief that self is dead), self-accusation, infidelity, 
erotomania, systematized, and control (including thought broadcasting, withdrawal, or insertion) 
delusions (Chadwick, Birchwood, & Trower, 1996 p.15; Sadock & Sadock, 2003). 
Hallucinations are perceptual experiences occurring without external stimulation (Beck & Rector, 
2003). They can occur in any sensory modality, including auditory, visual, tactile, olfactory, and 
gustatory, although the most commonly reported hallucinations are auditory, perceived as a voice 
(APA, 2000). The disorganisation featured in psychosis includes disorganised thought, observed 
when there is a loosening of associations, tangentiality, or incoherence in speech. That is, the 
person’s responses may be somewhat or completely unrelated to the topic at hand, he or she 
associates words phonetically, or, at worst, strings words together with no related meaning or 
concept. Disorganised behaviour includes a range of oddities, including agitation, inappropriate 
behaviour, or inappropriate apparel. While the above are the key features of an episode, a number 
of other symptoms can occur for people experiencing psychosis. The aforementioned symptoms 
have been classified as positive symptoms; the negative symptoms of psychotic disorders involve 
a restriction in a range of areas including emotions, thought, speech, and behaviour. In order for 
these symptoms to reach diagnostic significance, a considerable disruption in social or 
occupational functioning must occur (APA, 2000). An understanding of these symptoms then 
leads on to a clarification of disorder and diagnosis. 
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As many of these symptoms are seen in a range of disorders, including mood disorders, 
post-traumatic stress disorder, in grief reactions, and in survivors of abuse (Beck & Rector, 2003; 
Zubin & Spring, 1977), Australian health professionals currently employ the Diagnostic and 
Statistical Manual of Mental Disorders – Fourth Edition (DSM-IV-TR, APA, 2000) to classify 
and differentiate between psychotic and other disorders according to symptom presentation, 
length of illness, and causes. Included in the manual are nine psychotic disorder diagnoses: 
schizophrenia, schizophreniform, schizoaffective, delusional disorder, brief psychotic disorder, 
shared psychotic disorder, psychotic disorder due to a general medical condition, substance-
induced psychotic disorder, and psychotic disorder not otherwise specified, as well as subtypes 
dependent on the symptom presentation (paranoid, disorganised, catatonic, undifferentiated, 
residual), and episode (inter-episode residual symptoms, continuous, in partial or full remission, 
other or unspecified pattern) and symptom specifiers (with prominent negative symptoms). Of the 
psychotic disorders included in the manual, schizophrenia is the most prevalent and researched; 
investigators have spent over 100 years critically examining all aspects of the illness (Jablensky, 
2000).  
1.1.2 History and causes of the disorder 
Psychosis and schizophrenia have been observed as many as 60,000 years ago, based on 
descriptions of individual presentations (Polimeni & Reiss, 2005; Stone, 2006). It was not until 
the late 1800s that psychiatrists first began to thoroughly document and analyse psychotic 
symptoms and associated illnesses. Specifically, Kraepelin (2002) labelled the symptoms of 
psychosis ‘dementia praecox’, or ‘early dementia’. However it was Bleuler’s use of the term 
‘schizophrenia’ for the same illness presentations which has continued to be used by researchers 
and clinicians alike (Ban, 2004; Szasz, 1976). Kraepelin and Bleuler used their own criteria to 
discriminate between various presentations, developing the first differential diagnoses. These 
early researchers held a fairly strong biological model of the disease, believing that the origin of 
the illness could be attributed to hereditary causes. Thus, over the years, several groups have 
analysed the blood of those affected (Noll, 2006), and more recently, genetic anlyses. As a result 
of these investigations, it has been suggested that there is some genetic component that 
contributes to the onset of schizophrenia (Ban, 2004; Rapoport, Addington, Frangou, & Psych, 
2005). 
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Certainly, it has been found that schizophrenia aggregates in families (Bromet & Fennig, 
1999), and that mothers with psychosis have a higher frequency of having children with mental 
health issues (Schubert & McNeil, 2003). However, results of twin studies demonstrate 
concordance rates for monozygotic (MZ) twins of approximately 53%, that is, when one twin has 
schizophrenia, the other twin has a 53% chance of developing the disorder as well (Shih, 
Belmonte, & Zandi, 2004). A recent meta-analysis of twin studies has suggested that heritability 
was as high as 80%, although the authors pointed out that shared environmental etiological 
influences (including obstetric complications) were also contributing to these findings (Sullivan, 
Kendler, & Neale, 2003). Furthermore, adoption studies have shown that individuals with a 
biological parent with schizophrenia and non-schizophrenic adoptive parents show variable 
outcome, and that those with a higher genetic risk are more sensitive to stressful family 
environments (Tienari et al., 2004).  
As a result of this compelling evidence, it became clear that genetic inheritance could not 
fully account for the development of schizophrenia (Sullivan et al., 2003), and, over time, other 
theories were pursued. During the 1960s there was a great deal of backlash against psychiatry and 
the medical model, and a number of prominent psychiatrists including R.D. Laing proposed that 
schizophrenia could be attributed to social and environmental circumstances, including 
“schizophrenogenic mothers” and the double-bind hypothesis of disordered family 
communications (Laing, 1960; Neill, 1990). Szasz (1976) took this idea one step further by 
arguing that schizophrenia did not exist at all, but rather, was created in order for psychiatrists to 
preserve their power and position. His stance continues to be maintained by a number of 
individuals (Bentall, 1990b; Read, Mosher, & Bentall, 2004) who state that the symptoms of 
schizophrenia are not due to biological causes but are reactions to life events and stress. 
Other biological theories proposed to account for the development of schizophrenia have 
included obstetric complications (Kotlicka-Antczak, Gmitrowicz, Sobòw, & Rabe-Jablonska, 
2001), season of birth, infections, exposure to oestrogen, cannabis use, and social adversity 
(Bromet & Fennig, 1999; Di Forti, Lappin, & Murray, 2007; Jablensky, 2000; Kotlicka-Antczak 
et al., 2001; Leung & Chue, 2000; Rapoport et al., 2005). Additionally, early developmental 
delays, premorbid psychopathology, substance use, urban living, and genetics have all been 
suggested as risk factors for the disorder (Bromet & Fennig, 1999; Rapoport et al., 2005; Weiser, 
Davidson, & Noy, 2005).While there is some support for a number of these factors, several of 
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them, such as birth complications, are linked to a propensity to develop a number of other health 
issues (Rapoport et al., 2005), and some, such as seasonality of birth, may only provide a small 
contribution to the occurrence of schizophrenia (Bromet & Fennig, 1999). 
Neurological models that account for illness development have also been proposed. A 
number of studies have provided data indicating that the brains of people who develop 
schizophrenia show significant changes over time (Rapoport et al., 2005). In particular, there 
appears to be increased volume in the lateral ventricles, and decreased grey and white matter 
volumes, chiefly in the hippocampus, thalamus, and frontal lobes (Lieberman, 1999). This 
evidence supports a biological model of schizophrenia, indicating that it is a disease process that 
develops across the lifespan. However, as biological and genetic models were unable to provide a 
full understanding of the development of psychosis, researchers began to explore how 
environmental events could contribute to the development and onset of the disorder.  This led to 
an amended working model of the illness, labelled the diathesis-stress model.   
1.1.3 Diathesis-stress model 
The diathesis-stress model of schizophrenia proposes that the likelihood of developing 
schizophrenia is a result of an interaction between a person’s biology and their environment 
(Nuechterlein & Dawson, 1984). That is, a number of individuals possess some underlying 
genetic or neurological problems due to obstetric complications, which can then predispose them 
to developing psychotic symptoms (Di Forti et al., 2007; Van Os, Jones, Sham, Bebbington, & 
Murray, 1998). This genetic predisposition is of more significance for negative symptoms than 
positive (Rector, Beck, & Stolar, 2005). The likelihood of a particular individual developing 
psychotic symptoms is then based on the number and type of stressful life events he or she is 
exposed to. Additionally, each individual will have his or her own threshold for stressful events; 
as this is exceeded, the person is likely to develop a psychotic episode (Zubin & Spring, 1977).   
Environmental stressors were originally proposed to be dramatic life events, such as 
bereavement, promotion, marriage, or divorce (Zubin & Spring, 1977). More long-standing 
specific stressors, including social adversity, high expressed emotion in families, and substance 
use have also been suggested (Miller et al., 2001; Norman & Malla, 1993; Nuechterlein & 
Dawson, 1984). In terms of a person’s threshold for stress, Nuechterlein and Dawson (1984) have 
proposed that information processing deficits, reduced autonomic reactivity, and poor social 
skills noted in individuals with schizophrenia can mean that they struggle to cope with difficult 
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life events and strong emotional expression from others. This has been restated recently, 
suggesting that the individual’s appraisal of both the meaning and the potential impact of the 
event must be taken into account (Phillips, Francey, Edwards, & McMurray, 2007). Therefore, 
people with schizophrenia have fewer resources to negotiate stressors, which means that they 
may experience higher levels of stress in comparison to others. Zubin and Spring (1977) have 
suggested that in response to stressors, a person with a tendency to develop psychosis will 
implement deviant coping patterns, or their coping skills will break down in response to 
catastrophic situations, transitioning into a psychotic episode. When the stress is eliminated, the 
episode should then finish. As stressful events occur, these can be linked to symptom expression 
(Norman & Malla, 1993). This theory therefore accounts for individuals with a strong risk of 
developing a psychotic disorder who remain well by implementing effective coping strategies 
(Zubin & Spring, 1977), as well as the greater number of stressful life events reported by 
individuals with psychotic disorders in comparison to normal controls (Norman & Malla, 1993).  
While a number of difficulties have been encountered when attempting to collect 
evidence to support this theory, including defining and measuring stressors (Jones & Fernyhough, 
2006; Norman & Malla, 1993), and relating stressors to onset of psychotic symptoms (Phillips et 
al., 2007), results appear promising. In particular, the model has led to several groups 
investigating people at risk for developing psychosis and the stressors they experience, such as 
substance use, finding significant relationships between the two (Miller et al., 2001). When 
compared to controls, individuals with recent onset psychotic symptoms reported similar 
numbers of stressful life events, but reduced ability to cope with these (Horan et al., 2005). 
Additionally, when compared to controls and at-risk relatives, individuals in remission reported 
variations in psychotic symptoms associated with daily stressors (Myin-Germeys, Delespaul, & 
Van Os, 2005). The vulnerability-stress model has proved so popular amongst all fields that 
recent additions incorporate biochemical explanations of symptoms.  
Biochemical models integrated into the diathesis-stress model of psychosis are used to 
explain symptom presentations. While previous theorists suggested that psychotic symptoms 
occurred as a result of increased levels of the neurotransmitter dopamine in the brain (Davis, 
Kahn, Ko, & Davidson, 1991), currently, evidence supports the notion of a complex relationship 
between psychosis and neurotransmitters. It has been suggested that concurrent high and low 
dopamine levels in different areas of the brain can account for negative and positive symptoms 
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(Davis et al., 1991). The latest innovation in this biochemical diathesis-stress model includes the 
hypothalamus as well as dopamine. The model suggests that dysregulation of the stress response 
(Walker & Diforio, 1997) and dopamine dysregulation are the diathesis to developing psychotic 
symptoms (Di Forti et al., 2007; Jones & Fernyhough, 2006). Walker and Diforio (1997) have 
presented a summary of evidence indicating that hippocampal abnormalities and greater levels of 
cortisol can mediate the link between biology and psychosocial stressors in individuals with 
schizophrenia. It is posited that as stressors occur they cause release of cortisol in the brain, 
which exacerbates the abnormality of dopamine transmission, resulting in, or exacerbating 
psychotic symptoms (Jones & Fernyhough, 2006; Walker & Diforio, 1997). This model, and the 
supporting evidence for it are explored in-depth elsewhere in the literature (Corcoran et al., 2003; 
Davis et al., 1991). The biochemical model is now being used to explain some of the symptoms 
of psychosis. 
In the biochemical model of psychosis it has been proposed that because dopamine 
mediates the salience of environmental stimuli and internal events, increases in this 
neurotransmitter provide the suggestion that irrelevant stimuli or events are important (van der 
Gaag, 2006). Thus seemingly innocuous stimuli take on meaning and importance; providing an 
account for why irrelevant or ambiguous stimuli are often used as evidence to support a delusion. 
At present, there is also a link between biological evidence for biochemical processes, and the 
age of onset of schizophrenia (Thompson, Pogue-Geile, & Grace, 2004). 
1.1.4 Onset, course, and outcome 
The main period of risk for developing schizophrenia is from 15 – 30 years of age 
(Thompson et al., 2004). The initial illness period is often characterised by negative or non-
specific symptoms including restlessness, depression, anxiety, difficulties in thinking and 
concentration (an der Heiden & Häfner, 2000) as well as significant social disability (Häfner, 
2000). This period is labelled the prodrome (Perkins, Miller-Andersen, & Lieberman, 2006) and 
can last for approximately 5 years (an der Heiden & Häfner, 2000; Häfner, 2000). The individual 
may then experience a period of deterioration, including the presence of psychotic or negative 
symptoms, cognitive impairment, and a disruption in social and occupational functioning 
(Lieberman, 1999). These symptoms can then develop into an episode, which can vary in terms 
of length, severity, and discernible symptoms. Episodes can be brief or continuous, in partial or 
full remission, and inter-episode residual symptoms can be experienced (APA, 2000). The current 
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episode model is very different to the one originally proposed when the disorder was first 
catalogued. 
Kraepelin described dementia praecox as a chronic and continuous disease with a 
downhill course (2002). Manfred Bleuler then modified this view, suggesting more hopeful and 
positive outcomes; noting that over several years many of his patients showed fluctuations in 
functioning, with more improvements than deteriorations (1970; 1974). Of his sample of 208 
patients, only 10% lived permanently in hospital wards, and even amongst those who had spent 
time in hospital, they were often discharged and later readmitted (Bleuler, 1974). Several 
explanations have been generated to explain these differences in outcome, including changes in 
definitions and diagnostic criteria (Bentall, 1990b), changes in medication and hospitalisation, 
changes in therapeutic style (Bleuler, 1974), and even changes in outlook (Bellack, 2006). There 
is evidence to support each of these proposals, and it may be more likely that a combination of 
them has led to the present model of the long-term course of schizophrenia.  
Current perspectives on schizophrenia describe it as a variable and episodic illness with 
heterogeneous outcomes (Harrow, Grossman, Jobe, & Herbener, 2005). Included are individuals 
who may only experience one or a small number of episodes, those who experience multiple, 
frequent episodes over the course of their lifespan, and a large percentage of individuals 
(approximately 60%, an der Heiden & Häfner, 2000; Möller, 2004) fitting Kraepelin’s original 
description, showing a continuous and chronic course of illness (Harrow et al., 2005; Perkins et 
al., 2006). Similar outcome results have been found in Australia, where 70.8% of cases of 
psychotic disorder were chronic or recurrent with incomplete remissions (Jablensky et al., 2000). 
Yet more positive outcomes have been found in individuals with other psychotic disorders, 
suggesting that over 50% demonstrated favourable outcomes (Harrison et al., 2001). While many 
researchers have focused on the period during which individuals are unwell, others have 
concentrated on what recovery from psychosis means. 
The period during which a person experiences recovery and remission has been widely 
researched, and there are now broader views about what these terms may mean for different 
people, understanding that there is a significant difference between clinician and consumer views 
on this issue (Bellack, 2006). For example, when examining outcomes, researchers have 
examined both clinical outcomes: hospital admissions, time to relapse, symptomatology, 
medication adherence, and social outcomes: educational, occupational, and social functioning 
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outcomes, independent living, (Bellack, 2006; Harrow et al., 2005), marital status, and personal 
life goals (Häfner & an der Heiden, 1999). Due to these large and varied criteria, it is not hard to 
see why schizophrenia appears to show a stable course (Häfner & an der Heiden, 1999), with 
poorer outcomes in comparison to control and other psychiatric illness groups (Harrow et al., 
2005; Möller, 2004; Pillman & Marneros, 2005). However, even when compared to other 
psychiatric illness groups, approximately 40% of participants with a diagnosis of schizophrenia 
who receive treatment experience a period of recovery for one or more years (Harrow et al., 
2005). Moreover, a 3-year study conducted in over 10 European countries found that 64.6% of 
outpatients with schizophrenia achieved remission at some point (Haro et al., 2006), echoing 
research in other parts of the world (Rabinowitz, Levine, Haim, & Häfner, 2007). Recent research 
indicates that a subgroup of individuals who receive initial treatment can experience a very quick 
recovery, and can maintain wellness without antipsychotic medication (Harrow & Jobe, 2007). 
This data supports a very positive outlook of recovery (Bellack, 2006). However, it should be 
noted that the majority of these results are representative of individuals receiving treatment for 
their symptoms, and that untreated illness results more frequently in poorer outcomes 
(Addington, Mastrigt, & Addington, 2004; Clarke et al., 2006). It is thus important to understand 
what factors could contribute to, or increase better outcomes. 
Researchers examining long-term outcome data have found that a number of factors 
including female sex (Grossman et al., 2006; Usall et al., 2003), possessing good social 
functioning (Haro et al., 2006), good premorbid functioning (Haim, Rabinowitz, & Bromet, 
2006; Rabinowitz, Harvey, Eerdekens, & Davidson, 2006), being married, with acute or transient 
symptoms (Pillman & Marneros, 2005), and shorter duration of untreated psychosis (Addington 
et al., 2004; Möller, 2004) are all associated with more positive outcomes. Conversely, factors 
linked to poor outcomes include blunted affect, history of drug use, family involvement in 
treatment, and earlier age of onset (Harrison et al., 2001). Interestingly, a large study involving 
over 19 countries has indicated that individuals in developing countries tend to fare better than 
those in developed countries, although the factors involved in these different outcomes are yet to 
be determined (Harrison et al., 2001; Hopper & Wanderling, 2000). The research reviewed above 
has focused on the positive outcomes and associated factors. However it is also important to 
examine the research depicting the individuals with schizophrenia who demonstrate a poor 
outcome, and to understand where this outcome model may originate.  
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Some argue that poor outcome view of schizophrenia results in part to the official 
definition used, and is due to the fact that health professionals in public settings are more likely to 
see the worst cases of the illness, as more competent people are able to avoid hospitalisation, or at 
least, time in public hospitals (Kruger, 2000; Zubin & Spring, 1977). A large contributor to the 
poor outcome data is the high rates of suicide amongst individuals with schizophrenia (Brown, 
Inskip, & Barraclough, 2000). In one review, suicide accounted for 28% of excess mortality 
(Brown, 1997). Additionally, lifetime suicide rates for people with psychotic disorders appear to 
be higher now than they were approximately 100 years ago (Healy et al., 2006), suggesting that  
they are increasing despite more adequate treatment methods. A number of researchers are 
currently investigating risk factors associated with suicidal behaviour, suggesting that individuals 
with good premorbid functioning (high IQ, better adolescent social functioning, later age of 
onset) were at higher risk, with high risk periods occurring shortly following hospital discharge 
(Fenton, 2000). To better understand the outcome statistics for this population, it is necessary to 
have accurate data reflecting how many individuals at a time develop the disorder.  
1.1.5 Prevalence and incidence rates and burden of disease 
Due to the consequences of the disorder, researchers have been particularly interested in 
acquiring an accurate estimate of the number of people with a diagnosis of schizophrenia across 
the globe. Prevalence estimates that calculate the number of people affected at a particular time 
suggest that 1.4 – 4.6 per 1,000 population are at risk (Jablensky, 2000). In contrast, incidence 
rates measure the number of new cases over a specific time. Data from 33 countries suggests that 
the median incidence rate of schizophrenia is 15.2 per 100,000 (McGrath et al., 2004). 
Importantly, there are unequal representations of the disorder across a number of factors. This 
includes sex, with incidence rates suggesting that there is a higher proportion of males with the 
disorder; individuals in urban areas report higher rates when compared with urban-rural areas, 
and data suggests migrants report higher rates of schizophrenia compared to native-born 
individuals (King et al., 2005; McGrath et al., 2004). More specifically, in an Australian survey 
of psychotic disorders, a treated point prevalence rate of 4.7 per 1,000 was calculated, with a rate 
of 5.9 per 1,000 for Victoria (Jablensky et al., 2000).  
In terms of sex differences, it has been consistently shown that males tend to develop 
schizophrenia spectrum disorders at an earlier age (by 3 – 5 years) than women irrespective of 
culture, definition of symptoms, or diagnostic definition (Bromet & Fennig, 1999; Leung & 
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Chue, 2000). There have also been a number of differences noted between the sexes including 
symptom expression, premorbid functioning, treatment response, and course of illness, 
suggesting that women who develop the disorder tend to fare better (Leung & Chue, 2000; Usall 
et al., 2003). Additionally, longitudinal data supports significant sex differences on outcome 
measures for individuals with schizophrenia spectrum disorders, suggesting that overall, women 
experience better outcomes and more recovery periods (Grossman et al., 2006). Several 
hypotheses have been proposed as to why these differences exist, including the neuro-protective 
effects of oestrogen (Keltner & Folks, 2001), and later onset age in women, allowing them to 
develop more social and vocational skills (Leung & Chue, 2000; Perkins et al., 2006). 
Knowledge about the prevalence rates of the disorder, and the fact that schizophrenia can 
be chronic, requiring long hospital admissions (AIHW, 2006) led researchers to explore the costs 
associated with this diagnosis. This is often described as the burden of disease or cost of illness 
(COI: Knapp, Mangalore, & Simon, 2004). When calculating these amounts investigators include 
not only mental health care costs (such as general practitioners, ambulance services, medication), 
but also legal, accommodation, administration costs, criminal justice system costs, drug costs, 
mortality costs, and the indirect costs, including foregone earnings of patients and their caregivers 
(Knapp et al., 2004).  
In Australia, the annual estimated cost of psychosis is $1.45 billion from the government, 
and $2.25 billion from the societal perspective (Carr, Neil, Halpin, Holmes, & Lewin, 2003). 
These results are relatively similar to those found in 2004 in a Canadian study of costs of 
schizophrenia (Goeree et al., 2005), and to reviews of costs worldwide (Knapp et al., 2004). On 
an individual basis, it has been suggested that the mean lifetime costs of schizophrenia per patient 
is more than $1 million, with inpatient care contributing the greatest percentage to direct costs 
(Langley-Hawthorne, 1997). Due to these high costs, researchers and governments have vested 
interests in developing effective treatments for psychosis (Rössler, Salize, van Os, & Riecher-
Rössler, 2005). 
 
1.2 Treatments for psychosis 
1.2.1 History of treatments 
Since psychotic disorders were first labelled and categorised, a number of treatments for 
psychotic symptoms have been proposed. Initially, these treatments consisted of prolonged baths 
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or moist warm packs for excitement (Kraepelin, 2002), hospitalisation and psychosurgery 
(Keltner & Folks, 2001), and the removal of organs, including colon, cervix, testes, ovaries, and 
appendix, as a cure (Noll, 2006). Then, in the 1950s chlorpromazine was administered to a 
number of individuals; results suggested an improvement in positive psychotic symptoms and no 
change in negative symptoms (Ayd, 1991). At that time, researchers were unaware of the 
mechanism of the drug action, and it was not until approximately 10 years later that an 
association between dopamine receptor blockade and the anti-psychotic action of the drugs was 
made (Day & Bentall, 1996). Chlorpromazine, along with a number of other first-generation 
antipsychotic drugs such as haloperidol, fluphenazine, perphenazine, and thioridazine, was used 
in the treatment of psychotic symptoms for several decades, effectively proving its use in 
reducing positive symptoms (Ayd, 1991).  However, it was discovered that these drugs also 
produced devastating and sometimes permanent side effects including extra-pyramidal side 
effects (EPS): akathisia (restlessness), akinesia (absence or impairment in movement), dystonias 
(involuntary contractions of muscle groups), Parkinsonism (tremors, rigidity, bradykinesia), and 
tardive dyskinesia (abnormal involuntary movements) (Jibson & Tandon, 1998; Keltner & Folks, 
2001), anti-cholinergic, cardiovascular, hormonal, haematological, hepatic, metabolic effects, and 
allergic reactions (Day & Bentall, 1996). The presence of EPS, the link between dopamine and 
psychotic symptoms, and the need to treat negative symptoms encouraged researchers to 
investigate and improve upon psychotropic medication. Researchers then developed atypical or 
second-generation antipsychotics; the first of these was clozapine.  
 
1.3 Biological treatment approaches 
Consistent with the biological model of psychosis, a number of medical treatments have 
been developed to reduce and manage symptoms. Atypical antipsychotics (including clozapine, 
quetiapine, olanzapine, aripiprazole, and amisulpride) are currently the most effective and 
popular treatments for psychotic symptoms, with research to date indicating fairly comparable 
results across the different compounds. However, measurement of the efficacy of these 
medications is complicated by both treatment-resistant symptoms, and treatment non-adherence. 
In some cases Electro-Convulsive Therapy (ECT) has been successfully trialled and 
implemented. The following section will review current biologically-based treatment approaches 
for psychosis. 
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1.3.1 Antipsychotic medication 
After clozapine was withdrawn in the early 1970s as a result of a number of deaths 
associated with its use (attributed to agranulocytosis), it was then re-introduced in 1990 (Iqbal et 
al., 2003). Since then it has proven to be more effective than chlorpromazine (Kane, Honigfeld, 
Singer, & Meltzer, 1988), is effective in reducing suicidality (Meltzer et al., 2003), and has not 
been associated with extra-pyramidal side-effects or tardive dyskinesia (Iqbal et al., 2003). A 
number of other atypical antipsychotic medications have also been introduced, including 
risperidone, olanzapine, quetiapine, aripiprazole, and amisulpride; their effect profiles are 
reviewed elsewhere in the literature (Tollefson et al., 1997). These medications are currently used 
for individuals with schizophrenia during first-episode, acute, stabilisation, and maintenance 
phases of the illness; they have reduced EPS, and are effective for positive symptoms (Jibson & 
Tandon, 1998). 
In terms of differentiating between atypical antipsychotics, authors have suggested that 
there is little variation in their efficacy, safety, and tolerability (Mullen, Jibson, & Sweitzer, 2001; 
Srisurapanont, Maneeton, & Maneeton, 2004; Tandon & Jibson, 2005). Several reviews of these 
drugs have provided good support for their superiority when compared with placebos and 
conventional antipsychotics (Duggan et al., 2005; Harvey, Siu, & Romano, 2004; Mullen et al., 
2001; Tandon & Jibson, 2005; Turner & Stewart, 2006). In particular, a recent review of 
olanzapine for schizophrenia suggested that it is more effective than placebo, but for severe 
presentations of psychotic disorders there is little differentiation between typical and atypical 
antipsychotics (Duggan et al., 2005). The authors found it difficult to make definitive and 
accurate conclusions about the effects of these medications, as there were large attrition rates, and 
limited data regarding tolerability and social functioning outcomes. A multi-national study 
conducted by Tollefson and colleagues (1997) included 1,996 participants with diagnoses of 
schizophrenia, schizophreniform, and schizoaffective disorders, comparing olanzapine with 
haloperidol over a 14-month period. Researchers concluded that olanzapine was comparatively 
more effective for reduction of both negative and positive symptoms, resulting in fewer 
extrapyramidal side effects, and a lower attrition rate. While studies demonstrate positive results 
for the use of atypical antipsychotic medication in reducing psychotic symptoms, over several 
phases of the illness, there are a number of individuals who, for a number of reasons, are not 
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treated adequately, or are not able to be treated adequately with antipsychotic medication (Kane, 
1996). 
1.3.2 Treatment resistance  
A significant proportion of psychotic episodes (between 10% – 60%) is not responsive to 
neuroleptic medication (Conley & Buchanan, 1997; Lindenmayer, 2000). This phenomenon has 
been labelled treatment-resistant, or medication-refractory symptoms, and includes persistent 
positive, negative, depressive-anxiety, suicidal, and cognitive symptoms as well as social and 
occupational functioning problems (Lindenmayer, 2000). For clinical trials, treatment resistance 
has been defined by four criteria: persistent positive symptoms, the presence of moderately 
severe illness, a five-year period of poor social and occupational functioning, and at least three 
adequate antipsychotic trials (Conley & Buchanan, 1997; Kane et al., 1988). This definition has 
been altered to include individuals who do not show a satisfactory clinical improvement in 
symptoms despite two sufficient trials of antipsychotic medications (Lehman, Kreyenbuhl et al., 
2004; NICE, 2002). Treatment resistant symptoms occur for a number of reasons, including non-
compliance, epilepsy (Pantelis & Barnes, 1996), comorbid substance use (Kane, 1996), medical 
comorbidities, and psychosocial factors, including wanting to remain unwell (Lindenmayer, 
2000). Repeated episodes are also associated with a reduced response to treatment, and a longer 
period of treatment is generally required (Peuskens, 1996).  
When treatment resistance occurs, clozapine is generally the recommended treatment (Conley & 
Buchanan, 1997; Kane et al., 1988; Lewis et al., 2006; Lindenmayer, 2000), although risperidone 
has, at times, demonstrated equally effective treatment results (Bondolfi, Baumann, & Dufour, 
1996). Despite clozapine’s reputation as a gold standard for treatment resistant symptoms, 
approximately 30% of those receiving this treatment have an inadequate response (Buckley et al., 
2001). When this occurs, professionals have often attempted to augment clozapine with 
adjunctive medications, including atypical antipsychotics, thymoleptics, and electro-convulsive 
therapy to some effect (Conley & Buchanan, 1997; Pantelis & Barnes, 1996).    
1.3.3 Non-adherence 
In addition to treatment-resistance, it has been estimated that approximately one-third to 
one-half of individuals receiving antipsychotic medication are fully compliant with treatment 
(Janssen et al., 2006; Oehl, Hummer, & Fleischhacker, 2000), although non -adherence with 
medication is a difficult aspect to measure and assess accurately (Velligan et al., 2006). Research 
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suggests non-adherence results from a number of factors, including side effects, forgetting, lack 
of motivation, lack of insight, inadequate psychoeducation, perceived decreased quality of life 
(Möller, 2004), poor psychosocial supports, and demoralisation (Kane, 1996), poverty, and lack 
of transport (Velligan et al., 2006). Oehl and colleagues (2000) have attributed non-adherence to 
four factors: patient, environment, physician, and treatment-related, stressing the importance of a 
positive therapeutic relationship. Chue’s (2006) recent review of the relationship between patient 
satisfaction and compliance suggested that factors such as side effects and lack of involvement in 
treatment planning and decisions can significantly interfere with medication adherence. A survey 
of patients receiving depot (injection) medication indicated that those with poor compliance 
reported more negative symptoms, and that they had stopped medication in the past believing that 
there were no positive effects of taking medication (Smith, Hughes, & Budd, 1999).  Velligan 
and colleagues (2003) discuss the difficulties their participants had in remembering a specific 
medication regimen, suggesting that this is a larger and much over-looked area.  
In an attempt to address this issue of non-adherence, professionals have developed a 
number of strategies to increase the likelihood of consistency, including providing depot 
(injection) medication (Kane, 1996; Lehman, Kreyenbuhl et al., 2004; NICE, 2002), changing 
from a first-generation to second-generation antipsychotic, utilising a Community Treatment 
Order (CTO) to ensure treatment (McIvor, 1998), and providing psychoeducation (Chue, 2006).  
1.3.4 Electroconvulsive therapy 
  For individuals with medication-intolerant or refractory psychotic symptoms, ECT has 
been recommended (Lehman, Lieberman et al., 2004; McGorry, 2005). A review of ECT for 
schizophrenia indicates that it may lead to short-term benefits for individuals with treatment-
resistant symptomatology (Tharyan & Adams, 2005). A review of ECT as a concurrent treatment 
with clozapine for residual symptoms (for schizophrenia and schizoaffective disorders) also 
provided tentative support for the use of this option (Havaki-Kontaxaki, Ferenitinos, Kontaxakis, 
Paplos, & Soldatos, 2006), although there was limited data available, with the  review consisting 
of case studies and one open trial. These results show promising implications for ECT for these 
symptoms, although more research is required before a conclusive decision can be made as to 
whether it is the most beneficial option. 
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1.4 Psychological treatment approaches 
Psychological therapies for psychosis have been developed to supplement antipsychotic 
medication. The following section will review the psychological therapies developed for 
individuals with psychotic disorders designed to address psychotic symptoms (Garety, Fowler, & 
Kuipers, 2000), functioning (Penn & Mueser, 1996), cognitive deficits (Bellucci et al., 2002), 
education and family interventions (Pharoah, Rathbone, Maji, & Streiner, 2003), comorbid 
substance use (Barrowclough et al., 2001), and medication compliance (Kemp, Hayward, 
Applethwaite, Everitt, & David, 1996). A more recent innovation of CBT, Acceptance and 
Commitment Therapy (Gaudiano & Herbert, 2006), is producing promising results and may need 
to be included in future reviews when additional research has been completed. While some 
promising results have been found for psychoeducation, cognitive remediation, and social skills 
programs, the most convincing and extensive work to date has investigated the efficacy of 
Cognitive Behavioural Therapy for psychosis. As a result of the research to date, governing 
bodies recommend CBT, family interventions, social skills training, and psychoeducation 
(Lehman, Kreyenbuhl et al., 2004; McGorry, 2005; NICE, 2002) for the treatment of 
schizophrenia.  
1.4.1 Psychoanalytic therapy 
Briefly, psychoanalytic therapy involves investigating past events and experiences to 
determine their role in current functioning. A limited overview of Cognitive Analytic Therapy 
(CAT) and Psychodynamic Interpersonal Therapy (PIT) describes how these therapies can be 
implemented with individuals with psychotic symptoms (Margison, 2005).  A recent review has 
indicated that there is limited data and information regarding psychoanalytic or psychodynamic 
therapy for psychotic disorders; existing studies suggest that this intervention provides little 
therapeutic benefit for this population (Malmberg & Fenton, 2001). Mueser and Berenbaum 
(1990) proposed that psychodynamic therapy can sometimes result in deleterious effects as 
opposed to beneficial ones. The authors strongly recommend the discontinuation of this therapy 
for this population, particularly as its provision may result in depriving consumers of more 
effective treatments, including social skills training and family therapy. An updated variation of 
the psychoanalytic approach, personal therapy, which combined elements of psychoeducation 
and social skills training, has since been explored to specifically prevent relapse (Hogarty et al., 
1997). The results of a three-year trial of this intervention produced positive outcomes in the 
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form of preventing relapse in those living with family; however, it resulted in an increased rate of 
relapse for those living independently of family. At present, there is no satisfactory evidence to 
advocate for the use of psychodynamic or psychoanalytic therapy for individuals with psychotic 
symptoms at any stage of the illness. 
1.4.2 Psychoeducation and family education 
Providing individuals with information regarding their illness and treatment is an 
important first step for any health issue and is strongly recommended (McGorry, 2005; NICE, 
2002). In terms of psychotic disorders, it has been suggested that this information can enable 
people to cope with their diagnosis, and has been shown to have a positive effect on individuals’ 
well-being (Pekkala & Merinder, 2002). Included in the research investigating psychoeducation 
are interventions involving family members. These programs provide members with information 
regarding the illness, and teach them appropriate skills to manage the family environment and 
expressed emotion levels (Pharoah et al., 2003). A current meta-analysis suggests that further 
work is required to examine the process measures influencing the outcomes for this group 
(Pilling, Bebbington, Kuipers, Garety, Geddes, Orbach et al., 2002). Reviewers and meta-
analyses suggest that this therapy may reduce the risk of relapse and increase compliance with 
medication (Penn & Mueser, 1996; Pharoah et al., 2003; Pilling, Bebbington, Kuipers, Garety, 
Geddes, Orbach et al., 2002). Dyck and associates (2000) have demonstrated a reduction in 
negative symptomatology using multiple-family group psychoeducation. While results appear 
promising for family psychoeducation, studies attempting to incorporate it into routine practice in 
mental health settings have encountered difficulties including lack of time and resources 
(Kavanagh et al., 1993). Furthermore, this approach may not be appropriate or possible for many 
individuals without family support. It may be that for those individuals not suitable for family 
therapy who are resistant to taking medication, the CBT-based compliance therapy model could 
be more effective (Kemp et al., 1996). This is a new therapy that shows promising, long-lasting 
results. An appraisal of this field indicates that psychoeducation should be used as an adjunct to 
medication for psychotic symptoms, and that, where possible, families should be involved in 
treatment. 
1.4.3 Cognitive remediation  
A number of researchers have postulated that programs designed to enhance or restore 
cognitive ability would have positive benefits for individuals with psychotic disorders who report 
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cognitive impairment, negative symptoms, and low self-esteem (Bellucci et al., 2002). This type 
of therapy, labelled cognitive enhancement therapy (Hogarty et al., 2006) or cognitive 
remediation (Pilling, Bebbington, Kuipers, Garety, Geddes, Martindale et al., 2002) is often 
delivered through computer software programs providing exercises in areas such as attention, 
memory, problem-solving, concentration, visuo-spatial, and visuo-motor skills (Wexler & Bell, 
2005). Bellucci and colleagues (2002) report that their 8-week computer program demonstrated 
improvements on cognitive impairment and negative symptoms compared to a wait-list group, 
although self-esteem did not mediate symptom reduction. In contrast, Lewis and associates 
(2003) created a three-month program of cognitive rehabilitation delivered in small group 
settings. They produced similar improvements in cognitive areas when compared to a control 
group, with participants in both groups developing more severe positive symptoms. As worsening 
positive psychotic symptoms were contradictory to the authors’ expectations, they suggested that 
participants became increasingly familiar with the examiners and, over time, revealed the full 
extent of their symptoms. It should be noted that the control group in this study received more 
intensive treatment than is typically found in public mental health settings (including supportive 
psychotherapy and family therapy), which may have reduced the potential for the cognitive 
rehabilitation program to have additional effects. Furthermore, the small sample size may have 
reduced the power of the statistical analyses. A 2-year trial involving both cognitive enhancement 
therapy (CET) and social skills training compared with enriched supportive therapy (EST) 
reported that both groups showed positive benefits of therapy on cognitive deficits, although 
these effects were greater for the CET group. However, the authors warn that this treatment may 
not be effective for all individuals with a diagnosis of schizophrenia or schizoaffective disorder 
(Hogarty et al., 2006).  
A meta-analysis of cognitive remediation therapy could not find consistent positive 
effects for the therapy (Pilling, Bebbington, Kuipers, Garety, Geddes, Martindale et al., 2002). 
Contrasted with this is a study which combined therapy with work services, compared with work 
services alone, for individuals post-acute illness phase, and found consistent benefits for those 
receiving the therapy in both cognitive ability and work capacity (Wexler & Bell, 2005). Similar 
results from a ‘real world’ study have been demonstrated (McGurk, Mueser, & Pascaris, 2005). 
Consequently, this treatment intervention shows promise for some individuals with psychotic 
disorders who experience deficits in this area. However it may be more beneficial to incorporate 
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it into a program including other techniques and skills, which would thus target a greater number 
of individuals experiencing a wider range of problems. This intervention requires more research 
before definitive conclusions can be reached about the positive benefits involved, and cannot yet 
be recommended (NICE, 2002).  
1.4.4 Social skills training 
Experts are divided about the benefits and use of Social Skills Training (SST) for 
individuals with schizophrenia and psychotic disorders (McGorry, 2005; NICE, 2002). This 
training involves the use of behavioural techniques to improve social adjustment and independent 
living skills, an area in which this population appears to experience significant difficulties. 
Additionally, as these issues cannot be resolved by medication, they may then contribute to the 
commencement of a psychotic episode. However, reviews and meta-analyses by a number of 
different groups (Bustillo et al., 2001; Huxley, Melanie, & Sederer, 2000; Penn & Mueser, 1996; 
Pilling, Bebbington, Kuipers, Garety, Geddes, Martindale et al., 2002) all indicate that social 
skills training modules are of limited use to individuals; the skills they engender cannot be 
translated into improvements in social functioning or quality of life. In contrast, a multi-centre 
study conducted in several European countries produced results that strongly support the use of 
SST targeting residential, recreational, and vocational areas, compared to a typical SST control 
group (Roder et al., 2002). They also reported decreases in positive and negative symptoms, and 
improvement in cognitive functioning, in their experimental groups. The researchers have 
claimed that the difference in this particular study lies in the use of cognitive-behavioural 
techniques employed in teaching social skills. Certainly, other studies reviewed have 
demonstrated benefits when employing a combination of social skills and cognitive techniques 
(Hogarty et al., 2006). Thus it appears that considerable work is required in this area before any 
definitive conclusions can be made. At present however, it appears that the most effective use of 
SST may be to combine it with cognitive techniques. 
1.5 Cognitive-behavioural therapy for psychotic disorders  
Cognitive-behavioural therapy (CBT) is one of the interventions for psychosis that, over 
the past few decades, have received a significant amount of attention. CBT was originally 
developed by Beck for depression and anxiety (Beck, 1976; Beck, 1995), and has proved an 
effective treatment for a number of disorders, including anxiety, depression, and eating disorders 
(see Butler, Chapman, Forman, & Beck, 2006, for a review). The CBT approach views symptoms 
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as a reaction to, or strategy for, dealing with stressful stimuli and events. The model suggests that 
thoughts, behaviours, and feelings interact and influence each other. CBT theorists believe that 
disordered thoughts and behaviours occur in response to a person’s core beliefs and that these 
core beliefs develop as a result of a person’s lifetime experiences. Thus, therapy typically 
involves establishing a therapeutic relationship with an individual while assessing their 
symptoms and underlying core beliefs. The therapist then works with the individual using a 
number of techniques to teach them to modify their thoughts, feelings, and behaviours, as well as 
modifying the person’s core beliefs and transforming maladaptive strategies into more helpful 
approaches (Beck, 1976; Beck, 1995). 
CBT was never originally considered as a treatment for the psychotic disorders due to 
their theoretical conceptualisation. It was believed that schizophrenia was a distinct and discrete 
biological condition and could not be compared to ‘normal’ functioning or the neuroses 
(McGovern & Turkington, 2001). Thus, delusions and hallucinations were thought to be 
impermeable to psychological intervention (Beck & Rector, 2000; Chadwick et al., 1996; Garety 
& Hemsley, 1994), and it was thought that there was the potential that discussing symptoms 
could make them worse (McGovern & Turkington, 2001).  
However, this view slowly began to change as researchers noticed that psychotic 
symptoms could be induced by traumatic experiences, and that if ‘normality’ could exist in 
someone with schizophrenia, then the reverse could also be true (Bleuler, 1974). A number of 
researchers also noted the overlap between psychotic and neurotic symptoms (McGovern & 
Turkington, 2001). Subsequently, a large body of work has demonstrated that psychotic 
symptoms occur along a continuum, with auditory hallucinations existing in people without a 
psychotic disorder who are not receiving treatment (Beck & Rector, 2003; Romme & Escher, 
1989), and a significant percentage of the population holds overvalued and delusional ideas 
(Johns & van Os, 2001). This new and evolving view of psychosis supports the hypothesis that 
people with the disorder could be amenable to psychological treatment. 
1.5.1 CBT model of psychosis 
The CBT view of psychosis endorses the vulnerability-stress hypothesis of schizophrenia 
to explain that while biological factors contribute to the cause of schizophrenia, stressors can 
affect the onset and relapse of psychosis. It is now beyond dispute that psychological processes 
are involved in the onset and course of psychosis, and in the maintenance of psychotic symptoms. 
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Thus ‘normal’ cognitive mechanisms can be used to reduce symptoms and improve functioning 
(Fowler, Garety, & Kuipers, 1998). A normalising rationale, or de-catastrophising explanation is 
thus provided to explain symptom onset and maintenance (Kingdon & Turkington, 1991). Then, 
as the model suggests, the influence of adverse environmental factors can be moderated to reduce 
stress, and coping strategies can be enhanced and promoted to reduce the impact of these 
stressors (Fowler, Garety, & Kuipers, 1995). 
A number of theorists has provided cognitive models to account for the expression and 
maintenance of psychotic symptoms. Garety and Freeman (1999) have reviewed several 
cognitive theories regarding delusion formation, suggesting that people with delusions 
demonstrate a reasoning bias in regards to data-gathering, and an attributional bias that blames 
external events for negative outcomes. To explain auditory hallucinations, Bentall (1990a) 
proposed that people with auditory hallucinations have an impairment in their ability to 
discriminate between real and imaginary events; they make swift and overconfident decisions 
regarding the source of perceptions, and are more likely to attribute perceptions to external 
events. Beck and Rector (2003) concur with this proposal, although they suggest that cognitive 
schemas, a predisposition to auditory imaging, perceptualization, an externalising bias, deficient 
reality testing, and certain reasoning biases all lead to certain “hot” thoughts being transformed 
into auditory hallucinations. Finally, Rector, Beck, and Stolar (2005) have recently generated a 
cognitive model to explain the development and maintenance of negative symptoms, including 
affective flattening, alogia, and anhedonia. The authors suggest that while a genetic vulnerability 
to negative symptoms exists, they are expressed and maintained through negative beliefs, low 
expectancies for pleasure, success, and acceptance, and a perception of limited resources. These 
cognitive biases interact with each other and symptoms to maintain symptom expression. Thus, 
cognitive models of psychotic symptoms imply that strategies addressing cognitive processes can 
alter symptom expression and maintenance. These cognitive strategies have been outlined by a 
number of researchers in manuals for CBT for psychosis. 
1.5.2 CBT treatment goals and manuals 
In 1952 Beck was one of the first therapists to implement a cognitive treatment to address 
a medication-resistant delusional system (Beck, 2002). By utilising behavioural experiments and 
assessing the antecedents of the delusion, at the conclusion of therapy the patient was able to use 
reasoning to address his erroneous beliefs. Since then, three manuals detailing CBT for people 
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with psychosis (Chadwick et al., 1996; Fowler et al., 1995; Kingdon & Turkington, 1994) have 
been developed, serving as the main guidelines for implementing CBT for psychosis. As 
reviewed by Rector and Beck (2001), these manuals differ in terms of emphasis on target areas: 
Kingdon and Turkington (1994) place importance on normalising symptoms, Chadwick et al. 
(1996) concentrate on developing cognitive strategies to produce and correct self- and other-
evaluative beliefs associated with positive symptoms, and Fowler and colleagues (1995) have 
produced a six-step comprehensive strategy that encompasses many of the ideas of these two 
other groups. However, all of these manuals agree on treatment goals and method of therapy 
(Garety et al., 2000) and are thus often used in combination in current research (Durham et al., 
2003; Rector, Seeman, & Segal, 2003; Temple & Ho, 2005a). The first step in CBT for psychosis 
is to establish rapport between the client and clinician, and then use collaborative empiricism to 
discuss and modify symptoms. The central aim of CBT is then to reduce the distress associated 
with symptoms, and reduce their interference with functioning. This occurs through normalising 
the persons’ symptoms, correcting and challenging beliefs, and using problem-solving 
techniques. Further detail regarding therapeutic techniques is provided in relevant manuals 
(Nelson, 2005) and articles (Farhall, Greenwood, & Jackson, 2007). All authors stress the 
concept that the therapy approach is flexible, and should be tailored to the individual’s needs and 
level of distress. Treatment is time-limited and structured, but the intensity and frequency of 
therapy depend on the individual’s needs. The development of the CBT model and methods led 
to several groups of researchers exploring the effects of this treatment on therapeutic outcomes.  
1.5.3 Review of CBT for psychosis 
Researchers in the early 90s began by examining the efficacy of CBT as an adjunct 
treatment for schizophrenia, to accompany medication and routine care. Although it was 
originally appraised in terms of medication-refractory psychotic symptoms, there are now 
researchers working in many different environments and countries examining CBT’s worth in 
terms of early psychosis (Haddock, Tarrier et al., 1999; Jenner & van de Willige, 2001), 
medication-resistant positive symptoms (Kuipers et al., 1997), especially auditory hallucinations 
(Chadwick, Sambrooke, Rasch, & Davies, 2000), relapse prevention (Gumley et al., 2003), 
negative symptoms (Daniels, 1998), social functioning (Cather et al., 2005), acute psychosis 
(Drury, Birchwood, Cochrane, & MacMillan, 1996a), knowledge (Gledhill, Lobban, & Sellwood, 
1998), self-esteem (Wykes, Parr, & Landau, 1999) and compliance with treatment (Kemp et al., 
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1996). CBT interventions have also been presented in a number of formats including Coping 
Strategy Enhancement (CSE, Tarrier, Beckett et al., 1993), functional CBT (fCBT: Cather et al., 
2005), and Cognitively Oriented Psychotherapy (COPE: Jackson et al., 1998), and with a 
combination of other strategies including family therapy and psychoeducation (HIT: Jenner et al., 
2004; Jenner & van de Willige, 2001; Wiersma, Jenner, Nienhuis, & van de Willige, 2004), 
motivational interviewing (Haddock et al., 2003), and social skills training (Hornsveld & Nijman, 
2005), over different time periods, and in both individual and group formats.  
1.5.4 CBT trials with large sample sizes 
The results of the studies presented in Table 1 below all indicate the positive benefits 
derived from treatment with CBT for psychotic symptoms. On examination of Table 1, it can be 
seen that CBT is an effective treatment for both positive and negative symptoms, and for 
elements of functioning including self-esteem, rehospitalisation, relapse, anxiety, depression, 
insight, and burden of care. It has been shown to be effective when compared with routine care, 
which generally consists of medication and case management, and when compared to a 
comparison intervention which controls for therapist exposure. Furthermore, it is effective in 
strictly controlled trials, and community settings, in both individual and group format, and with 
variations in frequency and intensity. Follow-up data suggests that it can have long-lasting, 
residual effects for individuals. These trials have been reviewed previously and presented in a 
similar format (Gaudiano, 2005; Tarrier & Wykes, 2004) with authors validating the utility and 
efficacy of CBT for psychosis. To date, this is the first review that has presented previous trials 
grouped by symptom focus of the CBT for psychosis intervention. 
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Table 1.  
 
Recent studies examining the use of CBT for schizophrenia and related disorders 
 
 
Authors 
 
 
Participants and entry 
criteria 
 
 
Objectives/Aims 
 
Study design 
 
Therapy format 
 
Results 
 
1. CBT for positive symptoms 
 
 
Chadwick, 
Sambrooke, Rasch, 
& Davies (2000) 
 
N = 22 
Schizophrenia or 
schizoaffective disorder 
 
Weaken beliefs about 
omnipotence of 
voices, increase sense 
of personal control 
over voices  
 
 
CBT + RC 
 
Group, 5 groups, 1h 
weekly for 8 weeks 
 
Treatment had a significant effect on 
conviction of power and control but not 
personal meaning. 
Drury, Birchwood, 
Cochrane, & 
MacMillan (1996a) 
(1996b) Drury, 
Birchwood, & 
Cochrane (2000) 
N = 40 
Diagnosis of psychosis 
Psychotic positive 
symptoms in acute 
psychosis 
Random 
assignment to 
CT vs. ATY1 
Individual and group 
therapy 3 hr/week 
plus family therapy 
and activities 5 
h/week 
CT showed a faster rate of decline of positive 
symptoms over first 12 weeks; significantly 
less positive symptoms at weeks 7 and 12. 
Both groups showed reduced negative 
symptoms. CT associated with a 25 – 50% 
reduction in recovery time.  
 
At 9mth follow-up: CT group had 
significantly fewer positive symptoms than 
ATY group.  
 
5-year follow-up: CT group reported better 
‘control over illness’, no thought disorder. 
 
                                                 
1
 ATY = recreational activities 
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Farhall & Cotton 
(2002)  
 
N = 22 
Diagnosis of psychosis, 
persistent hallucinations and 
delusions considered to be a 
management problem 
 
 
 
Acceptance of 
therapy, incidence 
and severity of 
positive symptoms 
 
CBT + CM2 
 
Individual, average of 
18 sessions, mean 
duration of 10.6 
months 
 
High levels of acceptance, 7 participants 
showed symptom frequency reduction 
 
Jakes, Rhodes, & 
Turner (1999) 
 
N = 18 
Chronic delusions 
 
Reduce 
intensity/conviction 
of delusion 
 
Baseline, 
control 
treatment, CT 
 
Individual, 4 sessions 
of baseline and 
control, and 8 
sessions of CT 
 
 
6 showed reduced conviction in belief, 7 
participants showed no changes, 5 had a 
variable response 
 
O’Connor et al. 
(2007) 
N = 17 
Delusional disorder,  
delusions  >1 month 
duration 
 
Address delusion Random 
allocation to 
CBT or APC3  
24 weeks of 
individual sessions 
Significant post-treatment changes on belief 
dimensions for both groups, with CBT 
producing greater effects on some dimensions 
Pinkham, Gloege, 
Flanagan, & Penn 
(2004) 
N = 11 
Diagnosis of schizophrenia 
or schizoaffective disorder, 
medication-resistant, 
distressing auditory 
hallucinations 
 
Beliefs about voices CBT 2 Groups, one met for 
seven 1-h weekly 
sessions, group 2 had 
20 sessions, 1-h 
weekly 
Both had significant positive changes in 
beliefs about voices, and a trend for reduced 
negative reactions to voices. 
Valmaggia, van der 
Gaag, Tarrier, 
Pijnenborg & Sloof 
(2005) 
 
N = 62, diagnosis of 
schizophrenia, medication-
resistant positive psychotic 
symptoms  
 
Residual psychotic 
positive symptoms 
Random 
assignment to 
CBT vs. SC 
Individual, 22 weeks, 
sessions 1 – 12 
weekly, 13 – 15 
fortnightly, 16 – 4 
weeks later 
 
CBT had modest short-term benefits over 
supportive counselling in relation to auditory 
hallucinations and illness insight 
                                                 
2
 CM = Case Management 
3
 Attention Placebo Control 
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2. CBT for positive and negative symptoms 
 
 
Tayside-Fife: 
Durham et al. 
(2003) 
 
N = 66 
Diagnosis of schizophrenia, 
schizoaffective or delusional 
disorder, persistent and 
distressing hallucinations or 
delusions  
 
 
Positive and 
negative 
symptoms, 
treatment 
satisfaction 
 
Random allocation 
to CBT + TAU vs. 
SPT4 + TAU 
 
Individual, ½ h, 20 
sessions over 9 
months 
 
CBT group showed significant greater 
improvement in overall symptom severity. 
 
Pinto et al. (1999) 
 
N = 41 
Schizophrenia diagnosis, 
treatment-refractory 
psychosis 
 
Psychotic positive 
symptoms 
 
Random 
assignment to CBT 
+ social skills 
training vs. ST5 
 
Individual, 1h 
weekly for 6 
months 
 
CBT showed improvement in positive and 
negative symptoms from baseline to post-
intervention. At post-intervention, CBT plus 
social skills had reduced positive symptoms 
compared to ST. 
 
Rector, Seeman, & 
Segal (2003) 
N = 42 
Schizophrenia or 
schizoaffective disorder, 
persistent positive and 
negative symptoms 
 
Positive and 
negative symptoms 
Random 
assignment to CBT 
+ ETAU6 vs. 
ETAU 
Individual, weekly 
sessions over 
6mths, 20 sessions 
in total 
Both groups showed reductions in positive 
and negative symptoms. CBT had a 
pronounced effect in the reduction of negative 
symptoms. 
Sensky et al. 
(2000) 
N = 90 
Schizophrenia diagnosis 
(ICD-10 and DSM-IV), 
persistent, medication-
resistant symptoms causing 
distress or dysfunction 
Psychiatric 
symptoms 
Random 
assignment to CBT 
+ RC vs. BF7 + RC 
Individual, 45mins 
per week, up to 
9mths 
Both treatments showed significant positive 
and negative symptom improvements. At 
9mth follow-up, CBT had significantly greater 
improvement than BF for all outcome 
measures; CBT participants continued to show 
improvement, the BF group lost some of their 
earlier gains 
 
                                                 
4
 SPT = Supportive Psychotherapy 
5
 ST = Supportive Therapy 
6
 ETAU = Enhanced TAU 
7
 BF = Befriending 
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3. CBT for positive symptoms and functioning 
 
 
Cather et al. (2005) 
 
N = 30 
Schizophrenia or 
schizoaffective disorder, 
residual psychotic 
symptoms 
 
 
Psychotic symptoms 
and social 
functioning 
 
Random 
assignment to 
fCBT8 vs. PE9 
 
Individual, weekly 
sessions over 16 
weeks 
 
No significant differences between groups. 
Effect sizes favoured fCBT for reducing 
positive symptoms. 
 
Gledhill, Lobban, 
& Sellwood (1998) 
 
N = 4 
Schizophrenia diagnosis 
persistent positive psychotic 
symptoms 
 
Positive symptoms, 
self-esteem, mood, 
ability, control, 
knowledge 
 
CT 
 
Group, 1h weekly for 
8 weeks, follow-up at 
1mth 
 
All patients less depressed, most had higher 
self-esteem and greater knowledge of 
schizophrenia, half of the group felt better 
able to cope with symptoms 
 
 
London-East 
Anglia  
Kuipers et al. 
(1997), Garety et 
al. (1997), Kuipers 
et al.(1998)  
 
N = 60 
At least 1 medication-
resistant, distressing, 
unremitting positive 
symptom 
 
Positive psychotic 
symptoms, distress, 
emotional 
disturbance, risk of 
relapse, social 
disability 
 
Random 
assignment to 
CBT10 + RC11 
vs. RC  
 
Individual, 1h or less, 
weekly then 
fortnightly for 9 
months, average of 
18.9 sessions 
 
CBT group improved significantly on BPRS 
compared to control group, a key predictor of 
good outcome to CBT was cognitive 
flexibility. At 18 months: CBT group showed 
significant and continuing improvement, 
reduced frequency in hallucinations and 
delusional distress 
 
                                                 
8
 fCBT = functional CBT 
9
 PE = Psychoeducation 
10
 CBT = Cognitive Behavioural Therapy 
11
 RC = Routine Care 
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Tarrier et al. (1993) 
 
N = 27 
Schizophrenia diagnosis, 
medication-resistant 
psychotic symptoms <6 
months  
 
Positive psychotic 
symptoms and social 
functioning 
 
Random 
assignment to 
CSE12 vs. PS13 
 
Individual, 1h twice 
per week for 5 weeks, 
6 month follow-up 
 
Both groups had significant changes in 
number and severity of symptoms over 
treatment period, CSE group showed more 
improvement on delusions scale and trend 
towards greater improvement on anxiety scale 
of the PAS. No changes in social functioning. 
 
 
Tarrier et al. 
(Tarrier et al., 
2000; Tarrier, 
Wittkowski et al., 
1999; Tarrier et al., 
1998) 
 
N = 72 
Diagnosis of schizophrenia, 
schizoaffective psychosis or 
delusional disorder, 
persistent hallucinations or 
delusions > 6mths 
 
Positive psychotic 
symptoms, reduce 
hospital stay 
 
Random 
assignment to 
intensive CBT 
+ RC, SC14 + 
RC, or RC 
 
Individual, 1h, twice 
per week over 10 
weeks 
 
CBT group showed significant effects in 
number and severity of symptoms than RC. 11 
of them showed clinically significant 
improvement. CBT and SC also spent less 
time in hospital. At 1 year: CBT group had a 
lower score on positive symptoms than RC 
with trends towards significance for negative 
symptoms; 2 years: CBT and SC had a 
significant difference to RC on positive and 
negative symptoms 
 
 
Wiersma et al. 
(2004) 
 
N = 78 
Current auditory 
hallucinations, 
schizophrenia spectrum 
diagnosis  
 
Patient and relatives 
receive cognitive 
interventions and 
coping training 
 
 
HIT15 vs. RC 
 
Individual, 9 months 
 
HIT group demonstrated a significant 
improvement in quality of life and social role 
functioning. 
Wykes, Parr, & 
Landau (1999) 
N = 21 
Schizophrenia diagnosis, 
medication-resistant, 
distressing auditory 
hallucinations 
 
Insight and 
symptoms, 
particularly auditory 
hallucinations 
CT vs. WL 
control 
Group, 3 groups, up 
to 1h weekly, over 6 
weeks, follow-up at 
3mths 
Reduction in auditory hallucinations, insight 
into psychosis increased, self-esteem 
improved, all maintained at follow-up. 
                                                 
12
 CSE = Coping Strategy Enhancement 
13
 PS = Problem solving 
14
 SC = Supportive Counselling 
15
 Hallucination-focused Integrative Treatment 
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4. CBT for negative symptoms and functioning 
 
 
Daniels (1998)  
 
N = 40 
Diagnosis of paranoid 
schizophrenia, 
schizoaffective, 
undifferentiated, and 
catatonic schizophrenia 
 
 
Psychiatric symptoms 
and functioning 
 
Random 
assignment to 
IBT16 vs. wait-
list 
 
2 Groups, 10 
participants in each, 
16 sessions in total: 
50 minutes each, 
twice per week. 
 
For treatment groups: improvement in global, 
psychosocial, and occupational functioning. 
Positive trend towards social functioning, non-
significant decrease in negative symptoms. 
 
5. CBT for positive and negative symptoms and functioning 
 
 
Barrowclough et al. 
(2001) Haddock et 
al. (2003) 
 
N = 36 
Diagnosis of schizophrenia, 
schizoaffective or delusional 
disorder, and substance 
dependence or misuse 
 
 
Symptoms, substance 
use, functioning, 
carer, and health 
economy outcomes 
 
Random 
allocation to 
CBT + 
motivational 
intervention+ 
FI + RC vs. 
RC 
 
Individual – 29 
sessions, FI – 10 – 16 
sessions, over 9 
months 
 
Superior global functioning, lower positive 
symptoms, no difference in social functioning, 
fewer relapses, greater increase in percent of 
days of abstinence. 18-month follow-up: 
treatment group demonstrated specific 
benefits for global functioning and negative 
symptoms. Trends towards better personal 
outcomes for carers. Intervention was not 
more costly than routine treatment. 
 
Bechdolf et al. 
(2004) 
N = 88 
Met criteria for a 
schizophrenic or related 
disorder  
Rehospitalisation, 
relapse, symptoms 
and compliance with 
medication 
 
Random 
assignment to 
CBT + RC or 
PE + RC 
Group, 60 – 90 
minutes, 16 sessions 
in 8 weeks 
CBT group had less re-hospitalisations; both 
groups had significant psychopathological 
improvement 
                                                 
16
 IBT = Interactive-Behavioural Training, a combination of CBT and group process strategies 
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Bradshaw (2000) 
 
N = 15 
Schizophrenia diagnosis 
 
Psychosocial 
functioning, 
psychiatric 
symptomatology and 
hospitalisations 
 
 
Random 
assignment to 
CBT + DTP17, 
DTP or control 
 
Individual, Weekly, 
up to 36 months 
 
CBT group showed greater reduction in 
symptomatology and greater improvement in 
psychosocial functioning. Both groups had 
marked reductions in hospitalisations. 
 
Farhall et al. (2007; 
2004) 
N  = 92 
Diagnosis of psychotic 
disorder or mood disorder 
with psychotic features and 
a “recovery need” 
Minimise the effects 
of the disorder, living 
with the 
consequences of the 
disorder 
 
Random 
assignment to 
CBT & TAU 
vs. TAU 
Individual, between 
12 – 24 sessions over 
1 year 
CBT group indicated improvements in self-
esteem, reductions in anxiety. Both groups 
showed significant improvements in positive 
and negative symptoms, no advantage of CBT 
group.   
Haddock et al. 
(1999) 
N = 21 
Diagnosis of schizophrenia 
or schizoaffective disorder, 
onset or relapse of 
symptoms 
Psychiatric 
symptoms, relapse 
and readmission 
Random 
allocation to 
CBT vs. 
SC/PE 
Individual, up to 5 
weeks, booster 
sessions at 1,2,3 and 
4 months following 
discharge 
CBT and SC/PE had no significant differences 
between days in hospital. Both groups showed 
significant reductions in symptoms. CBT 
group had a lower number of patients who 
relapsed, less relapses and time to recurrence 
of psychotic symptoms, but time to 
readmission was shorter. 2-year follow-up 
indicated no significant differences between 
groups.  
 
Lecomte, Leclerc, 
Wykes, & Lecomte 
(2003) 
N = 6 
Diagnosis in the 
schizophrenia spectrum, 
first episode 
Coping with 
psychotic symptoms, 
self-esteem, stress, 
anxiety, depression, 
suicide, and 
substance abuse 
 
CBT Group, twice per 
week for 3 months 
Reduced symptoms 
                                                 
17
 DTP = Day Treatment Program 
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SoCRATES 
Lewis et al. (2002), 
Tarrier et al.(2004)  
 
N = 309 
Diagnosis of schizophrenia, 
schizophreniform, 
schizoaffective or delusional 
disorder, first or second 
admission 
 
Remission from acute 
symptoms, prevent 
further relapse 
 
Random 
assignment to 
CBT, SC or 
RC 
 
Individual, 3 – 4 hrs 
per week over 5 
weeks, booster 
sessions at 2 weeks, 
1, 2 and 3 months 
later 
 
All treatment groups improved on outcome 
measures. Trend for CBT group to improve 
fastest, effect greatest at 5 weeks from 
baseline. 18mth follow-up: CBT and SC 
improved symptom outcome. No significant 
difference in groups for hospitalisation or 
relapse. 
 
Morrison et 
al.(2004)  
N = 87 
Diagnosis of schizophrenia, 
schizophreniform, 
delusional or schizoaffective 
disorder; positive symptoms 
Psychotic 
symptomatology, 
mood and 
hospitalisation 
Naturalistic 
allocation to 
CT, WL18 or 
TAU. 
Delivered by 
trained 
therapists in a 
CMHT19. 
 
Individual, usually 
weekly, maximum 30 
sessions, up to 3 
booster sessions 
CT group showed improvements for positive 
symptoms, reduction in days in hospital and 
admissions 
 
Startup, Jackson, & 
Bendix (2004)  
 
N = 90 
Clinical diagnosis of 
schizophrenia, 
schizophreniform or 
schizoaffective disorder, 
acute psychotic episode 
 
 
Psychotic 
symptomatology and 
social functioning 
 
Random 
assignment to 
CBT + TAU 
vs. TAU 
 
Individual, 90 min, 
up to 25 sessions 
 
CBT group improved more on average than 
TAU group for positive and negative 
symptoms, and social functioning. Effect sizes 
between 0.6 to 0.8. 
Turkington, 
Kingdon, & Turner 
(2002), Rathod et 
al.(2005)  
N = 422 
Schizophrenia diagnosis 
Symptoms, insight, 
depression, burden of 
care 
Random 
allocation to 
CBT vs. 
TAU20  
 
Individual, 1h, up to 
six sessions over 2 – 
3 months 
CBT group improved in overall symptoms, 
insight and depression. Improvement in 
insight was deemed clinically significant. 
Most were satisfied with the programme. 
                                                 
18
 WL = Wait-list 
19
 CMHT = Community Mental Health Team 
20
 TAU = Treatment As Usual 
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Temple & Ho 
(2005a)  
 
N = 19 
Schizophrenia diagnosis, 
severe and persistent 
medication-resistant 
psychotic symptoms 
 
 
Symptom reduction 
and improve daily 
adaptive functioning 
 
Case-
controlled, 
CBT vs. TAU 
 
Individual, up to 20 
sessions 
 
CBT group showed improvements in overall 
psychosocial adjustment, decline in overall 
symptom severity and delusions, trend 
towards reductions in negative symptoms. 
Warman et al. 
(2005)  
N = 6 
Diagnosis of schizophrenia 
and schizoaffective 
disorder, predominantly 
positive symptoms 
 
Positive and negative 
symptoms, anxiety 
and depression 
CBT Individual and group 
over alternating 
weeks for 24 weeks 
Reduced positive and negative symptoms, 
conviction, anxiety and depression. 
 
6. CBT for functioning  
 
 
Hall & Tarrier 
(2003; 2004) 
 
N = 23 
Diagnosis of schizophrenia, 
bipolar disorder, and 
unspecified psychotic 
illness, acute inpatient 
admission 
 
 
Self-esteem 
 
Random 
allocation to 
CBT vs. TAU 
 
Seven weekly 
individual sessions 
 
Significant improvements in self-esteem and 
social functioning, significant reductions in 
symptoms and depression for treatment group. 
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1.5.5 Effect size and clinical significance   
Although the results of the research reported in Table 1 demonstrate the positive 
results of CBT, most trials have not reported effect size information and thus it is difficult to 
determine how it compares to treatment as usual, or with comparative treatment groups. This 
lack of information prompted Gould and colleagues (2001) to complete a meta-analysis for 
effect size from the results of seven studies, finding a large mean effect size of 0.65 (95% CI 
= 0.56 – 0.71) for change in psychotic symptoms from pre- to post-treatment. Furthermore, 
the combined mean effect size for improvement at follow-up was 0.93. Rector and Beck 
(2001) examined five studies in the field (Drury et al., 1996a; Kuipers et al., 1997; Pinto et 
al., 1999; Sensky et al., 2000; Tarrier, Beckett et al., 1993) and reported an average effect size 
of 1.31 (SD = .71) on measures of positive symptom functioning, and large treatment effects 
for negative symptoms (ES = 1.08, SD = .83) for three studies (Pinto et al., 1999; Sensky et 
al., 2000; Tarrier et al., 1998). Sensky and colleagues’ (2000) results continued to show gains 
at nine-month follow-up (ES = .88). In their meta-analysis Pilling and colleagues (2002) 
indicated that CBT demonstrates a clear, positive effect on mental state at follow-up, and 
lower drop-out rates than standard care. Zimmerman and colleagues (2005) conducted a meta-
analysis of 14 studies involving 1,484 participants. They reported a mean weighted effect size 
of 0.37 (95% CI: 0.23 – 0.47) for change in positive psychotic symptoms; these results were 
maintained at 12-month follow-up. These results are similar to a more recent meta-analysis, 
which also found significant effects for negative symptoms, functioning, and mood (Wykes, 
Steel, Everitt, & Tarrier, 2007). Dickerson and Lehman (2006) have presented a review of 
controlled CBT trials when compared to other treatments, demonstrating that CBT shows the 
greatest effect in reducing the severity of overall and positive symptoms, with no benefits for 
depressive symptoms or functioning. Thus, although the strength of the improvement induced 
by CBT is variable across studies, all meta-analytic studies to date demonstrate that CBT is 
effective in producing changes in psychotic symptoms, and that these changes are maintained 
over time.  
Several researchers have reported their results in terms of clinical significance. 
Previous methods of determining clinical significance are detailed in the clinical significance 
criteria subsection of methodological limitations (Section 1.6.3). Tarrier et al. (1998) found 
that eleven (of 33) participants in the treatment group demonstrated a 50% improvement in 
psychotic symptoms, although this effect was not demonstrated at 12-month follow-up. 
Sensky et al. (2000) reported that 52% - 70% of patients in the CBT group achieved clinically 
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significant results. Rector et al. (2003) found that 65% of CBT-ETAU and 62% of ETAU 
participants achieved this, whereas Cather and colleagues (2005) indicated that 60% of 
participants in the fCBT group demonstrated a clinically significant reduction in positive 
symptoms. In the Tayside-Fife trial (Durham et al., 2003), results indicated that 10 – 20% of 
participants in the CBT group attained a 25% reduction at post-treatment and one-third of 
them demonstrated this at follow-up. Three participants in this group achieved a 50% 
decrease in symptomatology whereas Warman et al. (2005) found that five participants 
achieved a 20% reduction in positive symptoms, with three demonstrating a 50% reduction. 
For negative symptoms, five had a 30% reduction and three had a reduction of 50% or more. 
Temple and Ho (2005a) also set a clinical significance level at 25%, indicating that 
participants in the CBT group achieved this symptom reduction in delusions and 
hallucinations. In the London-East Anglia trial (Kuipers et al., 1997), 21% of participants 
achieved a large clinical improvement and 29% achieved a reliable clinical improvement. 
Turkington and colleagues reported insight reaching a clinically significant level of 
improvement, but not symptom levels (2002). Finally, Gumley et al. (2003) reported that nine 
participants achieved clinically significant results in prosocial functioning. Taken together, 
these results are very persuasive, indicating that CBT is a useful and valuable intervention for 
many individuals suffering from the debilitating symptoms of schizophrenia. 
1.5.6 Single case studies 
In addition to trials with large sample sizes, single case studies of cognitive 
behavioural therapy for psychosis have also been reported in the literature. These case studies 
have been used to report the results of trials of CBT for comorbid panic attacks (Bufka & 
Hofmann, 1999), comorbid specific phobias (Dudley, Dixon, & Turkington, 2005; Good, 
2002), psychosocial dysfunction (Davis & Lysaker, 2005), early intervention (Wragg & 
Whitehead, 2004), hallucinations caused by epileptic fits (Siddle, Turkington, & Dudley, 
1997), to examine the impact of case formulation on therapeutic alliance (Chadwick, 
Williams, & Mackenzie, 2003), and interventions for individuals with a comorbid mild 
intellectual disability (Haddock, Lobban, Hatton, & Carson, 2004). Case examples have been 
used to describe individuals and their presenting problems, and particular techniques and 
styles used in larger trials of CBT (Bradshaw, 1998; Grazebrook et al., 2004; Pinto et al., 
1999), including fCBT (Cather, 2005). Illustrative case examples have also been recorded in 
CBT manuals to demonstrate techniques and presenting issues (Kingdon & Turkington, 1994; 
Morrison, 2002; Perris, Nordstrom, & Troeng, 1992). In these case reports participants’ pre- 
and post-therapy raw data or percentages representing this have been presented and compared 
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in tables, in text, and in figures, indicating clear changes in symptoms and functioning as a 
result of CBT. Weekly self-report data has also been recorded to track changes over the 
course of the intervention (Morrison, 2002; Wragg & Whitehead, 2004). 
1.5.7 Current status of CBT use 
The majority of the research investigating CBT has been performed in the United 
Kingdom, often by the same groups of researchers, although there are a small number of 
individuals working in Italy (Pinto et al., 1999), Canada (Rector et al., 2003), Germany 
(Bechdolf et al., 2004), the Netherlands (Hornsveld & Nijman, 2005; Wiersma et al., 2004) 
and Belgium (Valmaggia et al., 2005), Australia (Farhall, Freeman et al., 2007; Jackson et al., 
2001), and the US (Temple & Ho, 2005a). Based on current results, the National Institute of 
Clinical Excellence (NICE, 2002) in the UK now lists CBT as an empirically-supported 
treatment in its guidelines for interventions for schizophrenia.  
Comparatively, this type of research has been largely neglected in North America. As 
a result, Mueser and Noordsy (2005) indicate that few people with a mental illness have 
access to CBT. Instead, many individuals are prescribed combinations of two or more 
antipsychotic medications. They provide three hypotheses on why CBT for psychosis has 
been overlooked in the United States, including a potential pessimism regarding the 
effectiveness of psychotherapy for psychosis due to the lack of success of earlier 
psychodynamic trials, optimism about antipsychotic medication, and a cultural separation of 
psychotherapy versus pharmacology. Tarrier and colleagues suggest a number of other 
barriers to CBT, including an absence of appropriate knowledge and clinical skills within the 
workforce, and a belief that the symptoms of schizophrenia are not amenable to CBT (Tarrier, 
Barrowclough, Haddock, & McGovern, 1999). Moreover, in Australia, Farhall and Cotton 
(2002) propose that as CBT is seen as a low service priority, it is not allocated sufficient time 
for implementation, and subsequently not utilised in routine practice.  
If considered along a continuum, the situation and opinions in respect of Australia are 
located somewhere between the United Kingdom and the United States. For example, Pantelis 
and Barnes (1996) indicate that medication-resistant symptoms are often managed by giving 
patients excessive medication dosage, or a combination of a number of medications. In 
contrast, the Royal Australian and New Zealand College of Psychiatrists (McGorry, 2005) has 
recently recommended this therapy as a routine treatment for treatment-refractory symptoms, 
distress, and comorbidity. In terms of research, there are only a small number of Australian 
trials in existence (Farhall & Cotton, 2002; Farhall, Freeman et al., 2007; Jackson et al., 1998) 
although this number is greatly increasing and indicates a clear future for CBT for psychosis. 
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On the whole, these recommendations reflect the increasing popularity and success of CBT 
for schizophrenia.  
1.6 Methodological limitations and future directions 
1.6.1 Sample size  
While the results of current studies are easily replicated in clinical trials, a number of 
reoccurring methodological issues limit the transference of these results to real-word 
effectiveness trials.  First, most of these studies have been conducted with very small, and 
very select samples. There is a general tendency for researchers to exclude anyone with 
organic brain pathology or comorbid substance abuse disorder (Lewis et al., 2002; Tarrier, 
Beckett et al., 1993). However, recent trials that have not been so selective have demonstrated 
that effective results can be achieved with these populations as well (Barrowclough et al., 
2001; Haddock et al., 2003; Haddock et al., 2004; Pinkham et al., 2004).  In addition, most 
studies required positive symptoms to be present, but disregarded the status of negative 
symptoms. Garety and colleagues (2000) hypothesised that this occurs because previous 
research suggests that participants with solely negative symptoms respond poorly to CBT, as 
it is difficult to engage them in a verbally-based intervention. Given that a large percentage of 
individuals with a psychotic disorder present with co-morbid substance abuse (Kavanagh et 
al., 2004) and predominantly negative symptoms, excluding these individuals from a research 
population severely limits the conclusions that can be made about the efficacy of CBT with 
this greater group. 
In contrast, broadening the selection criteria to include multiple diagnoses enhances 
the ability of researchers to explore the efficacy of the intervention for the majority of 
diagnoses and individuals. For example, several studies have included participants with a 
diagnosis of schizoaffective, schizophreniform, or delusional disorder (Rector et al., 2003; 
Tarrier et al., 1998), others limited the study to people with a diagnosis of schizophrenia 
(Pinto et al., 1999; Sensky et al., 2000), and still other studies generalised to a diagnosis of 
some form of psychosis (Drury et al., 1996a; Farhall & Cotton, 2002). As these disorders all 
have very similar symptomatology and are thus grouped together by the DSM-IV-TR (APA, 
2000) it appears wise to include them in CBT for psychosis research, in order to make the 
approach translate to different individuals with different problems. Thus, future research 
should emulate this work by including a broad range of participants, with differing and co-
occurring diagnoses.  
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The small sample sizes of many CBT for psychosis studies may have resulted in non-
significant outcomes when the data is examined using statistical tests, reducing the support for 
CBT as an effective intervention (Pinkham et al., 2004). In a number of projects, reduced 
sample sizes can be explained by examining the high percentage of eligible participants who 
then declined to participate (Barrowclough et al., 2001; Bechdolf et al., 2004; Farhall et al., 
2004; Hall & Tarrier, 2003; Miles, Peters, & Kuipers, 2007; Startup et al., 2004; Trower et al., 
2004). Hall and Tarrier (2003) attribute their 61% refusal rate to the severity and chronicity of 
the illness, whereas Farhall and colleagues (2004) explain their refusals as due not only to 
psychotic symptoms, but also practical impediments and satisfaction with recovery rate. In 
contrast to these refusal rates, the consistently small percentage of participants who drop out 
or discontinue treatment in these trials speaks for the utility of the therapy (Cather et al., 2005; 
Durham et al., 2003; Kuipers et al., 1997).  
As a result of small sample sizes, several researchers have presented their positive 
therapeutic results using alternative methods to traditional statistical analyses. Results have 
been represented by descriptive data (Gledhill et al., 1998), percentage data (Miller, 1996), 
and effect size data (Key, Craske, & Reno, 2003; Warman et al., 2005). Studies investigating 
recovery and social functioning outcomes have often included qualitative data analyses. In 
these studies, results have been presented by describing individuals’ experiences (Lecomte et 
al., 2003; Sells, Stayner, & Davidson, 2004; Spaniol, Wewiorski, Gagne, & Anthony, 2002; 
Williams & Collins, 2002), using discourse methods (Messari & Hallam, 2003), and grounded 
theory methodology (McGowan, Lavender, & Garety, 2005). To date, several studies 
examining the qualitative outcomes of CBT research have been conducted (Chadwick et al., 
2003; Key, 2001; McGowan et al., 2005; Messari & Hallam, 2003), these researchers have 
used their data to outline and discuss participants’ experiences of the therapeutic process, and 
the strategies and tools they found most helpful. Hodgetts and Wright (2007) have indicated 
that very few qualitative investigations into therapy exist. They argue for an increase in 
qualitative research in order to guide therapists regarding their therapeutic practice.  
1.6.2 Group CBT for Psychosis 
Researchers have also examined the utility of CBT when provided in group format. Gledhill 
and colleagues (1998) argue that this format is superior to individual therapy on a number of 
levels, including reducing feelings of isolation, generalisation and modelling of coping 
strategies. In addition, peer pressure may increase compliance with homework tasks. 
However, these authors caution that there is a number of disadvantages to the group format, 
including the threat to confidentiality and lack of individualised formulation and intervention. 
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Nevertheless, group therapy is an important aspect to examine, as it is much more cost-
effective for health service providers and can thus become more widely available for 
consumers. Unfortunately, trials using a group format have usually been performed with 
smaller numbers of participants (Gledhill et al., 1998; Wykes et al., 1999), have not 
incorporated an appropriate control group (Chadwick, Sambrooke et al., 2000; Gledhill et al., 
1998; Wykes et al., 1999), or used a combination of individual and group treatments (Drury et 
al., 1996a; Warman et al., 2005). These features increase complexity in determining whether 
the treatment has produced significant changes for people with schizophrenia; whether the 
improvement was due to the treatment or some other factor; or whether the improvement was 
due specifically to this type of format respectively. There is thus a great deal of work to be 
done examining group CBT programs before any specific conclusions can be drawn.   
1.6.3 Clinical Significance Criteria 
There is considerable variability between researchers when defining criteria for 
clinical significance, making comparisons among their results very difficult. Tarrier and 
colleagues (1993) willingly admit that their definition of a reduction in symptoms of 50% or 
more and an increase in social functioning by at least one standard deviation (15 points) on 
the Social Functioning Scale (Birchwood, Smith, Cochrane, Wetton, & Copestake, 1990) is 
arbitrary. Sensky et al. (2000) also required a 50% reduction in symptoms to reach clinical 
significance, whereas Rector et al. (2003) and Cather et al. (2005) only required a 20% 
reduction on scale scores of the Positive and Negative Syndrome Scale (PANSS). Tayside-
Fife (Durham et al., 2003) investigators implementing the PANSS and PSYRATS, and 
Warman et al. (2005) employing the SAPS, SANS, and PSYRATS used both 25% and 50% 
cut-offs for clinically significant improvements in symptoms. Turkington and colleagues 
implemented a 25% improvement level for their main outcome measures, including the 
CPRS, Insight Rating Scale, and Burden of Care Questionnaire (2002). For Garety et al. 
(1997) an improvement of greater than 5 points on the Brief Psychiatric Rating Scale 
indicated a reliable clinical change, with an improvement equal to 10 points on the scale was 
considered a large clinical change. In contrast, so far only one trial has implemented 
recommended criteria: Gumley et al. (2003) used the Jacobson and Truax (1991) criterion of 
outcome response falling outside the range of the population by two standard deviations from 
the pre-treatment baseline score. In order to adequately assess whether participants’ responses 
to CBT are clinically significant, and therefore formulate decisions about healthcare, 
consistent criteria are vital to treatment-focused research. 
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1.7 Quality of life and social functioning 
An essential measurement of therapeutic outcome is how treatment has affected the 
individual in terms of his or her functioning and quality of life (QOL) (Gladis, Gosch, Dishuk, 
& Crits-Christoph, 1999). A number of experts has attempted to define quality of life, 
suggesting that it reflects a subjective sense of well-being, relates to a person’s understanding 
of what they have, his or her perception of life, and his or her social relationships (Basu, 
2004; Bobes & García-Portilla, 2006; Gladis et al., 1999).  More recently, researchers have 
included functioning in daily life as part of QOL (Katschnig, 2000). QOL measurements have 
had a fairly short history in the field of health and mental health; instruments began to appear 
in the 1980s (Gladis et al., 1999) and now consist of a number of characteristics, including 
subjectivity, an evaluation of satisfaction/dissatisfaction, and assess several dimensions, 
including psychological, physical, and social areas (Basu, 2004). QOL assessment tools are 
currently regarded as a central clinical significance measurement, and may be viewed as an 
alternative to traditional symptom-based measures (Gladis et al., 1999).  
1.7.1 Quality of life in schizophrenia 
A meta-analysis of validated measures of psychiatric symptoms and QOL has found 
that there are significant negative relationships between psychotic symptoms and QOL (Eack 
& Newhill, 2007). Additionally, recent research has suggested that individuals with psychosis 
are reliable reporters of functioning when provided with standardised measurements 
(Corrigan, Buican, & McCracken, 1996). As a result, measures designed for this population 
have been used to assess a number of areas including symptom levels, marital status, housing, 
financial independence, employment levels (Tulloch, Fearon, & David, 2006), education, 
leisure, spiritual, family, friends, and dental needs (Corrigan et al., 1996). Individuals with 
schizophrenia have been shown to have low functioning in a number of these areas. For 
example, employment rates in the UK have been reported to be between 4% – 31%, and in 
European studies, between 8% – 35% (Marwaha & Johnson, 2004); these are similar to 
employment rates in the US, reported at 17.2% (Salkever et al., 2007). However, as this is a 
relatively recent area to be explored and defined, difficulties have arisen when attempting to 
accurately measure and define QOL for individuals with psychosis.   
A number of limitations has emerged when attempts have been made to assess the 
QOL of individuals with schizophrenia. These limitations include the use of objective 
measures such as hospital readmissions, which may provide more information about the 
mental health service and housing situation than about the individual’s symptoms and needs 
(Becker & Diamond, 2006). When implementing subjective outcome measures, 
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measurements of changes in symptoms have typically been regarded as appropriate. However, 
some theorists suggest that symptoms are only loosely related to functioning and are thus a 
poor indicator of treatment outcome (Becker & Diamond, 2006). Additionally, researchers are 
finding that professionals have significantly different views from their patients about the areas 
that make up quality of life for them. Specifically, while individuals with schizophrenia were 
most commonly reporting work, health, leisure activities, social contacts, and joy of life as 
consistent with QOL, their psychiatrists’ conception of QOL for their patients was more 
illness-oriented, focusing on less medication side-effects and increased social contact 
(Angermeyer, Holzinger, Reinhold, & Matschinger, 2001)  These results have been repeated 
with young adults with a serious mental illness (SMI) and their parents, who all reported life 
goals and hopes similar to those reported by individuals without a mental illness (Stein, 
Mann, & Hunt, 2007). These limitations suggest that it is not sufficient to rely upon objective 
measures, symptom measures, or even measures designed by health professionals, as none 
may accurately capture the concepts of QOL as defined for individuals with schizophrenia.  
In order to address these issues, Katschnig (2000) has suggested that qualitative 
measures of QOL may be more sensitive to dissatisfaction levels, and should thus be 
implemented. Thus, interviewing individuals may provide a greater understanding of their 
functioning and QOL, which could help to understand the efficacy of treatments, and inform 
the development of more specific outcome measures. Alternatively, including others’ reports 
and evaluations on subjective and objective measures may reduce any distortion and provide 
further information on QOL (Gladis et al., 1999; Katschnig, 2000). Therefore, a combination 
of qualitative measures and other reports could be used to strengthen researchers’ 
understanding of this crucial area.   
1.7.2 Measures of QOL in CBT for psychosis research  
A review of past CBT for psychosis research indicates that a select number of trials 
have assessed the therapy in terms of changes in QOL, functioning, and self-concept. Many 
have measured QOL and functioning in terms of hospital readmissions (Lewis et al., 2002; 
Tarrier et al., 1998), insight (Wykes et al., 2005), or relapse prevention (Bechdolf et al., 2004; 
Haddock, Tarrier et al., 1999; Tarrier et al., 2004) (see Table 2 for a summary of these 
studies). While these are critical features, they are a rather crude measure of this aspect, and, 
as previously stated, may be a reflection of the mental health system and economic situation 
of the participant (Becker & Diamond, 2006). Additionally, CBT programs targeted towards 
functioning outcomes, including fCBT (Cather et al., 2005) and HIT (Wiersma et al., 2004) 
have examined outcomes with a self-report measure completed only by the participant. Given 
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that researchers focused on QOL and functioning have strongly recommended including 
others’ viewpoints and gathering qualitative data, it is likely to be far more meaningful to use 
these techniques to inspect the outcomes of CBT for psychosis.   
When researchers have examined functioning outcomes, implementing the Social 
Functioning Scale, Role Functioning Scale (RFS), and Clinical Global Impression for 
Improvement (CGI), they have reported contradictory findings for this outcome. Several 
researchers (Bradshaw, 2000; Gumley et al., 2003; Temple & Ho, 2005a) demonstrated 
improvements in functioning for the CBT group, whereas a number of other groups reported 
no such changes (Cather et al., 2005; Kuipers et al., 1997; Tarrier, Beckett et al., 1993; 
Turkington et al., 2002). Also, when trials have implemented the SFS, there has been a great 
deal of data missing from their reports. Specifically, almost all studies have reported a total 
scaled score, and have not provided the data for each subscale measure (Hall & Tarrier, 2004; 
Kuipers et al., 1997; Startup et al., 2004; Tarrier, Beckett et al., 1993). The only trial that has 
reported subscale measures, has provided raw scores, as opposed to the converted scaled 
scores (Gumley et al., 2003). The provision of a total score, or raw scores, creates difficulties 
in comparing and contrasting the results of past research, and also suggests that these 
outcomes have been considered secondary and unimportant in contrast to symptom measures.  
In terms of QOL, only a few studies have measured this outcome (Daniels, 1998; 
Jackson et al., 1998; Wiersma et al., 2004), with results suggesting that there may be 
improvement in this area post-treatment. While it was not explicitly stated, it appears that the 
two trials that have implemented the Quality of Life, Enjoyment and Satisfaction 
Questionnaire (Q-LES-Q, Endicott, Nee, Harrison, & Blumenthal, 1993) for individuals with 
psychosis have provided a total raw score, making it difficult to compare results across trials, 
and excluding important subscale information (Halperin, Nathan, Drummond, & Castle, 2000; 
Kingsep, Nathan, & Castle, 2003).  
Only a small number of trials to date (Gumley et al., 2003; Tarrier, Beckett et al., 
1993) have included social functioning when examining whether participants’ results have 
achieved clinical significance; as yet no trials have done this for QOL. This disregard of a 
crucial outcome, and the inconsistent results reported when examining social functioning and 
QOL suggest that further research expanding knowledge about these outcomes is now 
required. In particular, trials should further examine quality of life outcomes using qualitative 
information, and investigate others’ perceptions of the individual’s functioning. 
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Table 2.  
Functioning and QOL assessment instruments used in CBT for psychosis research 
 
Functioning outcome/measurement 
 
 
Trials 
 
Hospital readmissions/ relapse 
 
7 trials (Bechdolf et al., 2004; Bradshaw, 2000; 
Gumley et al., 2003; Haddock, Tarrier et al., 1999; 
Lewis et al., 2002; Pinto et al., 1999; Tarrier et al., 
1998) 
 
Meeting DSM-IV diagnosis of psychotic 
disorder 
 
1 trial (Morrison, French et al., 2004) 
Clinical Global Impression – Improvement 
(CGI) 
3 trials (Daniels, 1998; Durham et al., 2003; 
Temple & Ho, 2005a) 
 
Global Assessment of Functioning  
(GAF) 
4 trials (Daniels, 1998; Farhall & Cotton, 2002; 
Morrison, French et al., 2004; Startup et al., 2004) 
 
Global Assessment Scale (GAS) 
 
2 trials (Durham et al., 2003; Temple & Ho, 2005a) 
Groningen Social Disabilities Schedule (GSDS) 2 trials (Jenner & van de Willige, 2001; Wiersma 
et al., 2004) 
Quality of Life, Enjoyment & Satisfaction 
Questionnaire (Q-LES-Q, Endicott et al., 1993) 
 
2 trials (Halperin et al., 2000; Jackson et al., 2001) 
 
Quality of Life Scale (QLS) 2 trials (Daniels, 1998; Jackson et al., 1998) 
 
Robson Self Concept Questionnaire (SCQ) 2 trials (Hall & Tarrier, 2004; Kuipers et al., 1997) 
 
Role Functioning Scale  1 trial (Bradshaw, 2000) 
 
Rosenberg Self-esteem Scale  3 trials (Gledhill et al., 1998; Gumley et al., 2003; 
Wykes et al., 1999) 
 
Self-report Insight Scale  
 
1 trial (Wykes et al., 1999) 
Social Functioning Scale (SFS: Birchwood et al., 
1990) 
6 trials (Cather et al., 2005; Gumley et al., 2003; 
Hall & Tarrier, 2003; Kuipers et al., 1997; Startup 
et al., 2004; Tarrier, Beckett et al., 1993) 
 
World Health Organisation Quality of Life 
Schedule (WHOQoL) 
 
2 trials (Jenner & van de Willige, 2001; Wiersma 
et al., 2004) 
 
1.8 Conclusions 
This review has introduced the concept of schizophrenia, including symptoms, history 
of the disorder, course, outcome, prevalence, and incidence data. The history of treatments 
was outlined, including an overview of cognitive-behavioural therapy detailing its application 
and treatment format. Previous research on CBT for psychosis was reviewed, representing the 
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rising popularity and effectiveness of this intervention. An indication of government attitudes 
to the application of CBT for schizophrenia in the UK, USA, and Australia was also included 
in order to demonstrate its increasing acceptance and the support behind it. However, there 
are still a number of areas that could be improved upon in order to enhance the applicability 
of CBT. Future research should be concentrated on considering the effects of CBT on an 
individual’s functioning, both personal and interpersonal by implementing both quantitative 
and qualitative measures and having caregivers assess the individual. There is still a 
considerable amount of progress required in this field; however recent research outcomes and 
government attitudes towards CBT indicate a clear future for this intervention for 
schizophrenia. 
 
1.9 The current study 
The current research replicates and expands on previous investigations examining the 
utility of cognitive behavioural therapy for treatment-resistant psychotic symptoms. It 
investigated the efficacy of a cognitive-behavioural treatment program in a community mental 
health setting. Participants’ social functioning and quality of life outcomes were the main 
variables of interest. The responses of the participants and their caregivers regarding these 
variables were measured qualitatively and quantitatively. 
The current study implemented a six-week baseline design, where participants were 
assessed at baseline, re-assessed at pre-treatment, and then completed 15 weeks of CBT 
sessions and were assessed at post-treatment.  
While past researchers have briefly examined quality of life and social functioning 
outcomes with this population, the current study expands on this area by making them the 
focus of the study, utilising two separate measures to examine social functioning and quality 
of life in-depth. The current research also assesses both the participant’s view, and their 
caregiver’s view of social functioning. Additionally, while the majority of past research has 
focused on quantitative analysis of outcome data, the current study has included qualitative 
measures to provide further insight into the possible effects CBT can produce on functioning 
and quality of life outcomes. 
1.9.1 Research aims and hypotheses 
The primary aim of the study was to examine the effect of cognitive-behaviour therapy 
for people experiencing psychotic symptoms. In particular, this research examined the results 
of this therapy in terms of the individual’s social functioning, quality of life, and psychotic 
symptoms. Additionally, similar to past research, the current study assessed medication 
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levels, medication adherence, substance use, and co-morbid depression and anxiety levels. 
Participants’ data in these areas were analysed in order to compare the current results to past 
research, and to place key results into context.  
Hypothesis 1: It was predicted that participants receiving CBT would demonstrate a 
significant decrease in their psychotic symptoms after completion of the treatment. 
Specifically, it was expected that there would be a significant decrease in the severity, 
frequency, and intensity of psychotic symptoms. 
Hypothesis 2: It was predicted that participants would also demonstrate a significant 
improvement in social functioning and quality of life at the completion of treatment. 
Specifically, it was expected that there would be a significant increase in terms of social 
engagement, interpersonal behaviour, pro-social activities, recreation, independent living 
skills, and occupational skills. 
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Chapter 2: Method 
 
2.1 Participants 
 
2.1.1 Expected participant numbers 
A power analysis was performed to determine optimal sample size. To calculate this 
number, an appropriate effect size was required. An appropriate effect size was extrapolated 
from the average from two previous meta-analyses (Gould et al., 2001; Rector & Beck, 2001). 
An a priori power analysis was conducted, using an MSDOS program, G*Power (Faul, 
Edfelder, Lang, & Buchner, in press), with Cohen’s d = 0.98, p = 0.05, and power = 0.90. The 
results indicated that a sample size of 40 was required in order to obtain an effect size of this 
magnitude. As a comparable study conducted in the northern metropolitan area of Melbourne 
successfully recruited 92 participants (Farhall, Freeman et al., 2007) over a four-year period, 
it was predicted that the current study would obtain less than half these figures over a two 
year period.  
2.1.2 Achieved participant numbers 
Over an 18-month period during which participants were recruited and provided with 
therapy, nine individuals were successfully recruited and participated. Participants consisted 
of seven males and two females, with a mean age of 31.44 (SD = 8.71). Five individuals had a 
diagnosis of schizophrenia, two had a diagnosis of delusional disorder, one individual was 
diagnosed with schizoaffective disorder, and one had schizophreniform disorder; these 
diagnoses were all made by participants’ treating psychiatrists, and confirmed at baseline 
assessment using the Structured Clinical Interview for DSM (First, Spitzer, Gibbon, & 
Williams, 1996). The mean length of illness of 10.00 years (SD = 6.12 years). Greater 
information regarding participant flow, demographic information, and comparisons between 
participants and non-participants is included in the results section.  
2.1.3 Inclusion Criteria 
Four criteria used to determine eligibility for the current research, these criteria were 
based on the (1) age of the participant, (2) his or her ability to competently read, write, and 
speak English, (3) the presence of ongoing positive psychotic symptoms, and (4) comorbid 
drug and alcohol issues. 
 
1) All recruited participants were required to be over 18 years of age.  
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2) Based on case manager judgement, participants were required to be able to understand 
and discuss clinical issues. English language ability was required due to the nature of 
the therapy and the assessment measures participants completed. Intellectual ability 
was not an inclusion criteria, as previous research has suggested that CBT for 
psychosis can be implemented with individuals with a mild intellectual disability 
(Haddock et al., 2004). 
 
3)  Recruited participants were required to be experiencing positive psychotic symptoms 
that were considered to be interfering with functioning, after receiving both 
antipsychotic medication (typical or atypical) and routine clinical care. Psychotic 
symptoms were confirmed by several of the assessment instruments, including the 
Structured Clinical Interview for DSM-IV (SCID: First et al., 1996), and the 
PSYRATS (Haddock, McCarron, Tarrier, & Faragher, 1999). In Victorian public 
mental health centres, routine care is defined as multidisciplinary teams providing 
psychiatric, social, and financial support, psychoeducation, home visits, and crisis 
intervention. Case managers provide maintenance medication, community follow-up, 
access to community-based rehabilitation activities, and support for relatives.  
 
4) Participants whose use of alcohol or other substances occurred more frequently than 1-
5 times per week were not considered eligible. This criterion was defined by the 
implementation of the Texas Christian University (TCU) drug screen (Knight, 
Simpson, & Morey, 2002). 
 
2.1.4 Recruitment  
Participants were recruited through their case managers at an Area Mental Health 
Services (AMHS) in the Western Metropolitan area of Melbourne. Within this organisation, 
teams provide differential levels of support. These teams include a Community Care Team 
(CCT), Mobile Support and Treatment Services (MSTS), Community Care Unit (CCU), and 
an Adult Mental Health Rehabilitation Unit (AMHRU). In total, six participants were 
recruited from the CCT, two from the CCU, and one from AMHRU. 
Case managers from each team were informed of the study through brief group 
presentations of approximately 15 minutes. These presentations consisted of an outline of the 
project’s aims and methods, in order that case managers were better able to inform their 
clients about the project. At the end of each presentation, case managers were provided with a 
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flyer to keep, which outlined the project’s aims and methods and the researchers’ contact 
details. Following these presentations, case managers were then approached individually to 
discuss eligible participants. Group emails were also sent after several months, as a reminder 
of the study’s ongoing recruitment throughout the year, with a copy of the original flyer 
attached. Over the course of the study case managers were approached by researchers and 
reminded of the study. Researchers spent this time discussing the research aims and going 
through each case managers client list in the hope of identifying any new potential research 
participants.  
Clients were informed of the study by their case managers and then any interested 
individual met with the researchers to discuss the project and answer any questions they had. 
Furthermore, participants were given the opportunity to involve caregivers or family members 
in the project. Caregiver participation consisted of completing a brief questionnaire at three 
time points during the study, and caregivers were interviewed alone at the completion of the 
study by one of the two researchers. Participants were provided with an informed consent 
form for these individuals, and if they were interested in participating, this family member or 
caregiver then completed this and the relevant measure.  
 
2.2 Design 
Two researchers met with individuals referred to the study. In this initial meeting, the 
project’s aims were detailed, including the time commitments, assessment procedures, and 
expectations of participants. Participants who met inclusion criteria and agreed to participate 
then underwent an initial assessment, which consisted of approximately three sessions, or 
three hours in total. All assessment measures are detailed below in the Measures subsection.  
Following the initial assessment, each participant was then placed on a six-week 
baseline period, during which they continued to receive medication and routine care from the 
mental health services, and limited contact with the researchers. At the end of this six-week 
period, all participants were reassessed in a one-hour appointment. In the week following the 
assessment session, participants began the therapy sessions. Each therapy session lasted 
approximately 45 – 60 minutes, once per week, for a maximum of 15 weeks. During each 
session researchers kept track of each participant’s psychotic symptoms and the impact these 
were having on their lives.  
At the conclusion of the sessions, participants were re-assessed and interviewed for 
approximately 90 minutes. At these three assessment periods, caregivers were also provided 
with a questionnaire, and were also interviewed at the conclusion of the therapy sessions.  
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2.3 Measures
 
In order to determine which measures would be appropriate to use with this population 
a review of measures used in the research literature was conducted. The results of this review 
are presented in Table 3 below. More information regarding functioning and quality of life 
measures can be found in Table 2. Past research highlighted the importance of including a 
wide range of assessment instruments, not only covering psychotic symptoms, but also 
including mood and anxiety symptoms, medication adherence, and social and occupational 
functioning. The current measures were chosen on the basis of their relevance to, and past 
involvement in, CBT for psychosis research, their accessibility, and their efficiency.  
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Table 3.  
Assessment tools for psychotic and comorbid symptoms implemented in previous CBT for psychosis research 
 
Assessment tool 
  
 
Implemented in (number of studies and publication details):  
 
1. Psychotic symptoms 
 
 
 
Beliefs about Voices Questionnaire   
(BAVQ, Chadwick, Lees, & Birchwood, 2000) 
 
 
Three studies 
(Pinkham et al., 2004; Trower et al., 2004; Wykes et al., 1999) 
 
Brief Psychiatric Rating Scale  
(BPRS, Overall & Gorham, 1962) 
13 studies  
(Daniels, 1998; Haddock, Tarrier et al., 1999; Jackson et al., 1998; Kemp et al., 1996; 
Kuipers et al., 1997; Lecomte et al., 2003; Pinto et al., 1999; Startup et al., 2004; Tarrier, 
Beckett et al., 1993; Tarrier et al., 2001; Tarrier, Wittkowski et al., 1999; Tarrier et al., 
1998; Wykes et al., 1999) 
 
Comprehensive Psychiatric Rating Scale 
(CPRS, Asberg, Montgomery, Perris, Shalling, & Sedvall, 1978) 
 
Three studies  
(Sensky et al., 2000; Siddle et al., 1997; Turkington et al., 2002) 
Maudsley Assessment of Delusions Schedule 
(MADS, Garety & Hemsley, 1994) 
 
Two studies 
(Kuipers et al., 1997; O'Connor et al., 2007) 
Positive and Negative Syndrome Scale 
(PANSS, Kay, Fiszbein, & Opler, 1987) 
14 studies 
(Bechdolf et al., 2004; Cather et al., 2005; Daniels, 1998; Durham et al., 2003; Gumley 
et al., 2003; Hall & Tarrier, 2004; Lewis et al., 2002; Morrison, Renton et al., 2004; 
Pinkham et al., 2004; Rector et al., 2003; Trower et al., 2004; Valmaggia et al., 2005; 
Wiersma et al., 2004; Wragg & Whitehead, 2004) 
 
 
Present State Examination  
(PSE, Wing, 1980) 
 
 
Five studies  
(Kuipers et al., 1997; Tarrier, Barrowclough et al., 1999; Tarrier, Beckett et al., 1993; 
Tarrier et al., 2001; Tarrier et al., 1998) 
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Psychiatric Assessment Scale  
(PAS, Krawiecka, Goldberg, & Vaughn, 1977) 
 
 
Four studies  
(Drury et al., 1996a; Gledhill et al., 1998; Tarrier, Beckett et al., 1993; Tarrier et al., 
2001) 
 
Psychotic Symptom Rating Scale 
(PSYRATS, Haddock, McCarron et al., 1999) 
10 studies  
(Cather et al., 2005; Durham et al., 2003; Haddock, Tarrier et al., 1999; Lewis et al., 
2002; Morrison, Renton et al., 2004; Pinkham et al., 2004; Trower et al., 2004; 
Valmaggia et al., 2005; Warman et al., 2005; Wykes et al., 1999) 
 
Scale for Assessment of Negative Symptoms  
(SANS, Andreasen, 1983) 
 
8 studies  
(Jackson et al., 1998; Pinto et al., 1999; Sensky et al., 2000; Startup et al., 2004; Tarrier 
et al., 2001; Tarrier, Wittkowski et al., 1999; Temple & Ho, 2005a; Warman et al., 2005) 
 
Scale for the Assessment of Positive Symptoms  
(SAPS, Andreasen, 1984) 
 
Four studies 
(Pinto et al., 1999; Startup et al., 2004; Temple & Ho, 2005a; Warman et al., 2005) 
 
2. Mood 
 
 
 
Beck Anxiety Inventory  
(BAI, Beck, Epstein, Brown, & Steer, 1988) 
 
 
Four studies  
(Kuipers et al., 1997; O'Connor et al., 2007; Warman et al., 2005; Wykes et al., 1999) 
 
Beck Depression Inventory  
(BDI, Beck, Ward, Mendelson, Mock, & Erbaugh, 1961) 
 
Nine studies 
(Gledhill et al., 1998; Jackson et al., 1998; Kuipers et al., 1997; Morrison, Renton et al., 
2004; O'Connor et al., 2007; Rector et al., 2003; Tarrier et al., 2001; Warman et al., 
2005; Wykes et al., 1999) 
 
 
Beck Hopelessness Scale  
(BHS, Beck, Weissman, Lester, & Trexler, 1974) 
 
 
Four studies  
(Gledhill et al., 1998; Kuipers et al., 1997; Tarrier et al., 2001; Warman et al., 2005) 
 
Calgary Depression Scale for Schizophrenia 
(CDSS, Addington, Addington, & Schissel, 1990) 
 
 
One study  
(Trower et al., 2004) 
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Hospital Anxiety and Depression Scale  
(HADS, Zigmond & Snaith, 1983) 
 
 
 
Three studies  
(Chadwick, Sambrooke et al., 2000; Hall & Tarrier, 2004; Wragg & Whitehead, 2004) 
 
Montgomery-Asberg Depression Rating Scale  
(MADRS, Montgomery & Asberg, 1979) 
 
Two studies 
(Sensky et al., 2000; Turkington et al., 2002) 
 
3. Cognitive functioning 
 
 
 
National Adult Reading Test  
 (NART, Nelson, 1982) 
 
 
Two studies  
(Kemp et al., 1996; Kuipers et al., 1997) 
Wide Range Achievement Test 
(WRAT-3 Wilkinson, 1993) 
 
One study  
(Pinkham et al., 2004) 
 
4. Medication adherence 
  
 
 
Compliance measure for medication 
 
 
Two studies  
(Bechdolf et al., 2004; Tarrier et al., 2004) 
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Based on instruments utilised in previous literature, the measures for this study 
assessed eight domains: psychotic symptoms, cognitive functioning, co-occurring anxiety and 
depression, drug and alcohol use, medication adherence, and social functioning and quality of 
life (see Appendices A to H for scales not copyrighted). These areas were determined to be 
important, not only due to the impact they may have on the participants’ ability to engage in 
the therapy, including cognitive functioning, comorbid drug and alcohol use, but also the 
impact the study may have on these variables and hence participant outcomes, such as 
medication adherence, comorbid anxiety, and depression. All participants were provided with 
a Village Cinemas movie voucher or a Coles Myer voucher to the value of $15 as a 
reimbursement for their time spent completing assessment tasks. An overview of the time at 
which each measure was administered is provided in Table 4. Details and descriptions of 
these measures can be found in the following section.  
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Table 4.  
Assessment measures and their scheduled administration 
 
 
Measure 
 
 
Baseline 
 
Pre-Treatment 
 
Weekly 
 
Post-Treatment 
 
WAIS-III 
 
X 
   
SCID X    
BPRS  X X  X 
PSYRATS X X X X 
MARS X X  X 
TCU X X  X 
DASS-21 X X  X 
Q-LES-Q X X  X 
SFS-P X X  X 
SFS – C X X  X 
Social Desirability Scale    X 
Semi-structured 
interview 
   X 
 
2.3.1 Psychotic symptoms 
Participants’ psychotic symptoms were initially assessed with three scales: the SCID, 
the BPRS, and the PSYRATS. The former was used to confirm diagnosis and the latter two 
were implemented to provide fine detail regarding symptoms, and to track symptom change 
over time. Each of these measures will be described in turn.  
2.3.11 SCID-I-CV 
Participants’ symptoms were initially assessed and confirmed using the psychotic 
spectrum disorders section of the Structured Clinical Interview for DSM-IV (SCID: First et 
al., 1996). This semi-structured interview has been designed to assess and investigate the 
 54 
symptoms associated with mood, psychotic, substance use, and anxiety disorders as defined 
by the DSM-IV-TR (APA, 2000). The SCID-I has been demonstrated to have adequate 
reliability (Skre, Onstad, Torgersen, & Kringlen, 1991).  
2.3.12 BPRS  
The Brief Psychiatric Rating Scale (Overall & Gorham, 1962) provided a broader 
overview of participants’ psychotic symptoms and psychopathology. The scale was originally 
designed as a fast, efficient method for clinicians to assess treatment change (Overall & 
Gorham, 1962). It consists of 16 clinician-rated symptom constructs; each rated on a 7-point 
Likert scale (1 = not present, 7 = extremely severe) to provide a total score of 
psychopathology. Each item is rated based on both questioning and observation of the 
participant.  
2.3.13 PSYRATS 
To provide in-depth information in regards to the dimensions of psychotic symptoms, 
the Psychotic Symptom Rating Scale (PSYRATS: Haddock, McCarron et al., 1999) was 
administered. The PSYRATS consists of two subscales: Delusions (D) and Auditory 
Hallucinations (AH). Each subscale assesses the severity, frequency, intensity, conviction in, 
distress caused by, and controllability of these symptoms. The AH scale consists of 11 items, 
the D scale consists of six items. Each item is rated on a four-point scale, and either the total, 
or the totals of each subscale, are interpreted. This scale has been found to have excellent 
inter-rater reliability, good validity, and is sensitive to change (Haddock et al., 1999). The 
PSYRATS was implemented to track changes in psychotic symptoms over the course of the 
study.  
2.3.2 Cognitive functioning  
Participants’ cognitive functioning was assessed during the initial assessment sessions 
using the Wechsler Adult Intelligence Scale – Third Edition (WAIS-III: Wechsler, 1997). 
This instrument was used to provide a global measure of the participants’ intellectual and 
cognitive functioning. The WAIS-III contains 11 subtests, six in the Verbal Scale and five in 
the Performance Scale. The Verbal Scale IQ is a measure of verbal comprehension, whereas 
the Performance Scale IQ is a measure of perceptual organisation. These two scales are 
totalled to provide a full-scale score. This assessment took approximately 1.5 hours to 
complete. The WAIS-III has excellent reliability and validity and is the most widely used tool 
to assess cognitive functioning in normal and psychiatric populations (Wechsler, 1999).  
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2.3.3 Anxiety and Depression 
The short form of the Depression Anxiety Stress Scales (DASS, Lovibond & 
Lovibond, 1995) is a self-report measure which consists of 21 items each evaluated on a 4-
point Likert scale (0 = did not apply to me at all, 3 = applied to me very much, or most of the 
time). Each subscale score is calculated, doubled, and then compared to symptom severity 
categories (see Table 5 below). This instrument takes approximately 10 minutes to complete; 
it has been shown to have excellent reliability and validity (Brown, Chorpita, Korotitsch, & 
Barlow, 1997). The DASS-21 was used to track changes in depression, anxiety, and stress 
symptoms over the course of the study.  
 
Table 5.  
Severity categories for the DASS-21. 
 
Category 
 
Depression 
 
Anxiety 
 
Stress 
 
Normal 
 
0 – 9 
 
0 – 7 
 
0 – 14 
Mild 10 – 13 8 – 9 15 – 18 
Moderate 14 – 20 10 – 14 19 – 25 
Severe 21 – 27 15 – 19 26 – 33 
Extremely Severe 28+ 20+ 34+ 
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2.3.4 Drug and alcohol use 
A condensed version of the TCU Drug Screen (Knight et al., 2002) required 
participants to rate their drug and alcohol use over the previous three months. The first 9 items 
required a yes or no response to amounts of drugs used, and the potential effects of these 
drugs. Participants were then asked to rate the drugs they had used the most, and which had 
caused the most problems. This measure has been shown to have good reliability and validity 
(Knight et al., 2002). The TCU Drug Screen was implemented to determine eligibility for the 
study and to measure any changes in drug or alcohol use over the course of the project.  
2.3.5 Medication Adherence 
Enquiries were made into each participant’s medication type and amount. When 
participants were unsure of this information it was checked with their case manager. 
Medication type and dosage was recorded at baseline, pre-treatment, and post-treatment. 
Compliance with medication was assessed using the Medication Adherence Rating Scale 
(MARS) for the psychoses (Thompson, Kulkarni, & Sergejew, 2000). This inventory requires 
the participant to respond yes or no to 10 statements about medication adherence and the 
effects of medication, with higher scores indicating greater adherence to medication. The 
MARS has been found to be a valid and reliable measure of compliancy for psychoactive 
medications (Thompson et al., 2000).  
2.36 Social functioning and quality of life 
2.3.61 SFS: P 
The Social Functioning Scale – participant (SFS: P) consists of seven subscales 
addressing respondents’ Social Engagement or Withdrawal (W/E), Interpersonal 
Communication (Inter), Independence-Performance (IP), Recreation (R), Prosocial activities 
(P), Independence-Competence (IC), and Occupation or Employment (E/O). Several 
subscales require participants to rate their activities on a 4-point scale (0 = never, 3 = often). 
The scores for each subscale are then totalled and converted into a scaled score, which creates 
a social functioning profile for each individual (Birchwood et al., 1990).  The SFS was 
specifically designed to assess the strengths and weaknesses in areas of social functioning of 
individuals with schizophrenia in order to evaluate family interventions (Birchwood et al., 
1990). Birchwood and colleagues (1990) have indicated that the SFS demonstrates good 
reliability, validity and sensitivity. 
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2.3.62 SFS-C 
The caregiver version of the SFS (SFS: C) requires the caregiver to rate the participant 
on all areas excluding the occupation/employment subscale. Scores on the caregiver version 
are then translated into a scaled score, which can then be compared to the participant-rated 
version.  
2.3.63 Q-LES-Q 
The Quality of Life, Enjoyment, and Satisfaction Questionnaire (Q-LES-Q, Endicott 
et al., 1993) has been designed to measure an individual’s functioning in eight areas, 
including physical health/activities, social relations, feelings, work, household duties, 
school/course work, leisure time activities, and general activities. Each subscale consists of a 
number of statements; respondents state their level of agreement to each using a 5-point scale 
(1 = not at all or never, 5 = frequently or all the time). The sum of each subscale is then 
computed into a percentage of the maximum score possible, with higher scores indicating 
greater enjoyment and satisfaction. Endicott and colleagues (1993) have demonstrated that the 
Q-LES-Q has sound psychometric characteristics.  
There was a significant amount of overlap between the SFS: P and the Q-LES-Q on 
the independence-performance and household duties subscales, and the physical 
health/activities subscale was deemed to be not relevant to this population. Therefore, for 
brevity and ease of completion, the entire SFS: P was combined with six of the subsections of 
the Q-LES-Q: Social Relations (SR), Feelings (F), Leisure Time Activities (LTA), Work (W), 
School/Coursework (S/C), and General Activities (GA). Ritsner and colleagues have 
previously demonstrated the validity of a shortened version of the Q-LES-Q (2005). 
2.3.7 Semi-structured interview 
In order to provide qualitative data regarding social functioning and quality of life 
outcomes a semi-structured interview was conducted with each participant and a caregiver at 
the post-treatment assessment session. Interviews took between 10 and 40 minutes. Each 
participant and caregiver was interviewed alone by one of the two researchers, so that several 
participants were interviewed by the clinician who completed the therapy with them, and 
several participants were interviewed by a clinician they had met only during the initial 
recruitment and assessment phases. Participant interviews included a number of questions 
regarding the person’s experiences of the therapy and changes they had noticed in themselves, 
or their symptoms, as a result of participation in the project. Similar questions regarding 
changes in the participants’ functioning were asked of the caregiver. These questions were 
based on a previous study examining qualitative outcomes of CBT for psychosis (McGowan 
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et al., 2005; Messari & Hallam, 2003), and mindfulness training for distressing psychosis 
(Abba, Chadwick, & Stevenson, 2008), and were consistent with guidelines of how to 
conduct qualitative interviews with individuals who have experienced psychosis (p.69, 
Davidson, 2003). Specifically, Davidson’s (2003) list of “don’t” items, including avoiding 
closed-ended, “why”, vague, general or abstract, complex or compound questions were all 
avoided, and the researchers avoided interrupting or showing impatience when interviewing 
participants. Davidson’s recommendations were also followed. These included: asking open-
ended, specific, detailed, “how” questions, asking questions one at a time, asking questions 
that imply a temporal framework, communicating respect and interest, and portraying a 
relaxed posture. All responses were followed up with a summary by the researcher and, if 
required, were further clarified with questions from the clinician. As these interviews were 
conducted by the researcher implementing the treatment program, a shortened version of the 
Marlowe-Crowne Social Desirability Scale (Crowne & Marlowe, 1960; Marlowe & Crowne, 
1961) was administered to assess possible social-desirability responding by the participant. 
This scale consists of ten True/False statements; higher scores on this measure indicate greater 
social desirability responding. Each interview was digitally recorded and then transcribed.  
 
2.4 Procedure  
2.4.1 Treatment 
Treatment consisted of 15 weekly sessions of CBT for psychosis, lasting 
approximately 45 – 60 minutes per session. The therapy was based on the CBT manual 
designed specifically for psychotic symptoms, created by Fowler, Garety, and Kuipers (1995). 
Therapy also comprised components of the manuals by Chadwick, Birchwood, and Trower 
(1996) and Kingdon and Turkingdon (1994). The CBT program was structured to include a 
number of elements, progressing through a schedule of aims and important targets, defined by 
both the therapist and participant. Due to the varying nature of symptom presentations it was 
not possible to create a scripted treatment manual to be implemented with all participants. 
However, there were a number of core elements that featured with all participants. In sessions, 
researchers first established rapport and engagement with the client before discussing the 
symptoms that were currently distressing participants. Over the 15 sessions, researchers and 
participants worked collaboratively using a number of strategies, including normalising 
symptoms, generating alternative activities or thoughts, self-regulation, or correcting or 
challenging beliefs to reduce the distress associated with the symptoms, and reduce their 
interference with the individual’s social and occupational functioning. In the final sessions 
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participants were taught strategies to prevent relapse of symptoms and continue current 
progress. The course of therapy was separated into four main areas: rapport and engagement, 
addressing positive psychotic symptoms interfering with functioning, helping new beliefs and 
strategies stick, and relapse prevention. An overview of these main areas and their correlation 
with session numbers can be seen in Table 6.
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Table 6.  
An overview of CBT session plans implemented in the current project. 
 
Session number 
 
Content of sessions 
1 – 3 Rapport and engagement  
Discussion and exploration of current symptoms and how they affect functioning. Create personal timeline to develop a shared model of psychosis. 
4 – 11 Address positive psychotic symptoms that are interfering with functioning.   
Delusions: discuss evidence for belief, advantages and disadvantages of belief, consider alternative explanations, discuss misinterpretations and 
alternatives, create behavioural experiments, discuss changes in beliefs and consequences, highlight experiences that do not conform to belief.  
Auditory hallucinations: Enhance natural coping strategies (including distraction, subvocalisation, auditory competition), behavioural experiments, 
including bringing on voice and reducing it.  
12 – 13 Help new beliefs and strategies stick 
Participant acts on new beliefs or uses new strategies, recalls or explains them, utilises flash cards, experience approval from others for new beliefs 
and strategies.  
14 – 15 Relapse prevention  
Review model of illness, work done over course of therapy, helpful strategies. Encourage continued use of strategies and goal planning. 
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2.4.2 Treatment integrity 
As the therapy was delivered by two clinicians (one registered psychologist and one 
provisional psychologist), several efforts were made to maintain the integrity of the treatment. 
In particular, both clinicians reviewed past treatment manuals (Chadwick et al., 1996; Fowler 
et al., 1995) and then jointly made a list of essential points to cover in the sessions. The 
session guidelines outlined above were then created and these were repeatedly referred back 
to during the course of therapy. Clinicians consistently met each week to discuss any issues 
arising from the sessions, and to relate the stage of therapy they had reached.  
 
2.5 Data analysis 
2.5.1 Quantitative data analysis 
Data was examined using an SPSS statistical package for windows. Initial 
examination of the data included using descriptive analyses. The demographic variables of all 
individuals referred to the project were examined to describe this particular sample.  
Comparisons of participants with non-participants were then made based on demographic 
information to confirm that there were no significant differences between these two groups.  
As there were a small number of individuals who dropped out after an initial 
assessment, their data was compared to participants’ means and standard deviations on 
demographic variables. Participant baseline data was then presented. This demographic 
participant information was compared to the information provided in previous studies, to 
determine whether there were any significant differences between current and past 
participants.   
Further analysis was conducted using repeated measures ANOVAs, with time 
(baseline, pre, and post) as the within subjects variable for psychotic symptoms, quality of 
life, (including social relations, feelings, leisure time activities, and general activities), the 
MARS, participants’ medication dosages, and the DASS. Post-hoc analyses in the form of 
trend or profile analysis were used to examine change over time. As there were three time 
periods, only linear and quadratic trends could be examined. Pairwise comparisons were then 
conducted to assess change from baseline to pre-intervention, from pre-intervention to post-
intervention, and from baseline to post-intervention. Bonferroni corrections for multiple 
comparisons were made for these comparisons.  
Individuals’ ratings on the social functioning scale were then compared to the ratings 
provided by caregivers using two-way repeated measures ANOVAs with time (baseline, pre- 
and pos-treatment) and rater (participant and caregiver) as the within subjects variables. Trend 
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analyses and pairwise comparisons were also carried out. These ANOVAs were completed to 
determine whether there were any significant differences between these two groups on this 
measure over time.  
In a replication of past research, weekly data for psychotic symptoms were graphed on 
an individual basis to map changes in this area across time (Morrison, 2002; Wragg & 
Whitehead, 2004).  
The criteria implemented to determine whether changes in participants’ symptoms and 
functioning were clinically significant were determined using criteria from past research. The 
criteria implemented in the current study were as follows. A 20% reduction in symptoms 
indicated a ‘worthwhile improvement’ (Cather et al., 2005; Rector et al., 2003), and a 50% 
reduction in symptoms represented an ‘important clinical change’ (Durham et al., 2003; 
Sensky et al., 2000; Tarrier, Beckett et al., 1993; Warman et al., 2005). Thus, clinical 
significance in this study was determined by calculating 20% and 50% of the mean of 
participants’ baseline scores. Then, the difference between each participant’s score at baseline 
and post-treatment was calculated. If this number was larger than the 20% or 50% criteria, it 
was deemed to be significant. 
2.5.2 Qualitative data analysis 
In a replication of past research, a grounded theory methodology was implemented to 
code the transcripts of interviews in this study (McGowan et al., 2005). Therefore, small units 
of data were amassed into larger categories, providing a thematic analysis of the data.
 These broader themes or categories were then divided into sub-categories and clarified 
by sample quotes (Ambert, Adler, Adler, & Detzner, 1995). 
Similar to past research (Messari & Hallam, 2003), and according to qualitative 
research guidelines (Miles & Huberman, 1994; Pidgeon & Henwood, 1997), the data gathered 
was transcribed and coded by reading and re-reading of the interview material. Passages, 
words, and phrases were all marked to identify initial themes. This data analysis was all 
completed by the researcher, who consulted with an expert in qualitative data analysis in 
regards to emerging themes and interpretations made (Messari & Hallam, 2003). Using these 
methods was an attempt to ensure reliability.  
Validity was determined by comparing the results of the current study to past research 
implementing qualitative methods of analysing CBT for psychosis research (Chadwick et al., 
2003; Key et al., 2003; McGowan et al., 2005; Messari & Hallam, 2003). Participants’ 
responses to the interview questions were compared to their results on the self-report 
measures: the Social Functioning Scale (Birchwood et al., 1990) and the Quality of Life, 
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Enjoyment, and Satisfaction Questionnaire (Endicott et al., 1993) to ensure validity. 
Additionally, participants’ responses were compared and contrasted to those of their 
caregivers to verify the validity of the results. These methods of comparing the current data to 
past data and theoretical knowledge have been recommended to enhance an analysis and 
provide distance from the data (Pidgeon & Henwood, 1997).  
 
2.6 Ethical considerations 
The project was approved by the Melbourne Health Ethics Committee and RMIT 
University Ethics Committee in 2006 (Application code: MHREC 2006.11). Before 
commencing the study, each participant was provided with a participant information and 
consent document, which was verbally explained to them. Each participant read through the 
document before signing it and keeping a copy. This document outlines the aims and 
objectives of the study, background information, possible risks and benefits, privacy and 
confidentiality, how the results of the study would be presented, and the reimbursement 
provided for the assessment sessions. Participants were advised that if at any point they were 
dissatisfied with how the project was proceeding, or were uncomfortable with the treatment, 
they were able to contact the manager at the AMHS, a member from the Melbourne Health, or 
RMIT University Ethics Committees.  
Participants were advised that involving a caregiver in the study was supplementary, 
and that their involvement in the project was not dependent on a caregiver or family member 
being involved. Participants were informed that their participation in the study was voluntary 
and would not interfere with or compromise the services they received at the AMHS. They 
could withdraw, or withdraw any unprocessed data at any point in time. 
To ensure participant anonymity, each participant was identified by a research 
number. Participant data was stored at the AMHS in a locked filing cabinet and password 
protected files with access only available to the researchers involved in the project. Project 
data will be kept for a minimum of 5 years, after which it will be securely disposed of using 
services in place at the AMHS.  
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Chapter 3. Results 
 
3.1 Preparation of data for statistical analysis
 
Results were analysed using an SPSS 13.0 statistical package. There was no missing 
data from the clinician-rated scales (BPRS and PSYRATS). Any missing data from the 
questionnaires completed by participants and their caregivers (the MARS, TCU, DASS, SFS-
Q-LES-Q, and SFS-C) underwent Missing Values Analysis in SPSS, a procedure 
recommended for identifying and quantifying missing data (Tabachnick & Fidell, 2007). 
There were a total of 23 instances of missing data from the DASS, SFS-Q-LES-Q, and SFS-
C. The data were found to be randomly distributed. Missing data was estimated using the 
Expectation-Maximisation method. Missing data was replaced with estimated values before 
any analysis was conducted. Due to the small sample size, all statistical results in the 
following sections must be interpreted with caution as several of these results may be more 
likely due to chance than any actual difference in the data. 
Additionally, one caregiver did not complete an SFS:C at baseline, one caregiver did 
not complete the Prosocial component of the SFS:C at baseline, and one participant did not 
complete the Employment/Occupation section of the SFS:P at post-treatment. These sections 
were therefore not included in data analysis. 
 
3.2 Referral flow 
3.2.1 Referrals 
Despite consistent and continual recruitment processes for a period of 18 months, of 
the entire AMHS clients, a total of 27 individuals were considered suitable and approached by 
their case manager for referral to the project. In this group of 27 individuals, 17 (63%) were 
male. Ages ranged between 21 and 63 years of age (M = 33.81, SD = 10.58). Referrals to the 
project had a mean length of illness of 6.91 years (SD = 5.78, range: 6 months to 20 years), 
and varying diagnoses, including schizophrenia (51.9%), schizoaffective disorder (22.2%), 
delusional disorder (14.8%), and psychotic disorder NOS, depression with psychotic features, 
and schizophreniform disorder each accounting for 3.7% of diagnoses respectively. Of the 
total number of referrals, 26 individuals were receiving atypical antipsychotics, except one 
who was receiving flupenthixol decanoate, a typical antipsychotic. All antipsychotic 
medication doses were converted to mean chlorpromazine equivalents using equivalence 
tables (Atkins, Burgess, Bottomley, & Riccio, 1997; Bazire, 2005; Bezchlibnyk-Butler & 
Jeffries, 2005; Woods, 2003).  Individuals referred to the project were receiving a mean 
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dosage of 546.85mg (SD = 444.93) of antipsychotic medication, which is within the typically 
recommended therapeutic range (MIMS Australia, 2006).  
Of the 27 referrals, 16 individuals declined to participate or were considered 
unsuitable for the research. Of these 16 individuals, three were inappropriately referred as 
they were in remission from their positive psychotic symptoms, six were considered too 
unwell or did not possess sufficient insight into their illness, one declined due to work 
commitments, one was receiving psychological assistance privately, one had insufficient 
English to be able to participate, and four were not attending their appointments or had been 
discharged and were therefore considered inappropriate (see Figure 1). 
Thus, eleven individuals agreed to participate and were considered appropriate for the 
project. However, following the initial baseline assessment, one female participant was 
considered to be recovering sufficiently and did not require additional psychological input, 
and one male participant became too unwell and discontinued his participation in the study, 
and thus nine participants completed the treatment program (see Figure 1).  
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Figure 1. Flow of referrals and participants through the project. 
 
Agreed to participate 
and appropriate 
n = 11 (40.7%) 
Ineligible or inappropriate 
n = 16 (59.3%) 
Participated in 
treatment 
n = 9 (33.3%) 
Discontinued 
n = 2 (7%) 
Completed 15 
sessions 
n  = 7 (25.9%) 
Completed <15 
sessions 
n = 2 (7.4%) 
Referrals to research 
n  = 27 (100%) 
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3.2.2 Attendance and dropout 
Every effort was made to ensure that each participant received the maximum number 
of sessions possible. This was accomplished by providing participants with appointment 
cards, offering reminder telephone calls of the appointment time, scheduling appointment 
times to coincide with case manager and physician appointments and, when participants were 
unable to attend, offering make-up appointment times within the week, or for the following 
week. As a result of sporadic attendance, the program took, on average, approximately 3 – 4 
weeks’ longer to complete than originally scheduled. 
One participant discontinued attendance after 10 sessions, and one discontinued after 
13 sessions. All other participants completed the total number of sessions (see Figure 1). 
3.2.3 Comparison of participants to non-participants 
The 11 individuals who agreed to participate in the study were compared on a number 
of demographic variables to those who did not agree to participate, or were considered 
ineligible for the study. There was no significant difference in terms of sex between 
participants and non-participants (p = .45, Fisher’s Exact Test). There were no significant 
differences between the ages of accepted individuals (M = 31.73, SD = 9.23) and non-
participants (M = 35.25, SD = 11.47), t (25) = -0.85, p = .41. There was no significant 
difference between the length of illness reported by individuals accepted into the research (M  
= 9.36, SD = 5.87) in comparison to non-participants (M = 5.22, SD = 5.24), t (25) = 1.92, p = 
.07. There were no significant differences in antipsychotic medication levels between 
accepted individuals (M = 670.45, SD = 427.20) and non-participants (M = 461.88, SD = 
450.07), t (25) = 1.21, p = .24. Therefore, there were no significant differences between 
current and past participants on a number of demographic variables. 
3.2.4 Comparison of participants to dropouts 
Due to the small number of participants who dropped out of the study after baseline 
assessment, it was inappropriate to perform statistical analyses comparing their data to those 
who completed the study. However, by comparing the mean of the two dropouts’ data (one 
male, one female) to the mean of the participants’ data (n = 9), it appears that, in terms of 
demographic data, the two dropouts were within one standard deviation of the participants’ 
data, including age, length of illness, and medication levels (see Table 7 below), suggesting 
that there were no differences between these two individuals and participants in terms of 
demographic information.  
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Table 7.  
Comparison of participants’ and dropouts’ demographic information.  
  
Participants 
M (SD) 
 
Drop-outs 
M 
 
 
Age 
 
 
31.44 (8.71) 
 
33 
Length of illness 
 
10.00 (6.12) 6.5 
Medication levels 
 
600.00 (404.50) 650 
 
 
 
3.3 Baseline data
 
3.3.1 Psychotic symptoms 
The SCID-I-CV (First et al., 1996) was used to confirm diagnoses of all participants. 
Five individuals had a diagnosis of schizophrenia, one of schizophreniform disorder, two had 
delusional disorder, and one had schizoaffective disorder. At baseline, three participants were 
experiencing auditory hallucinations and delusional beliefs, four had delusional beliefs 
without auditory hallucinations, and two had auditory hallucinations with no delusional 
beliefs. All participants experiencing auditory hallucinations reported that the majority of 
these were derogatory voices. In regards to delusional beliefs, two participants had grandiose 
delusions, three participants had religious delusions, two participants had persecutory 
delusions, and one participant reported thought broadcasting. Baseline scores on the BPRS 
(Overall & Gorham, 1962) produced a mean of 40.44 (SD = 10.55). For the PSYRATS 
(Haddock, McCarron et al., 1999), participants achieved a mean score on the auditory 
hallucinations scale (AH) of 14.00 (SD = 14.71) and a mean score of 10.00 (SD = 6.56) on the 
Delusions scale (D).  
3.3.2 Cognitive functioning 
Eight participants were administered the WAIS-III. Results of the WAIS-III 
(Wechsler, 1997) indicated that participants had a mean full-scale IQ score of 84.88 (SD = 
17.30), which is in the low average range. Participants had a mean Performance Scale IQ 
score of 85.13 (SD = 16.92), and a mean Verbal Scale IQ score of 86.38 (SD = 15.24).  
One participant had a mild Intellectual Disability. One participant had received a full 
cognitive assessment within two years of the commencement of the study, and it was 
 69 
therefore deemed inappropriate to re-assess him using the WAIS-III. While a report of his 
results was available, the raw scores could not be obtained. However, the report revealed that 
his cognitive ability fell within the low average range, and was therefore similar to that of the 
mean obtained for the other eight participants.   
3.3.3 Anxiety and depression symptoms 
The 21-item version of the DASS (Lovibond & Lovibond, 1995) was used to measure 
participants’ depression, anxiety, and stress levels. Participants’ scores on the Depression 
subscale produced a mean of 10.22 (SD = 7.64, range = 0 – 24), which is indicative of mild 
depression. The mean Anxiety subscale score was 10.22 (SD = 6.82, range = 2 - 20), 
indicative of moderate anxiety. The mean Stress subscale score was 13.17 (SD = 10.00, range 
= 0 - 30), which is in the normal range. These initial ratings suggest that the participants were 
not greatly emotionally distressed.  
3.3.4 Drug and Alcohol Use 
Three of the nine participants admitted to substance use. Two were using marijuana 
between 1 – 5 times per week over the course of the study, one indicated that he was not at all 
affected by it, the other was slightly affected by the marijuana. One participant reported using 
‘ecstasy’ (MDMA) a few times in the three months prior to the study commencing, and 
during the study, reporting that he was moderately affected by this substance. All other 
participants reported no substance use over the course of the study.  
3.3.5 Medication adherence 
At baseline, participants were prescribed between one and seven medications, with 
two of the participants prescribed two antipsychotic medications. Eight of the nine 
participants were receiving atypical antipsychotic medication, including clozapine (2), 
quetiapine (2), amisulpride (1), risperidone (2), and aripiprazole (1). One participant initially 
refused to take antipsychotic medication, although this individual reported compliance with a 
prescribed antidepressant. From session 5 onwards, this participant was prescribed an 
antipsychotic medication (aripiprazole, and then quetiapine) in addition to the antidepressant. 
Medication levels were converted to mean chlorpromazine equivalents using equivalence 
tables (Atkins et al., 1997; Bazire, 2005; Bezchlibnyk-Butler & Jeffries, 2005; Woods, 2003). 
Participants were receiving a mean level of medication of 675.00mg (SD = 460.84) (CPZ 
equivalent), which is within the typically recommended therapeutic range (MIMS Australia, 
2006). During the baseline period, one participant’s medication was changed from quetiapine 
to clozapine, and one participant ceased taking his medication.  
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Participants’ scores on the MARS (Thompson et al., 2000) at baseline indicated a 
mean of  7.44 (SD = 1.88) representing adequate medication adherence. 
3.3.6 Social Functioning  
Five of the participants were recruited from the CCT, four of these were living with 
family and one was living alone; one participant was recruited from AMHRU and spent time 
at home on weekends, and two were recruited from the CCU, one went home on weekends 
and the other had very limited contact with family members. None of the participants had 
been married, and none were currently partnered. 
All participants agreed to have a caregiver involved in the study. Caregivers consisted 
of family members, or case managers. Case managers were utilised in situations where it was 
perceived that they spent more time with participants, and were therefore better informers, 
when compared to family members. Thus, three participants had case managers as their 
nominated caregiver. One participant’s case manager left the service over the course of the 
study, and was replaced by another individual; therefore two different individuals completed 
the SFS at pre- and post-treatment periods for this participant. All participants and their 
nominated caregiver completed the SFS: P and SFS: C, except one caregiver, who did not 
complete the SFS: C at baseline. Participants’ and caregivers’ scaled score results can be seen 
in Table 8. The data in this table suggests that for most subscales, participants’ and 
caregivers’ scores were very similar, and for some subscales, such as the Interpersonal 
Communication subscale, participants were reporting better functioning than caregivers 
reported for participants.  
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Table 8.  
Participants’ and caregivers’ ratings on the SFS-P and SFS-C at baseline. 
 
SFS Scale 
 
Participant ratings 
M (SD) 
 
Caregiver ratings 
M (SD) 
 
Withdrawal/Engagement 
 
103.50 (13.28) 
 
95.38 (10.21) 
Interpersonal Communication 127.44 (21.18) 112.63 (17.61) 
Independence Performance 108.22 (16.88) 99.75 (13.48) 
Independence Competence 104.33 (13.24) 103.06 (6.95) 
Recreation 104.56 (23.00) 106.94 (15.39) 
Prosocial Activities 104.33 (20.88) 105.50 (12.76) 
Employment/Occupation 99.78 (14.06) N/A 
 
 
3.3.7 Quality of life 
All participants completed the Q-LES-Q. At the commencement of the study, two of 
the participants were working part-time and none were studying. Therefore, the 
School/Courses and the Work sections of the Q-LES-Q were not completed for the majority 
of the participants. Data from these two subscales has therefore not been included in this 
thesis. The percentage of the maximum score possible for the remaining subscales is included 
in Table 9. The data in this table indicates that participants were reporting quality of life in 
each area at approximately 70% (out of a possible 100%), with participants reporting the 
lowest quality of life was experienced during leisure time activities. 
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Table 9. 
Participants’ baseline results on the Q-LES-Q. 
 
Q-LES-Q Scale 
 
Percentage maximum 
Mean (SD) 
 
 
Social Relations 
 
 
70.56 (25.08) 
Feelings 
 
70.22 (19.42) 
Leisure Time Activity 
 
57.67 (32.92) 
General Activities 
 
69.11 (18.31) 
 
3.4 Comparison of current participants to past research participants 
It was important to establish whether there were any significant differences between 
the current research participants, and individuals who have completed similar CBT for 
psychosis research trials. Therefore, comparisons were made between these two groups in 
terms of demographic information, symptoms, and functioning. While the design of the 
current study does not replicate that of previous studies, it is consistent with several seminal 
studies in terms of setting (Farhall & Cotton, 2002; Morrison, Renton et al., 2004), length of 
treatment (Cather et al., 2005), therapeutic aims (Sensky et al., 2000), and variables examined 
(Kuipers et al., 1997). A series of single-sample t-tests were conducted comparing the current 
research to past studies in regards to age, length of illness, and medication levels (Morrison, 
Renton et al., 2004), cognitive functioning (Kuipers et al., 1997), and the presence of 
psychotic symptoms (Cather et al., 2005). The results of these t-tests are presented in Table 
10, indicating that there were no significant differences between the current and past research 
participants on all variables except cognitive functioning, where participants in past research 
appeared to have significantly greater cognitive functioning when compared to current 
participants. 
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Table 10.  
Single-sample t-test comparisons of current participants to past CBT for psychosis research 
participants.  
  
Variable  
 
Current research 
M (SD) 
 
 
Past research 
M (SD) 
 
t (8) 
 
 
Age 
 
 
31.44 (8.71) 
 
36.8 (10.3)21 
 
-1.85  
Length of illness 
 
10.00 (6.12) 9.7 (6.7)22 0.15  
Medication dosage  
(CPZ equivalent) 
675.00 (460.84) 376.7 (380.6)23 1.94 
Cognitive functioning 
 
84.88 (17.30) 99.824 -2.44*  
Auditory hallucinations 
 
14.00 (14.71) 21.4 (12.5)25 -1.51  
Delusions 
 
10.00 (6.56) 11.9 (5.9)26 -0.87  
*p = .045, df = 7 
Note: When the results of the participant with the intellectual disability are removed from this analysis, there is 
no significant difference between the current sample’s results (M = 89.14, SD = 13.38), and that of past research, 
t (6) = -2.11, p = .08. 
 
In addition to comparisons on demographic information, it was also possible to 
compare current and past participants in terms of their social functioning. Gumley and 
colleagues (2003) provided their participants’ mean raw scores on the SFS subscales at 
baseline. A series of single-sample t-tests were thus conducted comparing the current 
participants’ raw scores on these subscales to the raw scores taken in past research. The 
results of these t-tests are presented in Table 11, indicating that there were no significant 
differences between past and current participants on the SFS subscales. 
 
                                                 
21
 Morrison, Renton et al., 2004 
22
 Morrison, Renton et al., 2004 
23
 Morrison, Renton et al., 2004 
24
 Kuipers et al., 1997  
25
 Cather et al., 2005 
26
 Cather et al., 2005 
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Table 11. 
Single sample t-tests comparing past and current research participants on the SFS subscales.  
 
SFS subscale 
 
Current research 
M (SD) 
 
 
Past research* 
M (SD) 
 
t (8) 
 
Withdrawal 
 
10.22 (3.38) 
 
9.3 (2.5) 
 
0.82 
 
Interpersonal 
Communication 
 
 
7.78 (1.72) 
 
6.5 (1.9) 
 
 
2.23 
Independence 
Performance 
 
28.78 (8.76) 26.1 (6.7) 0.92 
Independence 
Competence 
 
33.00 (4.92) 34.9 (3.9) -1.16 
Recreation 
 
17.56 (9.41) 14.7 (6.1) 0.91 
Prosocial 
 
16.00 (13.93) 12.6 (8.3) 0.73 
Employment 
 
4.11 (3.76) 3.0 (3.0) 0.89 
* Gumley et al., 2003 
 
3.5 Treatment outcomes
 
3.5.1. Repeated measures ANOVAs for psychotic symptoms, co-morbid depression and 
anxiety symptoms, medication levels and adherence, and quality of life. 
A series of one-way repeated measures ANOVAs were conducted to compare 
participants’ results at baseline, pre-treatment, and post-treatment for the BPRS, PSYRATS, 
DASS, medication levels, MARS, and Q-LES-Q. As the Employment/Occupation subscale of 
the SFS was only rated by participants, it was included in the repeated measures analyses. The 
descriptive data for these analyses are provided in Table 12. This descriptive data indicates 
that participants’ results on all measures appeared to vary over the three assessment periods, 
with several scales indicating symptoms were reducing over time. 
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Table 12.  
Descriptive statistics for baseline, pre-intervention, and post-intervention measures. 
 
Area 
 
 
Measure 
 
       Baseline 
 
Pre-intervention 
 
Post-intervention 
   
M 
 
 
SD 
  
M 
 
SD 
  
M 
 
SD 
BPRS 
 
40.44 10.55  41.22 13.14  37.78 11.42 
PSYRATS: AH 
 
14.00 14.71  8.67 13.78  8.11 12.47 
Psychopathology 
and psychotic 
symptoms 
PSYRATS: D 
 
10.00 6.56  14.11 5.60  6.88 5.25 
Depression 
 
10.22 7.64  12.22 13.02  9.11 10.15 
Anxiety 
 
10.22 6.82  10.89 6.17  6.67 6.32 
Anxiety and 
Depression 
Stress 
 
13.17 10.00  12.67 6.00  9.33 9.23 
Medication 
dosage 
 
CPZ equivalent 
 
675.00 460.84  582.44 495.72  571.33 481.06 
Medication 
compliance 
 
MARS 7.44 1.88  6.78 2.99  7.89 1.96 
Functioning 
 
SFS: E/O 99.78 14.06  99.78 14.99  102.81 12.50 
SR27 
 
70.56 25.08  66.44 23.54  59.67 23.02 
F28 
 
70.22 19.42  66.00 18.68  67.78 20.81 
LTA29 
 
57.67 32.92  53.78 32.44  43.00 29.52 
Quality of Life 
GA30 
 
69.11 18.31  62.56 25.61  58.56 24.65 
 
                                                 
27
 SR = Social Relations 
28
 F = Feelings 
29
 LTA = Leisure Time Activity 
30
 GA = General Activities 
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The results of the overall repeated measures ANOVAs for each scale are represented 
in Table 13. These results indicated that the PSYRATS: Delusions scale showed significant 
change over time, with the PSYRATS: Auditory Hallucinations scale approaching 
significance for change over time.  
 
Table 13.  
Summary of repeated measures ANOVAs for all variables. 
 
Area 
 
 
Measure 
 
df1 
 
df2 
 
F 
 
p 
 
BPRS 
 
 
2 
 
16 
 
1.29 
 
.303 
PSYRATS: AH 
 
2 16 2.88 .085 
 
Psychopathology and 
psychotic symptoms 
PSYRATS: D 2 16 8.66 .003 
 
Depression 
 
2 16 0.41 .670 
Anxiety 
 
2 16 1.65 .222 
Anxiety and Depression 
Stress 
 
2 16 0.65 .538 
Medication dosage CPZ equivalent 
 
2 16 0.98 .398 
Medication compliance MARS 
 
2 16 0.96 .405 
Functioning SFS: E/O 
 
2 14 0.14 .875 
SR 
 
2 16 1.12 .349 
F 
 
2 16 0.52 .603 
LTA 
 
2 16 1.34 .289 
Quality of Life 
GA 
 
2 16 1.21 .324 
 
Note: Bolded figures indicate significance where p <.05. 
 
Trend analyses were then conducted on the data to further explore the significant 
results for the PSYRATS: D scale, and the results for all other variables. The results of the 
trend analyses can be seen in Table 14. From this table it is apparent that the PSYRATS: 
Delusions scale was significant for both linear and quadratic trends, with a medium effect size 
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associated with these significant results (Cohen, 1992). Several of the mean scores on the 
scales showed small effect sizes (Cohen, 1992), including the PSYRATS: AH and Q-LES-Q: 
GA. 
 
Table 14. 
Summary of trend analyses for all variables.  
   
     Linear Trend 
 
 
Quadratic Trend 
 
Area 
 
Variable 
 
F 
 
p 
 
η2 
(95%CI) 
 
  
F 
 
p 
 
η2 
(95%CI) 
BPRS 
 
1.19 .308 .129 (.00, .49)   1.43 .266 .152 (.00, .41)  
PSRYATS: AH 
 
3.17 .113 .283 (.00, .60)  2.05 .191 .204 (.00, .55) 
Psychopathology 
and psychotic 
symptoms 
PSYRATS: D 
 
6.11 .039 .433 (.00, .69)  9.51 .015 .543 (.03, .75)  
DASS: 
Depression 
 
0.10 .761 .012 (.00, .30)  0.74 .415 .085 (.00, .43) 
DASS: Anxiety 
 
1.94 .202 .195 (.00, .54)  1.34 .280 .144 (.00, .50)  
Anxiety and 
depression 
DASS: Stress 
 
2.11 .185 .209 (.00, .55)  0.13 .724 .016 (.00, .34)  
Medication 
dosage 
CPZ equivalent 
 
0.98 .352 .109 (.00, .46)  0.99 .350 .110 (.00, .47)  
Medication 
adherence 
MARS 
 
0.50 .498 .059 (.00, .40)  1.15 .314 .126 (.00, .49)  
Functioning 
 
SFS: E/O 0.21 .664 .028 (.00, .35)  0.00 .960 .000 (.00, .00) 
Q-LES-Q: SR 
 
1.53 .251 .161(.00, .51)   0.08 .787 .010 (.00, .25) 
Q-LES-Q: F 
 
0.27 .619 .032 (.00, .36)  0.99 .348 .110 (.00, .47) 
Q-LES-Q: LTA 
 
1.88 .208 .190 (.00, .54)  0.27 .615 .033 (.00, .36) 
Quality of life 
Q-LES-Q: GA 
 
2.78 .134 .258 (.00, .58)  0.04 .845 .005 (.00, .15) 
 
Note. Bolded figures indicate significance, where p = .05 
 
As the results for the PSYRATS: Delusions scale were significant, post-hoc pairwise 
comparisons with Bonferroni corrections for multiple comparisons were conducted on this 
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scale. The Bonferroni-corrected p value was 0.14. The p values for these comparisons are as 
follows: Baseline – Pre-intervention: .250, Baseline – Post-intervention: .116, and Pre-
intervention – Post-intervention: .011. These results indicate that there was a significant 
difference between pre- and post-intervention scores for all participants on the Delusions 
scale.  
Visual representations providing a clearer picture of changes in scale scores over time 
are shown in Figures 2 to 8. From these figures it can be seen that, from pre-treatment to post-
treatment, there were reductions in scores on the BPRS, PSYRATS: AH and PSYRATS: D as 
expected. There were also decreases in scores on all three subscales of the DASS. There 
appeared to be slight reductions in medication levels from pre-treatment to post-treatment, 
and slight increases in medication adherence during this time. Unexpectedly, in regards to 
quality of life, all subscales appeared to show a drop in results across the three time periods, 
except for the Q-LES-Q: Feelings scale, which, increased somewhat from pre-treatment to 
post-treatment, but did not reach levels recorded at baseline.
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Figure 2. The BPRS and PSYRATS: AH over intervention phases.
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Figure 3. The PSYRATS: D and DASS: Depression scales over intervention phases. 
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Figure 4. The DASS: Anxiety and Stress scales over intervention phases.
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Figure 5. The MARS and medication levels over intervention phases.
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Figure 6. The Q-LES-Q: SR and F subscales over intervention phases. 
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Figure 7. The Q-LES-Q: LTA and GA subscales over intervention phases. 
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Figure 8. The SFS: E/O subscale over intervention phases 
 
 
 Further repeated measures analyses were conducted on each of the six 
Delusions subscale items to determine which items may be contributing to the 
significant result found previously. The descriptive data for these subscale items is 
presented in Table 15. From this data, it appears that ratings on each of these items 
decreased from pre-treatment to post-treatment.  
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Table 15. 
Descriptive data for the 6 items on the Delusions subscale over baseline, pre-
treatment, and post-treatment. 
 
Baseline 
 
  
Pre-treatment 
  
Post-treatment 
 
Subscale item 
M SD  M SD  M SD 
 
D1: Amount of pre-
occupation 
 
1.89 
 
1.36 
  
2.78 
 
1.48 
  
1.11 
 
1.05 
 
D2: Duration of pre-
occupation 
 
1.67 
 
1.12 
  
2.44 
 
1.42 
  
1.22 
 
1.09 
 
D3: Conviction 
 
2.22 
 
1.79 
  
3.22 
 
1.30 
  
1.67 
 
1.12 
 
D4: Amount of 
distress 
 
1.56 
 
1.13 
  
2.33 
 
1.50 
  
1.11 
 
1.17 
 
D5: Intensity of 
distress 
 
1.33 
 
1.12 
  
1.67 
 
1.12 
  
0.78 
 
0.67 
 
D6: Disruption to life 
 
 
1.22 
 
0.83 
  
1.67 
 
0.87 
 
  
1.11 
 
1.17 
 
 
 
The results of the overall repeated measures ANOVAs for these subscale items 
are presented in Table 16, indicating that Items D1, D3, D4, and D5 were all 
significant for change over time. Additionally, item D2 was approaching significance. 
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Table 16. 
Repeated measures ANOVAs for PSYRATS: D subscale items. 
 
Subscale item 
 
 
F 
 
p 
 
D1: Amount of pre-occupation 
 
6.47 
 
.009 
 
D2: Duration of pre-occupation 
 
2.99 
 
.079 
 
D3: Conviction 
 
9.44 
 
.002 
 
D4: Amount of distress 
 
3.82 
 
.044 
 
D5: Intensity of distress 
 
4.13 
 
.036 
 
D6: Disruption to life 
 
 
1.37 
 
.283 
 
Note: Bolded figures indicate significance where p< .05, df (2, 16) 
 
Due to the significant results found, trend analysis was conducted on the data; 
the results of these analyses are presented in Table 17. The results indicate that the 
aspects of the delusions that appeared to show the most change were amount of 
preoccupation and conviction, which were both significant for a quadratic trend. 
Medium effect sizes were associated with these results. Results for the amount and 
intensity of distress caused by the delusion approached significance. Visual 
representations for the Delusions subscale items over the three intervention phases are 
presented in Figures 9 to 11. These graphs suggest that there was an increase in 
delusions on all aspects from baseline to pre-treatment, and then decreases from pre-
treatment to post-treatment. 
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Table 17.  
Trend analyses for the PSYRATS: Delusions subscale 
  
Linear Trend 
 
 
Quadratic Trend 
 
Subscale item 
 
F 
 
p 
 
η
2 
(95%CI) 
 
  
F 
 
p 
 
η
2 
(95%CI) 
 
D1: Amount of 
preoccupation 
 
 
4.56 
 
.065 
 
.363 (.00, .65) 
  
7.32 
 
.027 
 
.478 (.00, .71) 
D2: Duration of 
preoccupation 
 
2.29 .169 .222 (.00, .56)  3.13 .115 .281 (.00, .60) 
D3: Conviction 
 
2.70 .139 .253 (.00, .58)  14.59 .005 .646 (.10, .81) 
D4: Amount of 
distress 
 
2.29 .169 .222 (.00, .56)  4.24 .074 .346 (.00, .64) 
D5: Intensity of 
distress 
 
5.26 .051 .397 (.00, .67)  3.64 .093 .313 (.00, .62) 
D6: Disruption to life 
 
0.10 .760 .012 (.00, .30)  2.57 .147 .243 (.00, .57) 
 
Note: Bolded figures indicate significance, where p< .05.
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Figure 9. The PSYRATS D1 and D2 subscale items over intervention phases. 
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Figure 10. The PSYRATS: D3 and D4 subscale items over intervention phases. 
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Figure 11. The PSYRATS: D5 and D6 subscale items over treatment phases. 
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Post-hoc pairwise comparisons with Bonferroni corrections for multiple 
comparisons were conducted on the Delusions subscale items D1 (Amount of pre-
occupation) and D3 (Conviction). The Bonferroni corrected p value was 0.14. The p 
values for these comparisons are as follows: for Amount of pre-occupation: Baseline 
– Pre-intervention: .363, Baseline – Post-intervention: .196, and Pre-intervention – 
Post-intervention: .031. For Conviction: Baseline – Pre-intervention: .159, Baseline – 
Post-intervention: .416, and Pre-intervention – Post-intervention: .002. The results of 
these analyses indicate that there was a significant decrease between scores at pre-
treatment and post-treatment for both items. 
3.5.2 Two-way repeated measures ANOVAs for the SFS 
Using two-way repeated measures ANOVAs, participants’ mean scores were 
compared with their caregivers’ mean scores on the SFS subscales to determine 
whether there were convergences in the raters’ scores over time, and to determine 
whether there were changes in functioning over time. The descriptive data for these 
analyses are presented in Table 19. The results of the main effects and interactions for 
these ANOVAs are shown in Table 20. The results suggest that there was a significant 
main effect for rater for the Interpersonal Communication subscale, and a significant 
main effect for time for the Prosocial scale. Results for the Independence Competence 
scale approached significance for a time main effect. Significant results were 
associated with medium effect sizes. 
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Table 19. 
Descriptive data for the SFS: P and SFS: C over baseline, pre-treatment, and post-
treatment. 
 
Area 
 
Measure 
 
Baseline 
 
  
Pre-treatment
 
  
Post-treatment
 
   
M 
 
 
SD 
  
M 
 
SD 
  
M 
 
SD 
W/E31 
 
103.50 13.28  102.17 12.24  100.94 11.26 
Inter32 
 
127.44 21.18  126.44 19.39  120.56 19.51 
IP33 
 
108.22 16.88  102.83 19.89  103.89 15.31 
IC34 
 
104.33 13.24  102.89 13.50  105.33 13.19 
R35 
 
104.56 23.00  101.83 18.27  103.39 18.53 
P36 
 
104.33 20.88  110.11 18.35  105.00 18.95 
Social 
Functioning 
Participant 
E/O37 99.78 14.06  99.78 14.99  102.81 12.50 
 
W/E 
 
 
95.38 
 
10.21 
  
98.78 
 
9.66 
  
99.89 
 
7.44 
Inter 
 
112.63 17.61  111.44 15.12  118.11 20.71 
IP 
 
99.75 13.48  102.06 14.84  106.11 15.53 
IC 
 
103.06 6.95  104.94 15.37  109.17 13.05 
R 
 
106.94 15.39  105.61 18.57  108.89 17.28 
 
Social 
Functioning 
Caregiver 
P 
 
105.50 12.76  109.11 16.40  109.44 15.20 
                                                 
31
 W/E = Withdrawal/Engagement 
32
 Inter = Interpersonal Communication 
33
 IP = Independence Performance 
34
 IC = Independence Competence  
35
 R = Recreation 
36
 P = Prosocial Activities 
37
 E/O = Employment/Occupation 
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Table 20. 
Two-way repeated measures ANOVAs for the SFS: P and SFS: C. 
 
 
Subscale 
 
Main effect or interaction 
 
F 
 
 
p 
 
η
2 
(95%CI) 
 
 
Time 
 
 
0.08 
 
.926 
 
.011 (.00, .16) 
Rater 
 
0.96 .360 .120 (.00, .48) 
 
SFS: W/E 
Time*Rater 
 
2.36 .131 .252 (.00, .50) 
Time 
 
0.23 .802 .031 (.00, .23) 
Rater 
 
5.66 .049 .447 (.00, .70) 
SFS: Inter 
Time*Rater 
 
0.84 .453 .107 (.00, .35) 
Time 
 
2.21 .146 .240 (.00, .49) 
Rater 
 
0.01 .926 .001 (.00, .04) 
SFS: IP 
Time*Rater 
 
2.34 .133 .251 (.00, .50) 
Time 
 
3.75 .050 .349 (.00, .57) 
Rater 
 
1.06 .338 .131 (.00, .50) 
SFS: IC 
Time*Rater 
 
1.49 .260 .175 (.00, .2) 
Time 
 
0.50 .616 .067 (.00, .29) 
Rater 
 
0.77 .410 .099 (.00, .46) 
SFS: R 
Time*Rater 
 
0.60 .560 .079 (.00, .31) 
Time 
 
4.45 .036 .426 (.00, .64) 
Rater 
 
0.22 .659 .035 (.00, .40) 
SFS: P 
Time*Rater 
 
0.31 .740 .049 (.00, .27) 
 
Note: bolded figures indicate significance where p < .05. 
 
 95 
As there were significant results obtained on the Prosocial subscale for time, a 
trend analysis was performed. This analysis revealed a significant linear trend, F (1, 6) 
= 8.65, p = .026, and a non-significant quadratic trend, F (1, 6) = 2.87, p = .141. Post-
hoc pairwise comparisons with Bonferroni adjustments were then conducted, with a p 
value of 0.14. The p values for these comparisons were as follows: Baseline – Pre-
intervention: .193, Baseline – Post-intervention: .078, and Pre-intervention – Post-
intervention: 1.00. These results indicate that the difference between mean scores at 
baseline and post-treatment approached significance. 
Graphical representations of participants and caregivers ratings on the SFS are 
presented in Figures 12 to 14. The graphs represent the data used for the repeated 
measures analyses, where any case with missing data was not included. The means 
and standard deviations for this data are included in Appendix I. These graphs suggest 
that while participants tended to rate themselves as functioning at similar levels all 
three phases of the treatment, caregivers’ ratings on these scales appeared to increase 
over time.  
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Figure 12. The SFS: W and Inter subscales over intervention phases. 
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Figure 13. The SFS: IP and IC subscales over intervention phases. 
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Figure 14. The SFS: R and P subscales over intervention phases.
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3.6 Clinical significance 
To determine clinically significant changes, it would have been preferable to 
use Jacobson and Truax (1991) criterion, defined as a person’s results falling outside 
the range of the population by two standard deviations. However, this was not 
possible as the large standard deviations produced by the current participants at pre-
treatment meant that on some measures, participants would have had to produce a 
negative score at post-treatment in order to attain clinical significance. Therefore, the 
criteria implemented to decide whether changes in participants’ symptoms and 
functioning were clinically significant were as follows: a 20% reduction in symptoms 
indicated a worthwhile improvement (Cather et al., 2005; Rector et al., 2003), and a 
50% reduction in symptoms represented an important clinical change (Durham et al., 
2003; Sensky et al., 2000; Tarrier, Beckett et al., 1993; Warman et al., 2005).  
Based on these criteria, 20% and 50% of the mean of participants’ pre-
treatment scores were calculated. The difference between each participant’s score at 
pre-treatment and post-treatment was then computed. If this difference score was 
larger than the 20% or 50% criteria, it was deemed to be significant, and the person 
exhibited a clinically significant change on that scale. 
These criteria were applied to the BPRS, PSYRATS: AH, PSYRATS: D, Q-
LES-Q, SFS: P, and SFS: C, with results indicating that in total, four participants 
(44.44%) had a worthwhile improvement in symptoms and/or functioning (20% 
improvement), and four participants (44.44%) experienced an important clinical 
change in symptoms (50% improvement) as rated either by themselves or their 
caregiver. Changes were shown on the BPRS, PSYRATS: AH, PSYRATS: D, and the 
Social Relations, Feelings, Leisure Time Activities, and General Activities subscales 
of the Q-LES-Q. For the SFS: P, changes were seen on the Recreation subscale. This 
is similar to the SFS: C where changes rated by caregivers were seen on the 
Recreation, Interpersonal Communication, and Independence Performance subscales.  
Clinically significant worsening in functioning was also found in regards to 
social relations, feelings, leisure time activity, general activities, 
withdrawal/engagement, interpersonal communication, and prosocial activities. Four 
participants (44.44%) demonstrated an important clinical decline (50% reduction) 
across three areas of functioning, and four participants (44.44%) experienced a 20% 
reduction in functioning.  
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These results are displayed in the following tables (Tables 21 and 22) for each 
participant, indicating that three participants demonstrated positive changes in both 
symptoms and functioning. Also, two of the participants (Participants Three and Six) 
who experienced the greatest reduction in delusions also demonstrated the greatest 
reduction in functioning and quality of life.
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Table 21. 
Clinical significance results across participants. 
 
Participant 
 
Psychopathology 
(BPRS) 
 
Auditory 
hallucinations 
(PSYRATS: 
AH) 
 
 
Delusions 
(PSYRATS: D) 
 
Social Relations 
(Q-LES-Q: SR) 
 
Feelings 
(Q-LES-Q: 
F) 
 
Leisure Time 
Activity 
(Q-LES-Q: 
LTA) 
 
 
General 
Activities  
(Q-LES-Q: GA) 
 
One 
 
 
 
20% 
 
20% 
 
-50% 
 
 
 
20% 
 
50% 
 
Two 
 
 
20% 
 
20% 
 
20% 
 
 
   
Three 
 
  50% - 50% -20% -50% -20% 
Four 
 
    20% 20%  
Five 
 
  50% 20%  -50%  
Six 
 
  50% -20% -20% -50% -50% 
Seven 
 
      -20% 
Eight 
 
20%  20%     
Nine 
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Table 22. 
Clinical significance across participants for the SFS: P and SFS: C.
 
 
Participant 
 
SFS: P 
Withdrawal/ 
Engagement 
 
SFS: P 
Interpersonal  
Communication 
 
SFS: P 
Prosocial 
 
SFS: P 
Recreation 
 
 
SFS: C 
Recreation  
 
 
SFS: C 
Interpersonal 
Communication 
 
 
SFS: C 
Independence 
Performance 
 
 
One 
 
  
-20% 
 
-20% 
   
 
 
Two 
 
      20% 
Three 
 
 -20%      
Four 
 
       
Five 
 
       
Six 
 
       
Seven 
 
    20% 20%  
Eight 
 
   20%    
Nine 
 
-20%       
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3.7 Individual weekly data 
Each individual’s psychotic symptoms were rated on the PSYRATS 
(Haddock, McCarron et al., 1999) by the treating clinician at the end of each therapy 
session. These scores provided a weekly progress report of symptoms, and tracked 
any changes over time. As only four individuals reported auditory hallucinations at 
the commencement of the study, and two individuals completed less than 15 sessions, 
it was deemed that the most accurate presentation would be weekly data on an 
individual basis. Graphical representation of this weekly data provides a good 
understanding of individual differences from baseline to post-treatment (Morrison, 
2002; Wragg & Whitehead, 2004). From the following graphs (Figures 15 to 23) it 
can be seen that there was some variation in participants’ psychotic symptoms over 
the baseline period, with four participants showing an increase in symptoms and the 
remaining participants showing a decline in symptoms. Over the treatment period, 
there appeared to be a slow decline in the psychotic symptoms of Participants One, 
Five, Six, Seven, and Eight. Participant Nine’s psychotic symptoms ceased early after 
therapy began, and participant Eight’s auditory hallucinations ceased from baseline to 
pre-treatment.  Participant Two’s hallucinations showed a decline, however the 
delusions remained relatively stable. For Participants Three and Four, their psychotic 
symptoms appeared to vary greatly from session to session; Participant Three’s 
delusions showed some decline over time with the greatest drop in symptoms towards 
the end of treatment, whereas Participant Four’s Auditory Hallucinations were at 
almost the same level from baseline to post-treatment.  
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Figure 15. Participant One’s delusions and auditory hallucinations rated over 
baseline, pre-treatment, sessions 1 to 10, and post-treatment. 
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Figure 16. Participant Two’s delusions and hallucinations rated over baseline, pre-
treatment, sessions 1 to 13, and post-treatment.
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Figure 17. Participant Three’s delusions rated over baseline, pre-treatment, sessions 1 
to 15, and post-treatment. 
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Figure 18. Participant Four’s auditory hallucinations rated over baseline, pre-
treatment, sessions 1 to 15, and post-treatment. 
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Figure 19. Participant Five’s delusions rated over baseline, pre-treatment, sessions 1 
to 15, and post-treatment.  
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Figure 20. Participant Six’s delusions rated over baseline, pre-treatment, sessions 1 to 
15, and post-treatment.  
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Figure 21. Participant Seven’s delusions rated over baseline, pre-treatment, sessions 1 
to 15, and post-treatment.  
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Figure 22. Participant Eight’s auditory hallucinations and delusions rated over 
baseline, pre-treatment, sessions 1 to 15, and post-treatment. 
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Figure 23. Participant Nine’s auditory hallucinations and delusions over baseline, pre-
treatment, sessions 1 to 15, and post-treatment. 
 
3.8 Qualitative analysis 
Eight participants and their caregivers completed a qualitative interview with 
the therapist. One caregiver was interviewed through an interpreter. Before 
completing the interview each participant was administered the short version of the 
Marlowe-Crown Social Desirability Scale (Crowne & Marlowe, 1960; Marlowe & 
Crowne, 1961). Participants reported a mean score of 6.50 (SD = 2.93) on this 
measure, indicating high socially desirable responding. 
Each interview was transcribed, and similar to past research, a grounded 
theory methodology was implemented to code the transcripts of interviews in this 
study (McGowan et al., 2005). As a result, the information provided by participants 
and their caregivers was classified into a number of categories that are then described 
by further sub-categories.  
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In total, five categories were generated: expectations of therapy, experiences 
of therapy, changes noticed over therapy period, attributions of change, and issues 
raised during interviews. Three of these categories comprised responses from both 
caregivers and participants, and two categories were unique to participants.  The 
categories and subcategories are described below, with the first two specific to 
participants only. All names have been altered to protect confidentiality. 
3.8.1 Category One: Expectations of therapy 
 The first category generated described participants’ expectations of activities 
and areas addressed in therapy sessions. From the data gathered, it was clear that these 
expectations could be clarified as: working on psychotic symptoms, talking, 
performing practical activities, and receiving education about illness and medication. 
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Table 23. 
 
Category One: Expectations of therapy 
 
Sub-categories 
 
 
Participant sample quotes 
 
Work on psychotic 
symptoms 
 
“Friendship and love. How to achieve it”. 
 
“Reduce voices and find a way that make me comfortable with 
the hearing voices” 
 
“I hoped that I would be cured. … That I didn’t have the 
disorder anymore, I wasn’t, that I wasn’t suffering depression, 
anxiety or stress, that I didn’t require medication. That I could 
wake up one morning and be able to detect which things in my 
thoughts were the actual delusions, and that the delusions would 
stop.” 
 
Emotional  “Just make me feel better about myself” 
 
Talking  
 
“Get a few things off my chest” 
“Report on what happened to me” 
Practical 
 
“Writing, drawing pictures, asking questions” 
Receiving education and 
relapse prevention 
 
“Just to learn a few things about medications and the illness 
itself” 
 
“I just wanted to know the underlying stress factors, sort of 
umm, and all the elements that could be umm, included when I 
become unwell. Like there’s a certain few factors like my 
physical wellbeing, like not eating properly, not sleeping 
properly as well as the importances and as well medication 
factors. Just wanted to map out like what are the things that sort 
of trigger a sort of response in my body” 
 
 
3.8.2 Category Two: Experiences of therapy 
The second category describes participants’ experiences and memories of what 
took place during sessions. It is apparent from the subcategories that again, for 
participants, emphasis was placed on the role of talking in therapy. It was also noticed 
that some participants could remember some of the strategies discussed and taught to 
them, including enhancing coping strategies, testing the evidence, and using 
information to prevent relapse. 
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Table 24.  
Category Two: Experiences of therapy 
 
Sub-categories 
 
 
Participant sample quotes 
 
Coping or 
distraction 
strategies 
 
“Put my mind off it, turn your interest to something else” 
 
“Listen to music, think of stop sign sing a song, watch TV, sleep, take a walk, 
reduce the voices” 
 
“Pay a lot more attention to my breathing, and it does help to breathe, ummm, 
more calmly. It does relax you more” 
 
Evidence testing “He had a sheet of paper of different things on it, like, evidence for something that 
you can prove and evidence that you can’t prove. And I couldn’t prove the mind 
reading so I got rid of it. It was just theories.” 
 
“When you were playing devil’s advocate, as you said, it helped sort of ahhh, 
lessen my beliefs in things, and the things that I was pretty sure about, made me 
think that, I wasn’t, after a session with you, it weren’t as strong as well” 
 
“I’ll continue to use the strategy of questioning memories, finding evidence to 
refute the memory or finding evidence to support it, and accepting it, what the 
evidence is” 
 
Psychoeducation 
and relapse 
prevention 
“Just gave me, you know, a few answers and that … that I’ll be able to put 
together later on, or if I get into trouble again with my illness” 
 
“When you helped me draw the bucket and each level of water was just, each of 
the elements of pressures and stressors in my life, and what made it overflow, 
overflow meaning that I was ill” 
 
Talking “Basically you were asking me, what, what I went through with the voices, and 
what about, like, the mental illness that affect my life” 
 
“I got to tell him everything, you know” 
 
“Like we started talking. We started talking a lot of things about things that had 
happened in the past” 
 
“Talked about issues and any of the issues I had problems with or liked, it would 
be discussed” 
 
“With just being able to express what I was going through on a day-to-day basis 
as well as honestly telling you the whole ordeal and sort of going back and 
looking at it and dissecting it” 
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3.8.3 Category Three: Changes noticed over therapy period 
 The third category includes responses by both participants and their caregivers 
in regards to any changes noticed over the period during which the participant was 
involved in the project. When asked about whether there were any changes in the 
participants over the course of therapy, these responses could be separated out into 
changes in thoughts, feelings, behaviours in regards to psychotic symptoms, attitude 
and self-esteem, relationships with others, activities and independence, hygiene and 
self-care. In each of these subcategories, both participants and caregivers indicated 
that there were positive changes, although these changes were noticed and recognised 
more often by caregivers than participants.
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Table 25. 
Category Three: Changes noticed over therapy period.  
 
Sub-categories 
 
 
Participant sample quotes 
 
Caregiver sample quotes 
 
Thoughts 
 
“Sometimes I don’t think about it, sometimes I do – away from 
house, I’m perfectly alright, when I come home, that’s when all 
the worries start happening” 
 
“I think clearer after I see him, and happier” 
 
“Reassuring myself, there’s nothing there, you know, that I’m 
just normal” 
 
“I still think that people do talk about me, but it’s very localised 
in my own town, and going to other suburbs it’s not the same” 
 
“There was a point in time where I thought that the authorities 
were following me just to find out my, you know what I was 
doing, things like social security and things like that with my 
family but now it’s become more vague to me, and I’m not as 
sure as what happened” 
 
 
“I think he realises now that they were ummm, … his, umm brain not 
functioning properly at the time” 
 
“That doesn’t exist anymore, he has no time for that, or think about it, he 
doesn’t even talk about it” 
 
“I think maybe he’s, maybe accepting things, or he’s maybe processing 
things, and he’s realising how these things may impact on him … a little bit” 
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Feelings 
 
“Just, haven’t been as worried, umm, of what people can see 
when I’m thinking.  So I’ve just been a bit more relaxed” 
“I’m not as angry as I was before, that wasn’t me” 
 
“When I tried reading or listening to music or take a walk it’s ... 
working, and it reduce the voices and I can feel more 
comfortable”  
 
“There’s a change in my anxiety levels like I dwell on that 
person thinking something bad about me, but now it’s like I feel 
as though I don’t care what they think so I don’t really dwell on 
something as much” 
 
“I was quite narky and I over-reacted a lot and I was quite bitter 
and mean, and that normally wouldn’t be the person that I was, 
… whereas now I don’t need to do that anymore, I don’t feel the 
need to be so over-reactive and so defensive of my position, so 
I’m not that hostile anymore” 
 
 
“He used to be very aggressive and he used to be moody. His mood was sort 
of like always negative, anything he did or said was all negative. So with all 
that now it’s all, doesn’t happen and it’s changed” 
 
“So he actually can talk about it now without being upset. He doesn’t get 
defensive or angry. …He’s not so pessimistic” 
 
“Yeah, so he’s really happy and just his whole face and affect has changed” 
 
“Well, he’s comfortable with that so it couldn’t be bothering him much” 
 
“My son reported that he hear less voices and he feel less stress” 
 
Behaviours in 
regards to 
psychotic 
symptoms 
“When those voices happen I just let it happen … I know that I 
feel uncomfortable and I’m afraid of them but I like to act like it 
doesn’t mean much to me, because I feel that the more that I do 
that when it happens I’m just less affected by it.” 
“He doesn’t listen to them as much… He said the other day … he tries to 
ignore the voices now and not let them worry him… that’s probably quite a 
change as well” 
 
“He’s concentrating on his driving now. So, that, he has no time for that, or 
think about it” 
 
“Doesn’t often talk about it, a change in the way he actually talks about it” 
“I’ve noticed a big difference … he doesn’t talk about any of that at all” 
 
“The general gist at the moment isn’t, as much about this, people feeling his 
thoughts and seeing his thoughts, he’ll still now and them bring ‘em up. But 
when we have like a longer conversation its not centred around that 
specifically” 
 
“She doesn’t talk about it or bring it up as much as she used to” 
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Attitude and self-
esteem 
 
“I am confident that in the future this will be over with the 
voices” 
 
“I think he’s got a more positive attitude” 
 
“Before, you know, everything was a weed. Whereas now he takes an interest 
in the garden” 
 
“Now he just wants to live, he’s trying to make up for what he’s missed in the 
last 10 or 12 years” 
 
“He seems to umm, have more confidence in himself and he seems to uh, 
think of himself as a bit, umm, he thinks of himself as a bit nicer person than 
he thought of himself before” 
 
Relationships with 
others 
“I listen better. Not completely to my satisfaction, but it has 
improved, listening has improved. My social skills have 
improved, my talking’s improved” 
“He will approach people and ask for things now, a lot more … he’s not as 
closed, he’s not as isolative as he was” 
 
“Yeah, he can actually, like, he’ll smile and have, like, a limited conversation 
but at least he can communicate. I mean it might be just about I don’t know, 
something he’s seen on TV, or you know, whereas before he had nothing to 
talk about” 
 
“He’s getting better in the way that he’s talking to me” 
 
“I’ve noticed too that occasionally now he’ll eat a meal with us. He usually 
takes it in his room…” 
 
“I think he has been trying to communicate to people more” 
 
“I guess, some of the things that I have noticed is that he is, he is engaging a 
little bit more, he has periods when he can be a little bit warmer with some 
people” 
 
Hygiene and self-
care 
 “His hygiene has improved slightly… and now to be doing all his own 
laundry and, so there is a change in that respect and his hygiene” 
“He’s taking more pride in how he dresses, he takes care of himself really 
well” 
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Activities and 
Independence 
 
“I plan the future, get a girlfriend, and working” 
 
“I’ve sort of matured and I’m more level-headed and I sort of 
not, they used to describe me as someone who had like my head 
up with the fairies and stuff, but I guess I don’t portray that 
persona anymore” 
 
“So that’s one of the things that’s changed about myself, I’ve 
got to realise it’s my responsibility and my own sense of duty to 
take care of myself with the medication” 
 
“I tend to feel that like, if I get on with my life now and start 
looking for work and get a job and start socialising a little bit 
more that I’ll think less and less about all these things. They just 
won’t have any bearing.” 
 
“I’m more willing and want to go more outdoors, like, I’ll go to 
the shopping centre and have a coffee and I’ll sit outdoors and 
I’ll read the newspaper, and rather than leave in 15 minutes I’ll 
sort of make it an outing.” 
 
 
“He’s going out a lot more, he’s happier when he goes out” 
 
“To be able to move on, even to be able to move into another place like, 
we’ve done that for the last… each year we’ve gone and looked at other 
places and he’s said “no, no, no” and this time he’s very happy to go” 
 
“Well he’s taken an interest in tennis, umm, he wants to play squash. With 
Outdoors Inc. they do a lot of bike riding, camping, he goes along with 
everything that they accept him into cause he just wants to get out and 
experience it” 
 
“And he seems to be slowly putting little things into his life to fill it up” 
 
“He’s hoping that his illness will be recovered, then he can go to get a job and 
work” 
 
“So she’s been doing all those sorts of things by herself and hasn’t asked for 
help from me.” 
 
 
3.8.4 Category Four: Attributions of change 
 The fourth category to arise entailed the reasons individuals gave for the changes they had noticed. These changes could be broken down 
into medication, attendance at a mental health service, having someone to talk to, CBT, a reduction in substance use, having activities to occupy 
the individual, and having motivation and utilising coping strategies. 
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Table 26. 
Category Four: Attributions of change 
 
Sub-categories 
 
 
Participant sample quotes 
 
Caregiver sample quotes 
 
Medication 
 
“When I was having the seroquel and the voices like you know, 
reduce, that’s when I able to like you know sing and thoughts of 
the future all the time” 
 
“But since coming here, taking the tablets, my dad has noticed a 
bit of change in me.” 
 
 
“Medication in the night, which works out for the next day” 
Mental health 
service 
 “Then he started coming here and seeing Harry [case manager]… and he sort of 
started coming out of himself, changing. It’s a big difference from 12 months ago 
to what there is now” 
 
Talking “I felt better, knowing someone was there” “It’s changed for the, for the better since he’s … been going to MidWest and had 
people to talk to” 
 
“So he’s actually had that person to work one on one with him, I think it’s made 
the difference to him” 
 
“Talking with somebody about actually his fears and, yeah, his symptoms which 
has enabled him to move on” 
 
“That he’s actually talking to somebody about his problems, and they can actually 
help him” 
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CBT 
 
“And the cognitive behaviour therapy actually was the catalyst” 
 
“His medication hasn’t changed, so something has actually changed for Dean in 
that time, and I think some CBT. There’s been a … an approach, how Sam’s 
worked with Dean” 
 
“It’s probably been CBT, she hasn’t … there’s been some, some minor changes to 
her medication in the middle” 
 
Reduced 
substance use 
“I’m really happy about myself, like my view because I’m out of 
drugs” 
“The fact that he stopped taking, he took ecstasy was it?…. That he stopped taking 
that of course that certainly helped” 
 
Occupying 
activities 
“If I’m out somewhere, doing something, I’m away from the 
house, I’m ok, I’m perfectly alright. But when I come home, that’s 
when all the worries start happening” 
 
“I think it’s just adapting back to normal life and sort of hanging 
around friends” 
 
“I think when he’s bored or he’s got nothing to do, it’s just as what they say: ‘Idle 
mind is a devil’s workshop’” 
 
“But as long as he’s got something to do and he’s concentrating on something, no 
way he, he doesn’t even talk about it” 
 
Motivation and 
coping strategies 
“Caused this change, is probably, as you said, like you know try 
some other stuff to uhh, reduce the voices” 
“So I don’t think it was just the medication, I think it was him trying very hard, 
you know, to, to umm… get back on track with his life” 
 
“He’s willing, he wants to be able to improve” 
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3.8.5 Category Five: Issues raised during interviews 
 Category Five consists of a number of issues or problems raised by participants and 
their caregivers during the interviews. Several participants could not remember any of the 
topics of strategies taught to them during the sessions. Furthermore, participants and 
caregivers combined spoke about what they had not found helpful, both in terms of the CBT 
and other treatments, past and present. A number of caregivers reported finding it difficult 
being unaware of what took place during therapy sessions, and commented on this.  
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Table 27. 
Category Five: Issues raised during interviews. 
 
Sub-categories 
 
 
Participant sample quotes 
 
Caregiver sample quotes 
 
None 
 
“No, nothing. God still wants to 
punish me when I die and then go to 
heaven” 
 
“That hasn’t changed” 
 
 
“I don’t know that there’s any 
change” 
 
“No, I probably haven’t noticed 
that” 
 
Can not remember “I don’t remember” 
 
“I can’t remember any of it” 
 
 
Least helpful 
treatments and 
unpleasant experiences 
“Least helpful is probably the umm, 
the stop sign … because you can’t 
just think of the stop sign all the 
time” 
 
“I mean, the psychiatrist gives me 
pills, you know, and that doesn’t 
even work. …Just that the tablets 
don’t help, how’s a psychologist 
going to help?” 
 
“Some of the weeks were I felt a bit 
repetitive, but I sorta understand that 
that’s what you had to do to ummm, 
yeah, change my sort of thought 
processes” 
 
“It was painful to sort of reflect but I 
suppose it was pretty good for me to 
be able to do that as well” 
 
“He did come back from one of 
Sam’s sessions so depressed … he 
was really down and I was really 
worried about him… whatever 
they’d discussed that day I’d say 
played on his mind” 
 
“I’ve never got the help… One night 
here, one night there, and they’d 
send him home” 
Non-disclosure of 
information 
 “I was actually quite concerned 
because I didn’t know what they 
were actually talking about. … 
Cause I know it’s private and I don’t 
ask him anything” 
 
“A lot of times after he’d had these 
sessions I’d kind of try and get his 
perspective of it and say “You know, 
what sort of things are you 
discussing? And what sort of things 
are you practising?” To see if we 
could follow-up with any of it. And 
he was just very … not very keen to 
talk about these things” 
 
“I would like to know how Chris is 
progressing, because when I asked 
him after seeing you and then he 
didn’t tell me much.” 
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3.8.6 Summary of qualitative data 
 The five categories created to summarise the information given by participants and 
caregivers paints an interesting and complicated picture of the process of therapy. In 
particular, it appears that many participants expected and enjoyed the process of talking, and 
of having someone with whom to talk. While participants were able to recall and reflect on 
some of the skills learnt during the sessions, most of the information about the changes 
experienced during therapy was reported by caregivers. This bias in information suggests that 
participants in this project were poor reporters of any changes in symptoms, functioning, and 
behaviours. Alternatively, while caregivers often reported that they were unaware of what the 
therapy comprised, they could provide accurate and detailed descriptions of changes in 
participants’ thoughts, feelings, behaviours, and functioning. It was salient to note the many 
caregivers and participants reported being disappointed with and let down by previous 
treatments and services received. However, the fact that they took part in the current research 
suggested that participants and caregivers had not given up hope that positive changes could 
be made. The information provided by the qualitative interviews afforded further 
understanding and insight into participants’ experiences of CBT, and what they and their 
caregivers received or found most useful about the treatment. In the section that follows, 
information is compared to the quantitative data gathered, in order to understand where the 
similarities and differences lie between these two key outcome areas.  
3.9 Integration and comparison of qualitative and quantitative data  
 In general, the results of the quantitative data gathered suggest that there were some 
positive changes in participants’ symptoms as a consequence of the CBT program. 
Specifically, the data indicate that participants were less pre-occupied by their delusions, and 
less convinced by their beliefs at the end of treatment. The data also indicate that participants 
and caregivers differed in their evaluations of participants’ interpersonal communication 
skills, and that there was a significant increase in participants’ prosocial functioning over 
time.  
 More specifically, when using criteria to determine clinical significance, not only did 
several participants attain reductions in terms of their delusions, there were others who 
showed reduced auditory hallucinations, and psychopathology in general. Moreover, a 
number of participants reported increased quality of life and social functioning, and several 
caregivers indicated significant increases in functioning over time for some participants. The 
graphical display of psychotic symptoms rated over assessment periods and sessions suggests 
that individuals varied greatly on this measure. While some participants showed little 
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variation over time, others demonstrated a gradual decrease in symptoms, and two 
participants’ symptoms ceased almost immediately between the baseline and pre-treatment 
periods. A further explanation of the changes noticed over time is provided in the qualitative 
data gathered. 
The data from the qualitative interviews echoes the results from the statistical 
analyses, suggesting that both participants and their caregivers noticed changes over a number 
of areas, including thoughts, feelings, behaviours, and attitudes, as well as changes in social 
relationships and other areas of functioning. Thus, while there appears to be some agreement 
between the two data sets, both indicating that there is a reduction in psychotic symptoms, 
and the individual data suggesting there are changes in several areas, the qualitative data 
provided a more fine-grained understanding of how symptoms may have changed, and how 
this change has affected them. 
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Chapter 4. Discussion 
 
4.1 Summary of findings and integration with the literature
 
 The current research examined the outcomes of a program of cognitive behavioural 
therapy for individuals experiencing positive psychotic symptoms despite receiving 
medication and routine care. The outcome variables of interest were psychotic symptoms, 
quality of life, and social functioning. Specifically, it was predicted that there would be a 
decrease in psychotic symptoms in terms of their severity, frequency, and intensity. 
Additionally, it was predicted that there would be significant increases in participants’ 
functioning and quality of life, in the areas of social engagement, interpersonal behaviour, 
prosocial activities, recreation, independent living skills, and occupational skills. These 
domains were examined using both quantitative and qualitative measures. Due to the small 
sample size the following information should be interpreted with caution. Specifically, a 
number of statistical tests were performed on a very small data sample, indicating that some 
of these significant results could be attributed to chance and are not an accurate reflection of 
the data. 
From the quantitative analyses, results suggested that participants experienced 
significant decreases in their delusions in terms of amount of preoccupation and conviction in 
beliefs in them. The weekly data indicated that there was a gradual decrease in psychotic 
symptoms over time for several participants. The quantitative analyses indicated that there 
was no statistically significant improvement in the quality of life or social functioning of 
participants. In terms of clinical significance, several participants had significant reductions in 
psychotic symptoms, and increases in quality of life and functioning as rated by themselves, 
the clinicians, and caregivers. Several participants also experienced clinically significant 
declines in the quality of life and social functioning. From the qualitative analysis, results 
suggested that there were significant decreases in psychotic symptoms, and increases in social 
functioning, from the perspectives of participants and their caregivers. Therefore, it appears 
that Hypotheses 1 and 2 were only partially supported. The following sections will explore 
the results of these analyses. Limitations and future research directions will then be discussed. 
There were a number of implications of this research for both clinicians and future research.  
4.1.1 Participant information 
In regards to demographic information, there were no significant differences between 
individuals who were referred to the project, and those who participated in the research. 
Further, while statistical tests were not feasible when comparing individuals who were 
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accepted into the research, to those who then went on to participate, a comparison of non-
participants’ demographic information to participants’ means and standard deviations on these 
variables suggested there were no systematic differences between these two groups of 
individuals. As a result of uniform data, there were no differences between individuals who 
participated in the project, and those who did not in terms of demographic characteristics. The 
absence of outliers or contradictory evidence suggested that the sample of individuals who 
completed the therapy were representative of the population receiving treatment at the 
community mental health service.  
On several demographic variables the current participants appeared to be very similar 
to individuals who have completed past CBT for psychosis research programs. However, 
significant differences between the data may not have come to light due to the small sample 
size of the current research. In particular, there were no differences between the current 
participants and past research participants in terms of age, length of illness, medication levels 
(Morrison, Renton et al., 2004), and severity of psychotic symptoms (Cather et al., 2005). 
However, current participants’ cognitive functioning was significantly lower in comparison to 
that of individuals in past research (Kuipers et al., 1997). While this significant difference is a 
result of the inclusion of one participant with a mild intellectual disability, it is important to 
take into account how cognitive variables may mediate the acceptance of CBT for psychosis. 
A previous set of case studies have indicated that CBT, when modified, can be used 
effectively with individuals with an intellectual disability (Haddock et al., 2004), suggesting 
that it is unlikely that the current participants’ cognitive ability greatly impacted on the 
efficacy of the treatment. However, it may have been useful during the initial assessment 
period to provide participants with scenarios assessing their cognitive flexibility (Haddock et 
al., 2004), as the results of these scenarios may have affected the way particular sessions were 
conducted, and how information was presented to several of the participants, including the 
individual with an intellectual disability.  
It is also noteworthy that a comparison of past (Gumley et al., 2003) and current 
research participants using single sample t-tests indicated that there was no significant 
difference between the two groups in terms of raw scores on the SFS: P (Birchwood et al., 
1990). Therefore, based on demographic information, clinician-rated scales of psychotic 
symptoms, and a social functioning scale, it can be said that the individuals who completed 
the current research were very similar to those who declined to participate, and to the 
population who have completed comparable research in the past. Consequently, the outcome 
data can be safely compared with past research outcome data. 
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4.1.2 Psychotic symptoms 
The results of the repeated measures ANOVAs for psychotic symptoms and 
psychopathology indicated that over the course of the therapy, the only symptoms to show 
significant changes were delusions, which reduced from pre-treatment to post-treatment. A 
visual analysis of participants’ results over time suggested that all scales measuring psychotic 
symptoms showed non-significant decreases in these symptoms as expected.   
Past research reviewed earlier (see Table 1) all indicated that CBT for psychosis 
appears to produce changes in a range of symptoms, functioning, and other outcomes. When 
comparing current and past results in terms of psychotic symptoms, there are both similarities 
and differences. In general, the current results echo past research with a reduction in psychotic 
symptoms (Kuipers et al., 1997; Pinto et al., 1999). When compared on a more specific level 
by examining changes in auditory hallucinations and delusions with the use of the PSYRATS 
(Haddock, McCarron et al., 1999), various researchers have noted significant reductions in 
delusions (Durham et al., 2003; Warman et al., 2005) and hallucinations (Cather et al., 2005; 
Trower et al., 2004; Wykes et al., 1999) and both delusions and hallucinations (Lewis et al., 
2002). Others have demonstrated no significant reductions in delusions (Valmaggia et al., 
2005), or delusions and hallucinations (Pinkham et al., 2004). The current study replicates 
some of these past results; participants showed no significant reductions in auditory 
hallucinations, but significant reductions in delusions. 
When the Delusions subscale was subject to further investigation, the recorded levels 
for each subscale item appeared to reduce over time between pre-treatment and post-
treatment. The aspects of the delusions that showed significant change over time included pre-
occupation, conviction, and amount and intensity of distress. Specifically, pre-occupation 
with, and conviction in the delusion reduced significantly between pre-treatment and post-
treatment. This data indicates that for this project, the aspects of delusions that appeared to 
change the most during a course of CBT for psychosis were the amount of time participants 
spend thinking about their delusions, their belief that the delusion was true and accurate, and 
the distress caused by the delusion.   
When comparing results from an in-depth analysis of changes in delusions, Haddock 
and colleagues (1999) noted significant reductions in disruption to daily life (subscale Item 6), 
with pre-occupation (subscale Item 1) and duration (subscale Item 2) approaching 
significance. These results are comparable to those of the current study with regards to 
reductions in pre-occupation (subscale Item 1) of delusions from pre-treatment to post-
treatment. The current results are also similar to past trials demonstrating reductions in 
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conviction (Jakes et al., 1999; Kuipers et al., 1997) and in preoccupation with beliefs 
(O'Connor et al., 2007). Hence, the current research results are in concordance with several 
past larger trials, indicating that there appear to be specific aspects of delusions showing the 
most change after a course of CBT for psychosis, while auditory hallucinations appeared to 
show no significant changes. 
4.1.3 Co-morbid symptoms  
Statistical analyses suggested that there were no significant changes in participants’ 
anxiety, depression, and stress levels over the course of the project. However, graphical 
representations of this data indicated that there were decreases in depression, anxiety, and 
stress scores.  
When a comparison is made between past and current research in regards to these co-
morbid symptoms, several differences are apparent. While some studies have shown a 
significant change in depression scores (Hall & Tarrier, 2003; Morrison, Renton et al., 2004; 
O'Connor et al., 2007; Turkington et al., 2002), some noted changes in anxiety and depression 
levels (Warman et al., 2005), others have shown no differences when compared to a control 
group (Kuipers et al., 1997; Rector et al., 2003; Sensky et al., 2000), and no change over time 
(Trower et al., 2004; Wykes et al., 1999). The current study’s results are consistent with the 
results of several of the latter studies, as there were no significant changes in depression and 
anxiety scores over time. However, it should be noted that the present trial employed an 
assessment measure different to those used in past research. Specifically, the current measure 
was shorter, and attempted to measure all three aspects of depression, anxiety and stress in a 
limited number of statements. It may be that more specific measures such as the Beck 
Depression Inventory – Second Edition (BDI, Beck et al., 1961) or the Beck Anxiety 
Inventory (BAI, Beck et al., 1988) can provide greater detail into these areas, and are thus 
able to demonstrate significant changes.  
Additionally, the current participants reported lower depression and anxiety scores 
when compared to previous research participants who did show changes in these areas 
(Morrison, Renton et al., 2004; O'Connor et al., 2007; Warman et al., 2005). It may be that, 
similar to past research (Rector et al., 2003), individuals with lower depression and anxiety 
levels are less likely to show changes in these areas after receiving CBT for psychosis. 
Therefore, the current results can be cautiously interpreted, indicating that CBT for psychosis 
did not have an impact on co-morbid anxiety and depression. However, considering a number 
of factors may have impacted on these results, further research is needed to investigate 
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whether there are differences in outcomes for individuals with pre-existing high and low 
anxiety and depression levels. 
4.1.4 Medication levels and adherence 
While not statistically significant, there appeared to be a slight decrease in medication 
levels, and a slight increase in medication adherence during participation in the CBT program. 
The results of this research are similar to that of a past study by Bechdolf and colleagues 
(2004); both studies indicated that although there were no statistically significant results, 
medication adherence appeared to increase over the treatment period. Other past researchers 
have reported no differences between treatment groups in terms of medication (Tarrier et al., 
2004). While research by Kemp and colleagues (1996; 1998) has specifically examined 
medication adherence in the hope of increasing adherence, the results of the current trial 
indicate that this is a variable that deserves more attention in the future. In particular, it may 
be important to examine whether, during a course of CBT for psychosis, a link exists between 
reduced psychotic symptoms and medication adherence. While there is likely to be a 
connection between these variables, particularly if clinicians spend time focusing on relapse 
prevention and maintaining wellness strategies (Fowler et al., 1995), there is little statistical 
data to support this relationship. Researchers may be able to examine these variables further 
using a medication adherence rating scale similar to that used in the current research (MARS, 
Thompson et al., 2000), measuring medication levels by pill counting methods or blood 
samples, and comparing these with changes in psychotic symptoms over time. A full 
investigation may increase the current understanding of how to maintain and increase 
treatment compliance, as well as methods of enhancing CBT for psychosis. 
4.1.5 Quality of life 
Contrary to predictions, for many subscales of the quality of life measure there 
appeared to be non-significant decreases in scores over time. While decreases in co-morbid 
symptoms, and increases in medication adherence were somewhat expected, the reduction in 
quality of life areas was surprising and unanticipated.  
Several previous studies have reported QOL as improved after receiving treatment 
(Jackson et al., 1998; Wiersma et al., 2004), with results approaching significance for one trial 
(Daniels, 1998). Clearly, the current results are inconsistent with previous findings. As the 
current study is the first to implement this particular quality of life measure in a CBT for 
psychosis study, it is difficult to determine what may have produced these results. It is 
hypothesised that reductions in quality of life are associated with increases in insight into, and 
reductions in pre-occupation with, delusions. With increasing insight into their symptoms, 
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individuals may become less satisfied with their relationships with others, leisure activities, 
and general functioning. These unexpected and confounding results demonstrate the need for 
further research exploring both quality of life outcomes for CBT for psychosis, and the links 
between psychotic symptoms and quality of life.  
4.1.6 Social functioning 
 When participants’ responses were compared to those of their caregivers on the SFS, 
results indicated that there was agreement between the two groups on all subscales except for 
interpersonal communication, where participants rated themselves as more highly functioning 
than caregivers rated participants. Overall, this suggests that participants and caregivers 
possess good understanding of these areas, and both are aware of how the individual is 
functioning across several domains over time. This is a particularly intriguing result as results 
on all other scales suggested that caregivers were likely to provide higher ratings of 
participants’ skills, with these ratings increasing over time. The significant difference between 
results for the interpersonal communication scale suggests two possibilities: either 
participants are over-rating themselves on this scale, or caregivers under-rated participants. 
Given the limited knowledge available in this area, it is difficult to determine which 
hypothesis is more accurate. However, as items on this scale investigate how well the 
individual is able to communicate with others, it is suggested that caregivers may be able to 
provide more accurate information in this area. Corroborating evidence for this proposal is 
provided by the detailed and extensive information provided by caregivers during post-
treatment interviews, suggesting that they may have greater insight into the changes and 
functioning of participants.  
There were also significant increases in the prosocial functioning scale over time, as 
rated by both participants and caregivers. This data suggests that the only area of functioning 
to show change over the course of the project was one involving participants’ willingness and 
likelihood to engage with others on a more frequent basis. While the statistical results 
indicated that the change occurred from baseline to post-treatment, an examination of the data 
suggested that the greatest change was from baseline to pre-treatment. 
Many past trials have measured functioning outcomes by examining readmission and 
relapse data (Lewis et al., 2002; Tarrier et al., 1998). The present research has measured 
functioning and quality of life through two questionnaires completed by participants. In 
general, there have been mixed results reported in the past for this area, with some trials 
reporting increases in functioning (Temple & Ho, 2005b; Wiersma et al., 2004), and others 
reporting no such changes (Turkington et al., 2002). More specifically, when implementing 
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the SFS (Birchwood et al., 1990), some past researchers have reported significant increases in 
functioning in general (Gumley et al., 2003; Hall & Tarrier, 2004), and in more specific areas 
including performing independent tasks and prosocial activities (Gumley et al., 2003). In 
contrast, others have reported no significant changes (Cather et al., 2005; Kuipers et al., 1997; 
Tarrier, Beckett et al., 1993). The current results appear to support those found by the latter 
groups, with increases found in prosocial skills, and no statistically significant changes over 
time in any other areas of social functioning as measured by the SFS.  
To date, this trial is the first to administer the SFS to both participants and their 
caregivers, and to use these results to determine whether there is concordance between these 
two groups. The results of the trial suggested that there is agreement across all functioning 
domains between participants and caregivers except when reporting on interpersonal 
communication skills, where caregivers rated participants as less skilled in this domain. The 
data provides some support to past research stating that individuals with psychosis are reliable 
reporters of their functioning (Corrigan et al., 1996), and that there is concordance between 
individuals and their parents when asked to report on goals and hopes (Stein et al., 2007). 
This information could be used by future researchers examining concordance between 
participants and their caregivers for domains of functioning, and also by clinicians who are 
providing help to individuals and their families, attempting to enhance lines of 
communication.  
The results of the statistical analyses should be interpreted with caution for several 
reasons. First, it was originally predicted that a group size of 40 was required to find 
statistically significant results, however this group size was not achievable due to limitations 
in recruitment. Consequently, the relatively small number of participants in this study may 
have resulted in reduced power and fewer significant results. Second, the effect sizes 
associated with the significant results were medium, with some small effects associated with 
non-significant results. This information hints at the possibility that with a larger sample size, 
some of these analyses may have produced significant results. Finally, while it was originally 
expected that participants’ symptoms and functioning would not change from baseline to pre-
treatment assessment points, an examination of the group data demonstrates that there were 
non-significant differences over this time in many of areas, including auditory hallucinations, 
delusions, medication levels, and quality of life. This variability suggests that participants’ 
symptoms may not have been stable over time, specifically for the two individuals whose 
symptoms appeared to decrease significantly over the baseline and early intervention periods. 
Therefore, these individuals did not strictly meet the criteria of the study, and the inclusion of 
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their responses may have skewed the results. Variability in symptoms and functioning 
suggests that there may have been other factors influencing these outcome variables, 
including medication, making it difficult to determine the effects of CBT on these areas. 
When implementing a baseline-treatment design in future research, it would be 
advisable to establish a stable baseline using continual assessment until stable results are 
achieved (Key et al., 2003). These limitations, the effect sizes, and variation across baseline, 
suggest that the further analysis examining individual data using clinical significance criteria, 
and the qualitative data, may provide a more accurate and detailed understanding of the 
results of the research.  
4.1.7 Clinical significance results 
 When analysed for clinical significance, the data suggested that several participants 
experienced a substantial reduction in psychotic symptoms, and increase in quality of life and 
functioning over the course of the program. Specifically, two participants had reduced 
psychopathology, six participants had reduced delusional symptoms, and two reported 
reduced auditory hallucinations. For quality of life, three participants reported increases on 
the subscales examining Social Relations, Feelings, Leisure Time Activity, and General 
Activities. For functioning, one participant reported an increase in Recreation. When 
caregivers rated participants, one participant had an increase in Interpersonal Communication 
and Recreation, and one experienced an increase in Independence Performance. 
 In regards to clinically significant worsening, three participants demonstrated 
worsening on the Social Relations, Leisure Time Activities, and General Activities scales, 
two participants had declined on the Feelings and Interpersonal Communications subscales, 
and one participant had declined on each of the Prosocial and Withdrawal/Engagement 
subscales.  Participants Three and Six who showed the greatest reduction in delusional 
symptoms, also demonstrated the greatest decline in functioning, and over a range of areas. 
This information seems to suggest that for these participants, a decline in psychotic symptoms 
was associated in some way to a decline in functioning, and that it could be damaging for an 
individual to experience a reduction in these.  
The clinically significant increases confirm the repeated measures analysis results for 
participants’ delusions, and provide further information about clinically significant changes in 
other areas. The results further suggest that the statistical measures used in this research may 
not have provided a full explanation of changes in symptoms and functioning.  
When comparing the current results to past research in terms of clinical significance, a 
number of similarities become apparent. In total, over 80% of the present sample experienced 
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a clinically significant improvement in either symptoms or functioning, or both, with 44.44% 
experiencing a 20% change in either symptoms or functioning, and 44.44% experiencing a 
50% improvement in symptoms. Similarly, Sensky and colleagues (2000) reported that 52 – 
70% of their CBT group achieved clinically significant results, while Rector and colleagues 
(2003) and Cather and colleagues (2005) both reported a 20% change rate of over 60% for 
their CBT groups. In past studies implementing 25% and 50% criteria, Warman et al. (2005) 
indicated that five participants achieved the former, and three reached the latter, which is very 
similar to the results of a larger trial (Kuipers et al., 1997). In terms of a small trial, Key et al. 
(2003) found that they had three treatment responders, three non-responders, and one mixed 
case, similar to the current research, where there was one treatment non-responder.  
In comparison to past research examining clinically significant changes for 
functioning, Gumley et al. (2003) reported changes in prosocial functioning, whereas the 
current participants demonstrated changes in interpersonal communication, independence, and 
recreational activities as rated by themselves and their caregivers. To date, no other trials have 
examined clinically significant changes in terms of quality of life, and it is therefore not 
possible to draw comparisons in the literature. In summary, when using clinical significance 
criteria, the percentage of the current population showing change in psychotic symptoms is 
very similar to that of past research implementing both 20%, and 25% and 50% levels of 
change. However, there are differences when examining this data for social functioning 
changes, with the current data supporting changes in several areas when rated by participants 
and their caregivers. The data supports the proposition that CBT for psychosis results in 
clinically significant changes in psychotic symptoms and functioning, although these may not 
be in a positive direction. Future research may be required to determine whether the 
improvements in quality of life areas can be replicated and explored further implementing 
different assessment measures. Also, researchers need to spend more time exploring the 
negative effects of intervention, and the impact of reducing psychotic symptoms on an 
individual’s functioning. 
4.1.8 Individual session data 
Graphical representations of participants’ psychotic symptoms from session to session 
provided further detail about psychotic symptoms across individuals over time. When 
represented in a graph, the data suggested that there was considerable variation in delusions 
and auditory hallucinations from baseline to pre-treatment, and then from session to session, 
and across participants. This variation in symptoms over the baseline period could be 
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attributed to individual variation, improvement due to receiving treatment as usual, or may be 
a result of rater bias. 
Over the treatment period several participants showed a gradual decline in symptoms 
over time, two participants’ symptoms disappeared almost from baseline to pre-treatment, and 
one participant showed minimal change in their symptoms from baseline to post-treatment. 
The data provided by the latter participants could account for the non-significant differences 
in statistical results when pre-treatment and post-treatment data was compared. In particular, 
as there were only four participants with auditory hallucinations at baseline assessment, and 
ratings of symptoms varied greatly across participants over time, it may be that there was 
insufficient data, and the data was so varied, that it could not show change when examined as 
a whole. Therefore, an examination of each individual’s data provides greater insight into how 
psychotic symptoms can be variable, and how each participant’s data contributed to the group 
data. 
When examining data on an individual basis, several researchers have graphed 
participants’ results in order to demonstrate how each individual has progressed, and how 
symptoms have varied (Chadwick et al., 2003; Haddock et al., 2004; Key et al., 2003; 
Pinkham et al., 2004; Wragg & Whitehead, 2004; Wykes et al., 1999). All of the graphs in 
previous trials have indicated that participants have consistently shown a reduction in 
psychotic and comorbid anxiety and depressive symptoms over time, similar to the current 
research where a number of participants’ psychotic symptoms appeared to decrease over time. 
More specifically, the results are comparable to those of Key et al. (2003) and Haddock and 
colleagues (2004), in which several participants’ symptoms reduced over time, while others 
appeared to show little change in this aspect. Consequently, the results demonstrate that some 
individuals who receive CBT for psychosis will experience reductions in their psychotic 
symptoms, whereas others will not benefit from the treatment. Crucial research is now 
examining what are the fundamental elements of CBT for psychosis (Chadwick et al., 2003; 
McGowan et al., 2005), and what types of symptoms would reduce the most after treatment 
(Kuipers et al., 2006) to determine who would benefit the most from treatment.    
4.1.9 Qualitative results 
 A grounded theory methodology was implemented to examine the post-treatment data 
gathered from participants and caregivers. When this data was coded and analysed, a total of 
five categories emerged, each with a number of sub-categories. An overarching theme of the 
data was talking, and the beneficial effects participants associated with this aspect. 
Participants and their caregivers noted a number of useful strategies learnt in therapy, and 
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how their feelings, thoughts, behaviours, and attitudes were all changed as a result of taking 
part in the project. In addition, there were changes noted in participants’ independence and 
activity levels, relationships with others, and self-care. There was a discrepancy in this data, 
with participants often reporting or noticing fewer changes than those noted by their 
caregivers. The changes noticed were attributed not only to taking part in therapy, but a 
myriad of other events and treatments occurring, including taking medication, reduced 
substance use, increased activity level, and the participants’ motivation. Of particular interest 
were the issues and concerns raised by participants and caregivers, reflecting their attitudes 
towards treatment, difficulties with remembering information, and for caregivers, the 
difficulty they had not being involved and not being informed of the content of sessions and 
the treatment. The results of this data suggest that when collecting data from small groups, it 
may be useful to examine this data on an individual level using qualitative methods. In 
particular, this type of data can provide a fine-grained understanding of the possible changes 
and difficulties involved in implementing a therapeutic intervention. The data could then be 
used to inform future treatment groups of possible difficulties arising, allowing them the 
possibility of evading these problems, perhaps by involving caregivers in treatments, or by 
explaining the need for confidentiality at the commencement of a therapeutic program.  
 As the current study employed a grounded theory methodology to analyse the 
qualitative data provided, it is difficult to compare and contrast the information provided by 
this method to the research and results of previous studies. However, there were a number of 
similarities noted across the research in terms of the emerging themes. Messari and Hallam 
(2003) conducted a discourse analysis of clients’ and therapists’ experiences of CBT for 
psychosis, many of the themes from their research are echoed in the current trial, including 
the experience and benefits of talking, the educational experience of CBT, the individuals 
who did not perceive receiving any help from CBT, and the individuals who noted a power 
differential between themselves and the therapist. There were also similarities in accounts of 
the most helpful therapy tools, including breathing, examining alternatives or questioning the 
evidence, and hypothesis or evidence testing (Key, 2001). Interestingly, there were 
similarities in the negative emotional responses resulting from some aspects of therapy 
(Chadwick et al., 2003), and in the changes in conceptualisation of symptoms (McGowan et 
al., 2005). Subsequently, it appears that many of the key aspects and categories identified in 
the present study replicate and enhance information provided, and categories identified 
previously, supporting the validity of the current results. Consequently, the qualitative results 
can be used to further understand the results produced by the statistical analyses. 
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First, it may be that similar to previous research, the participants who were unable to 
recall or remember the content of sessions and understand this information, were those least 
likely to benefit from the treatment (McGowan et al., 2005). Second, as the results support the 
importance of the therapeutic relationship as an active ingredient in therapy, it is difficult to 
separate out the effects of this from other important elements of CBT for psychosis (Messari 
& Hallam, 2003). Therefore, there appear to be several factors that have confounded the 
results of the current research, making it difficult to interpret how useful the course of CBT 
for psychosis was, and what the key ingredients or factors may be. Further clarification was 
provided by the emerging themes of the research. These consisted of changes in thoughts, 
feelings, behaviours, and other domains as a result of CBT for psychosis, and the key aspects 
or areas that individuals attributed these changes to, including medication, the mental health 
service, the opportunity to speak with someone, reduced substance use, occupying activities, 
and motivation and coping strategies. These new themes indicate that while CBT for 
psychosis was found to be useful by many of the participants, several confounding and 
extraneous factors may have impacted on progress in treatment.  
 
4.2 Theoretical implications
 
 The current research is the first to conduct an in-depth examination, using both 
quantitative and qualitative methods, of social functioning and quality of life outcomes for 
individuals receiving CBT for psychotic symptoms. It is also the first known study to evaluate 
these outcomes using data provided by caregivers. Information from this research suggests 
that when these areas are assessed in a group format, only the prosocial skills domain is 
significant for changes over time. However, when the data is examined on an individual basis, 
using clinical significance criteria and qualitative methods, clear changes and improvement 
are shown. Specifically, the data indicates that after taking part in CBT for psychosis sessions, 
individuals experienced increases in several domains of quality of life and social functioning. 
The data also suggests that there are clear changes in individuals’ thoughts, feelings, and 
behaviours in relation to psychotic symptoms after taking part in CBT for psychosis. While 
these are the areas posited for change (Chadwick et al., 1996; Fowler et al., 1995), this is the 
first known study to provide evidence to indicate that there are changes occurring in these 
areas. 
There also appeared to be changes in other areas, including attitude and self-esteem, 
relationships with others, hygiene and self-care, and activities and independence. While it was 
difficult to determine whether all of these changes occurred as a result of the research, or 
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whether they occurred as a result of several factors interacting, there were clear improvements 
and changes noticed by both participants and their caregivers. Accordingly, the current study 
adds importantly to the body of research on the outcomes of CBT for psychosis, and the 
changes individuals and their caregivers notice when they begin to recover from psychosis.  
 
4.3 Clinical implications 
The results of this study are relevant when considering treatment options for 
individuals with medication-resistant positive psychotic symptoms. While recommendations 
have been made to use CBT for psychosis (McGorry, 2005; NICE, 2002), there is limited 
evidence to suggest that these suggestions have been followed up (Jones, 2002). Certainly, the 
acceptance of the current trial in an AMHS and the referrals received from case managers 
suggests that they and other staff employed at the facility were not already implementing this 
treatment with their consumers. While this project was limited to a small number of 
individuals, when the results are combined with a larger, recent trial (Farhall, Freeman et al., 
2007), results suggest that this treatment is both acceptable and feasible in a community 
mental health setting.  
It appears important then, to highlight the efficacy of this treatment both to mental 
health staff and consumers. While a number of researchers have investigated the best methods 
of disseminating information to staff, there appear to be no best-practice methods. Some of 
the most favourable suggestions involve assigning roles to individuals who provide the 
information, and creating changes at an organisational level in order for changes to be made 
permanent (Tarrier, Barrowclough et al., 1999). After this information is disseminated to staff, 
and is made permanently available to them and consumers, staff will then require training in 
CBT for psychosis techniques.  
In order to ensure that this treatment is provided adequately and effectively, staff in 
community settings need to attend CBT for psychosis training sessions, and be provided 
appropriate reading material from the several relevant manuals (Chadwick et al., 1996; 
Fowler et al., 1995; Nelson, 2005). Once case managers are fully trained in this therapy, they 
require additional supervision on a case-by-case basis, as they begin to implement their skills, 
in order to provide support and advice. It may be more cost-effective and efficient to initially 
train a limited number of individuals, who can then be referred clients with specific needs 
(Fowler et al., 1998). Alternatively, it has been recommended that more generic teams are 
taught specific skills for interventions for psychosis, as this would reduce costs (Jones, 2002). 
While both methods initially appear to be lengthy and costly interventions, the long-term 
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gains and improvements by individuals who have received the therapy may outweigh the 
initial layout costs (Tarrier, Barrowclough et al., 1999).  
In addition to the costs involved, a number of limitations to implementing CBT for 
psychosis in the community have been suggested. These include time constraints (Kavanagh 
et al., 1993), attitudes to psychosis, the difficulties inherent in developing a relationship with 
individuals with psychosis (Fowler et al., 1998), and the possibility that more than techniques 
are required for effective implementation of CBT (Tarrier & Wykes, 2004). It seems then, that 
a great number of changes is required in community mental health settings before CBT for 
psychosis can be made widely available to consumers of these services. It may be that the 
provision of this research trial in a public mental health service has, at least, educated a 
number of case managers of this service about the treatment and its possibilities, which may 
impact on their future treatment decisions for consumers.  
The results of this research have demonstrated the importance of evaluating each 
individual’s progress, and assessing a number of areas including symptoms, functioning, 
quality of life, and medication adherence. It is recommended that when this therapy is 
implemented in community mental health settings, similar assessment tools be implemented 
in order to provide a good understanding of how individuals respond to the treatment, and 
may also highlight important changes to be made to the delivery and focus of the treatment.   
 
 4.4 Methodological Limitations 
The current research had a number of advantages, including recruiting participants 
from a community setting, widening the inclusion criteria to include individuals with 
intellectual disabilities and drug and alcohol issues, and accessing information using both 
questionnaires and interviews. However, there were also several limitations of the research, 
that may have affected the outcome of results, and could be improved in future research. 
These limitations include the length of therapy, participant numbers, lack of control group, 
non-blind raters, medication levels, and the assessment measures.  
4.4.1 Length of therapy 
On a continuum, the period of time over which therapy was delivered in the current 
study (15 sessions over 15 weeks) was located between that implemented in past studies, with 
a few trials employing short-term sessions lasting between one to two months (Chadwick, 
Sambrooke et al., 2000; Gledhill et al., 1998; Haddock, Tarrier et al., 1999), and the majority 
of trials offering up to nine months of treatment (Farhall & Cotton, 2002; Kuipers et al., 1997; 
Sensky et al., 2000; Wiersma et al., 2004). Practice manuals suggest that therapy lasts 
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between six and nine months (Fowler et al., 1995; Nelson, 2005) because the presence of 
cognitive deficits and psychotic symptoms can interfere with engagement, attendance, the 
ability to concentrate and understand new concepts, and the ability to implement new 
strategies and coping methods addressed in sessions. Thus, therapists implementing CBT with 
this group need to be flexible both in session length, and with the period of time an individual 
may require to adjust to the therapy process and make significant changes.  
As the session numbers were kept the same for each participant, it may be that similar 
to past studies (Key et al., 2003), some participants were not provided with sufficient sessions 
to demonstrate significant changes in symptoms and functioning. Alternatively, in the past 
when sessions have been contracted in blocks of six (with a maximum of 30 sessions), 
participants have contracted for a mean of 17.7 sessions (Morrison, Renton et al., 2004), 
indicating that this has been a suitable and sufficient number for participants. Therefore, the 
lack of changes may be explained by other, individual factors, including the strength of the 
delusional beliefs, and difficulty engaging in a talking-based therapy.  As the current project 
was designed as a research trial in which every participant was expected to receive the same 
length of treatment, it was not possible to be flexible with the time period over which sessions 
were conducted. Future trials may need to offer sessions in blocks, with a maximum number 
of available sessions, to be flexible and adjust to individual needs.    
4.4.2 The sample 
While it was originally proposed that the research would include a group of 40 
participants, the difficulties in recruitment, in combination with a constrained time during 
which to conduct the research and minimal resources, led to limited number of participants 
being recruited and completing the study. This small number of participants significantly 
impacted on the power and type of analyses performed on the data. The data from such a 
small sample is often unstable and any conclusions or generalisations made should be 
recognised as tentative and provisional. This has also been the case with other trials involving 
limited participant numbers (Key et al., 2003). Recruiting participants with psychotic 
symptoms for a long-term talking therapy has always been difficult (Barrowclough et al., 
2001; Bechdolf et al., 2004; Farhall et al., 2004; Hall & Tarrier, 2003; Miles et al., 2007; 
Startup et al., 2004; Trower et al., 2004). In this study, similar to past research, recruitment 
was affected by lack of insight, work commitments, and non-attendance to outpatient services.  
If the inclusion criteria had been broadened to consist of psychological needs and not 
just positive psychotic symptoms, a greater number of participants may have been recruited. 
On the one hand, this could have resulted in therapy less strictly focused on the impact of 
 142 
persistent positive symptoms, and provided greater insight into the needs of such a population 
(Farhall, Freeman et al., 2007). On the other hand, greater inclusion criteria may have limited 
the specificity of the therapy, making it difficult to determine the effects of a course of CBT 
for psychotic symptoms on quality of life and social functioning. Therefore, future researchers 
may find that widening the inclusion criteria will result in greater participant numbers, but 
may need to consider this when analysing and interpreting their data. 
 One of the aims of the study was to recruit a wide and varied sample by not limiting 
recruitment through diagnostic categories, and allowing individuals with drug and alcohol 
use, and with intellectual disabilities to take part. However, it could be argued that the sample 
was biased simply by its recruitment techniques. As the research was voluntary, and 
participants were informed that their role in the project would involve discussing their 
symptoms and using psychological strategies to manage these, only individuals wanting to 
modify their symptoms and attempt such strategies agreed to take part. This suggests that the 
results of this trial, and of previous research, may only be generalised to a limited population 
of individuals with psychotic symptoms at a particular phase of their illness.  
4.4.3 Control group 
Similar to several past research trials (Farhall & Cotton, 2002; Gledhill et al., 1998; 
Key et al., 2003; Lecomte et al., 2003; Warman et al., 2005), the most severe limitation of the 
current study was a lack of a control group against which changes in the treatment group 
could be compared. Therefore, the findings of this research should be interpreted with 
caution, as the results shown by participants in this trial cannot be directly attributed to the 
intervention alone. 
In fact, it could be argued that the changes made by the current participants may be 
due to factors other than the treatment, including the therapeutic relationship (Warman et al., 
2005) and expectations of benefit (Tarrier & Wykes, 2004). However, as Farhall and Cotton 
(2002) have stated, it is unlikely that changes in this population occur by chance. Indeed, 
change is often minimal and slow with individuals who have experienced chronic, 
unremitting positive symptoms and despite adequate adherence to medications such as 
clozapine, which is typically used for medication-resistant symptoms (Kane et al., 1988). It 
may be cautiously proposed then that some of the changes noted in the symptoms of the 
current research participants could be attributed to participation in the CBT program.   
4.4.4 Non-blind raters 
Due to resource constraints, the clinicians implementing the treatment also 
administered all assessment measures. Some argue that a researcher who has not delivered the 
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therapy should administer all assessment instruments, as this would reduce bias in regards to 
clinician-rated instruments and provide an objective measure of change. In the current study, 
clinicians may have inadvertently distorted ratings on assessment measures as they were 
aware at all times of participants’ functioning, leading to non-objective findings, which may 
have contributed to some of the variation in participants’ symptoms over the baseline period. 
The significant findings on the PSYRATS Delusions scale may thus be a result of rater 
expectancy and may have significantly compromised the results of the current study, and any 
conclusions that could be drawn from it. However, as Tarrier and Wykes (2004) have noted, 
some individuals with psychotic disorders are reluctant to discuss their symptoms with people 
they are not familiar with or trust. Also, in current community practice the clinician delivering 
treatment completes all independent measures with the participant. Thus, it could be argued 
that therapists who have established a consistent and trusting relationship and who have been 
monitoring the individual’s psychotic symptoms for the past few months are the best 
candidates to rate these symptoms on standardised measurement tools. It may be helpful in 
future research to compare the results of participants who complete measures with their 
treating clinician, to those who complete measures with a blind rater, to determine what 
effects familiarity with the assessor has on participants’ reports.    
4.4.5 Medication 
As the researchers in this project were independent of the service providing 
participants with medication, it was not possible to control for medication levels or any 
changes made in them over the course of the study. Changes in medications and their amounts 
could have affected participants’ symptoms and functioning outcomes in both positive and 
negative directions. In particular, as one individual initially refused all antipsychotic 
medication at the commencement of the trial, one individual ceased medication during the 
baseline period, and one individual’s medication was changed from quetiapine to clozapine 
during the baseline period, it is very difficult to estimate how these changes may have 
impacted on participants’ results.   
Additionally, although medication adherence was measured at the commencement and 
conclusion of the research, it is difficult to say how adherent each participant was with 
medications over the course of therapy sessions. It may be that fluctuating medication 
adherence, and changes in medication may have affected the sessional ratings of psychotic 
symptoms, both worsening and improving them. Medication adherence is a very difficult 
aspect to measure, and while a number of techniques have been proposed to measure it, none 
are perfect. It may be that until more precise and consistent measures are developed, 
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researchers must continue to rely on self-report and objective measures, including pill 
counting, prescription-filling, and blood tests. In the current research, asking participants 
whether they were taking their medication each session may have improved the clinician’s 
ability to correctly judge the effects of the therapy in conjunction with antipsychotic 
medication.  
4.4.6 Measurement tools 
 The assessment instruments implemented in the current study are some of the most 
popular, reliable, and valid measures to date.  However, there appears to be a growing need to 
create more specific instruments for this population, and more self-report instruments. Over 
the course of the research, it became apparent that used weekly, the differentiation provided 
by the PSYRATS was not fine enough to capture the changes in symptoms reported by 
participants. For example, at the conclusion of the study, the descriptive information provided 
by participants in regards to their symptoms suggested that there were minor, but fairly 
significant changes. In the current study, and in future research requiring weekly psychotic 
symptoms ratings, it may be better to create a personalised measure of symptoms, such as a 
graphical display of severity that participants could mark or colour in (i.e. thermometer, 
Wade, 2007), or provide some opportunity to include qualitative descriptions of symptom 
changes. 
 Additionally, while the Q-LES-Q (Endicott et al., 1993) has been implemented in past 
research for individuals with psychotic disorders in Australia (Halperin et al., 2000; Kingsep 
et al., 2003), it may not have been the most appropriate measure for the current population. 
Specifically, both the School/Courses and Work subscales results were not included in the 
results as, at the commencement of the study as only two of the participants were working, 
and none were studying. The removal of these subscales may also be indicative of the poor 
functioning of the current research population, and reflects a growing body of research 
suggesting that employment levels for individuals with psychosis are particularly low 
(Marwaha & Johnson, 2004; Salkever et al., 2007). To provide a more accurate level of 
quality of life, future researchers may want to utilise an assessment tool that has been 
specifically designed for individuals with psychosis, or work with individuals with psychosis 
to collaboratively design an accurate and appropriate measure of functioning and quality of 
life.   
4.5 Recommendations for further research
 
Currently there exists a large body of research exploring the utility of CBT for 
individuals with psychotic symptoms. Due to the nature of psychotic disorders and symptoms, 
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and the possible areas that could be affected by treatment, further research is required to 
create an in-depth understanding of the key components of the therapy, and the areas that are 
affected by the treatment. While there is research demonstrating the impact of case 
formulation (Chadwick et al., 2003), and others have explored specific coping strategies 
(Farhall, Greenwood et al., 2007), and the therapeutic relationship (Messari & Hallam, 2003; 
Warman et al., 2005), the current qualitative data provided information about how thoughts, 
feelings, and behaviours can alter as a result of the treatment. This information could be used 
as a preliminary step towards determining which strategies or techniques are the most 
effective, with which types of delusions. These areas could be examined through an 
assessment of participants’ thoughts, feelings, and behaviours at the commencement, during, 
and at the conclusion of a trial.  This information could then be used to guide future 
assessments of these areas, helping to refine clinicians’ skills and targeted treatment areas. 
More specific treatment strategies and tools would not only aid individuals’ recovery from 
psychosis, but may be implemented at a reduced cost to mental health services, making them 
more appealing in terms of training staff and providing them the time to implement 
treatments.   
In terms of the future research required to explore social functioning and quality of life 
outcomes, a number of recommendations are made. In particular, future studies using a range 
of different measurement tools including daily diary ratings, behavioural observations by 
mental health staff or families, and further qualitative exploration may provide finer and more 
specific details of these domains. Additionally, more specific measures for this population 
could be created by interviewing individuals on their perceptions of what QOL consists of and 
how it may be altered or reduced during psychotic episodes. Increasing the knowledge base in 
this area leads not only to a better understanding about how treatment affects these outcomes, 
but it can also lead to tailoring treatments based on individual needs and strengths. Greater 
understanding of quality of life and social functioning and how these are affected by 
psychosis could result in researchers creating profiles or models of relationships and 
connections across areas, providing an enhanced understanding of how to target them directly 
and specifically.  
It may also be important to explore the utility of CBT for psychosis combined with 
other treatments. While this has been done on several occasions in the past (Haddock et al., 
2003; Hornsveld & Nijman, 2005; Wiersma et al., 2004), the data from this trial suggests it 
requires further exploration. Specifically, several caregivers indicated that they found it 
difficult because they were not involved in the therapy process, in terms of understanding why 
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participants may be upset or distressed, and also knowing whether individuals were 
improving, and how they could help with this. Future research may need to explore involving 
caregivers further, examining the effects of a combination of family therapy, 
psychoeducation, and CBT for psychosis. This type of research could reduce the distress and 
discomfort caregivers experience as a result of not being included in the therapeutic process, 
and may result in positive benefits for both participants and caregivers. 
Finally, the current research involved a limited number of participants, with no control 
group as a comparison, exploring novel areas that had previously received minimal attention. 
In order to better understand and replicate the results of the current trial, future research with a 
large sample size and a comparison or control group is required. The data from a large, 
controlled study could be used to determine whether the treatment effects seen in the current 
study were due to the treatment alone, or whether other factors were at play, and could thus 
further explore quality of life and social functioning outcomes.   
 
4.6 Conclusions 
The results of this study provide important information about the utility of CBT for 
psychosis for individuals experiencing psychotic symptoms despite receiving routine care in a 
community mental health service. Specifically, the results partially support the proposition 
that individuals who receive this treatment experience significant reductions in their 
delusions, and increases in quality of life and social functioning. This treatment allows 
individuals who have been experiencing the devastating effects of psychotic symptoms for 
long periods of time the possibility of managing these symptoms by reducing their conviction 
in their delusions, the distress associated with the delusions, and the time they spend thinking 
about the delusions. Given that a significant percentage of psychotic episodes are treatment-
resistant, in addition to the significant proportion of individuals who do not adhere to 
medication, it is vital that treatment options for individuals with psychosis are expanded and 
explored. This research has provided further information about the results of CBT for 
psychosis, and added to the literature supporting the efficacy of CBT for psychosis.   
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Appendix A 
 
Brief Psychiatric Rating Scale (BPRS) 
Individual's name:   
Date:   
Rater's name:   
Instructions: 
This form consists of 24 symptom constructs, each to be rated in a 7-point scale of severity ranging 
from 'not present' to 'extremely severe' If a specific symptom is not rated, mark 'NA' (not assessed). 
Circle the number headed by the term that best describes the patient's present condition. 
1 2 3 4 5 6 7 
 
 
      
not present very mild mild moderate moderately 
severe 
severe 
extremely 
severe 
 
1 Somatic concern NA 1 2 3 4 5 6 7 
2 Anxiety NA 1 2 3 4 5 6 7 
3 Depression NA 1 2 3 4 5 6 7 
4 Suicidality NA 1 2 3 4 5 6 7 
5 Guilt NA 1 2 3 4 5 6 7 
6 Hostility NA 1 2 3 4 5 6 7 
7 Elated Mood NA 1 2 3 4 5 6 7 
8 Grandiosity NA 1 2 3 4 5 6 7 
9 Suspiciousness NA 1 2 3 4 5 6 7 
10 Hallucinations NA 1 2 3 4 5 6 7 
11 Unusual thought content NA 1 2 3 4 5 6 7 
12 Bizarre behaviour NA 1 2 3 4 5 6 7 
13 Self-neglect NA 1 2 3 4 5 6 7 
14 Disorientation NA 1 2 3 4 5 6 7 
15 Conceptual disorganisation NA 1 2 3 4 5 6 7 
16 Blunted affect NA 1 2 3 4 5 6 7 
17 Emotional withdrawal NA 1 2 3 4 5 6 7 
18 Motor retardation NA 1 2 3 4 5 6 7 
19 Tension NA 1 2 3 4 5 6 7 
20 Uncooperativeness NA 1 2 3 4 5 6 7 
21 Excitement NA 1 2 3 4 5 6 7 
22 Distractibility NA 1 2 3 4 5 6 7 
23 Motor hyperactivity NA 1 2 3 4 5 6 7 
24 Mannerisms and posturing NA 1 2 3 4 5 6 7 
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Appendix B 
 
PSYCHOTIC SYMPTOM RATING SCALES 
 
A Auditory hallucinations 
1 Frequency 
0 Voices not present or present less than once a week 
1 Voices occur for at least once a week 
2 Voices occur at least once a day 
3 Voices occur at least once an hour 
4 Voices occur continuously or almost continuously i.e. stop for only a few seconds or minutes 
2 Duration 
0 Voices not present 
1 Voices last for a few seconds, fleeting voices 
2 Voices last for several minutes 
3 Voices last for at least one hour 
4 Voices last for hours at a time 
3 Location  
0 No voices present 
1 Voices sound like they are inside head only 
2 Voices outside the head, but close to ears or head. Voices inside the head may also be present 
3 Voices sound like they are inside or close to ears and outside head away from ears 
4 Voices sound like they are from outside the head only 
4 Loudness 
0 Voices not present 
1 Quieter than own voice, whispers. 
2 About same loudness as own voice 
3 Louder than own voice 
4 Extremely loud, shouting 
5 Beliefs re-origin of voices 
0 Voices not present 
1 Believes voices to be solely internally generated and related to self 
2 Holds < 50 % conviction that voices originate from external causes 
3  Holds 50 % convic t ion (but  < 100 %)  tha t  voices originate from external causes 
4 Believes voices are solely due to external causes (100% conviction) 
6 Amount of negative content of voices 
0 No unpleasant content 
1 Occasional unpleasant content (< 10 %) 
2 Minority of voice content is unpleasant or negative (< 50%) 
3 Majority of voice content is unpleasant or negative (,> 50%) 
4 All of voice content is unpleasant or negative 
7 Degree of negative content 
0 Not unpleasant or negative 
1 Some degree of negative content, but not personal comments relating to self or family e.g. swear 
words or comments not directed to self, e.g. ‘the milkman’s ugly’ 
2 Personal verbal abuse, comments on behaviour e.g. ‘shouldn’t do that or say that’ 
3 Personal verbal abuse relating to self-concept e.g. ‘you’re lazy, ugly, mad, perverted’ 
4 Personal threats to self e.g. threats to harm self or family, extreme instructions or commands to harm 
self or others 
8 Amount of distress 
0 Voices not distressing at all 
1 Voices occasionally distressing, majority not distressing (< 10%) 
2 Minority of voices distressing (< 50 %) 
3 Majority of voices distressing, minority not distressing (> 50 %) 
4 Voices always distressing 
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9 Intensity of distress 
0 Voices not distressing at all 
1 Voices slightly distressing 
2 Voices are distressing to a moderate degree 
3 Voices are very distressing, although subject could feel worse 
4 Voices are extremely distressing, feel the worst he/she could possibly feel 
10 Disruption to life caused by voices 
0 No disruption to life, able to maintain social and family relationships (if present) 
1 Voices causes minimal amount of disruption to life e.g. interferes with concentration although able to 
maintain daytime activity and social and family relationships and be able to maintain independent living 
without support 
2 Voices cause moderate amount of disruption to life causing some disturbance to daytime activity and/or 
family or social activities. The patient is not in hospital although may live in supported accommodation or 
receive additional help with daily living skills 
3 Voices cause severe disruption to life so that hospitalisation is usually necessary. The patient is able to 
maintain some daily activities, self-care and relationships while in hospital. The patient may also be in 
supported accommodation but experiencing severe disruption of life in terms of activities, daily living skills 
and/or relationships 
4 Voices cause complete disruption of daily life requiring hospitalization. The patient is unable to maintain 
any daily activities and social relationships. Self-care is also severely disrupted. 
11 Controllability of voices 
0 Subject believes they can have control over the voices and can always bring on or dismiss them at will 
1 Subject believes they can have some control over the voices on the majority of occasions 
2 Subject believes they can have some control over their voices approximately half of the time 
3 Subject believes they can have some control over their voices but only occasionally. The majority of the time 
the subject experiences voices which are uncontrollable 
4 Subject has no control over when the voices occur and cannot dismiss or bring them on at all 
B Delusions 
1 Amount of preoccupation with delusions 
0 No delusions, or delusions which the subject thinks about less than once a week 
1 Subject thinks about beliefs at least once a week 
2 Subject thinks about beliefs at least once a day 
3 Subject thinks about beliefs at least once an hour 
4 Subject thinks about delusions continuously or almost continuously 
2 Duration of preoccupation with delusions 0 No delusions 
1 Thoughts about beliefs last for a few seconds, fleeting thoughts 
2 Thoughts about delusions last for several minutes 
3 Thoughts about delusions last for at least 1 hour 
4 Thoughts about delusions usually last for hours at a time 
3 Conviction 
0 No conviction at all 
1 Very little conviction in reality of beliefs, < 10% 
2 Some doubts relating to conviction in beliefs, between 10–49 % 
3 Conviction in belief is very strong, between 50–99% 
4 Conviction is 100 % 
4 Amount of distress 
0 Beliefs never cause distress 
1 Beliefs cause distress on the minority of occasions 
2 Beliefs cause distress on < 50 % of occasions 
3 Beliefs cause distress on the majority of occasions when they occur between 50–99 % of time 
4 Beliefs always cause distress when they occur 
 
5 Intensity of distress 
0 No distress 
1 Beliefs cause slight distress 
2 Beliefs cause moderate distress 
3 Beliefs cause marked distress 
4 Beliefs cause extreme distress, could not be worse 
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6 Disruption to life caused by beliefs 
0 No disruption to life, able to maintain independent living with no problems in daily living skills. Able to 
maintain social and family relationships (if present) 
1 Beliefs cause minimal amount of disruption to life, e.g. interferes with concentration although able to maintain 
daytime activity and social and family relationships and be able to maintain independent living without 
support 
2 Beliefs cause moderate amount of disruption to life causing some disturbance to daytime activity and/or 
family or social activities. The patient is not in hospital although may live in supported accommodation or 
receive additional help with daily living skills 
3 Beliefs cause severe disruption to life so that hospitalisation is usually necessary. The patient is able to 
maintain some daily activities, self-care and relationships while in hospital. The patient may be also be in 
supported accommodation but experiencing severe disruption of life in terms of activities, daily living skills 
and/or relationships 
4 Beliefs cause complete disruption of daily life requiring hospitalization. The patient is unable to maintain 
any daily activities and social relationships. Self-care is also severely disrupted. 
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Appendix C 
 
TCU Drug Screen II 
 
The following questions ask about your drug use (including alcohol) in the past 3 months.  Please 
answer them by marking only one box for each question. 
  
During the last 3 months - 
 
 Yes No 
1. Did you use larger amounts of drugs or use them for a longer time 
than you had planned or intended?     
2. Did you try to cut down on your drug use but were unable to do it?    
3. Did you spend a lot of time getting drugs, using them, or recovering 
from their use?     
4. Did you get so high or sick from drugs that it –     
a. kept you from doing work, going to school, or caring for 
children?    
b. caused an accident or put you or others in danger?    
5. Did you spend less time at work, school, or with friends so that you 
could use drugs?    
6. Did your drug use cause –    
a. emotional or psychological problems?     
b. problems with family, friends, work, or police?     
c. physical health or medical problems?    
7. Did you increase the amount of a drug you were taking so that you 
could get the same effects as before?    
8. Did you ever keep taking a drug to avoid withdrawal or keep from 
getting sick?    
9. Did you get sick or have withdrawal when you quit or missed taking 
a drug?    
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10. Which drugs caused you the MOST serious problems?  [SEE LIST BELOW]  
 
  
 
11. How often did you use each type of drug during the last 3 months? 
  
 
DRUG USE IN LAST 3 MONTHS 
 
Never 
Only a 
few 
times 
1-3 
times / 
month 
1-5 
times / 
week 
About 
every 
day 
a) Alcohol             
b) Marijuana          
c) Cocaine (by itself)             
d) Heroin (by itself)            
e) Amphetamine (Speed)       
f) Tranquilizers/Sedatives(Diazepam,  
‘Benzos’”)      
g) Other (specify)      
  
  
  
13. How serious do you think your drug problems are? (Circle Response) 
     
Not at all Slightly Moderately Considerably Extremely 
  
 
 Marijuana  Cocaine  Amphetamines 
(Speed) 
 Tranquilizers or 
sedatives (diazepam 
or ‘Benzos’) 
 Inhalants 
(Chroming) 
 Opiates (Heroin) 
A. Worst 
 Alcohol  None   
 Marijuana  Cocaine  Amphetamines 
(Speed) 
 Tranquilizers or 
sedatives (diazepam 
or ‘Benzos’) 
 Inhalants 
(Chroming) 
 Opiates (Heroin) 
B. Next Worse 
 Alcohol  None   
 Marijuana  Cocaine  Amphetamines 
(Speed) 
 Tranquilizers or 
sedatives (diazepam 
or ‘Benzos’) 
 Inhalants 
(Chroming) 
 Opiates (Heroin) 
C. Next Worse 
 Alcohol  None   
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Appendix D 
 
The Medication Adherence Rating Scale (MARS) 
 
Please respond to the following statements by circling the answer which best describes your 
behaviour or the attitude you have held toward your medication in the past week. 
 
1. Do you ever forget to take your medication?  Yes / No 
2. Are you careless at times about taking your medicine?  Yes / No 
3. When you feel better, do you sometimes stop taking your medicine?  Yes / No 
4. Sometimes if you feel worse when you take the medicine, do you stop 
taking it?  Yes / No 
5. I take my medication only when I am sick.  Yes / No 
6. It is unnatural for my mind and body to be controlled by medication.  Yes / No 
7. My thoughts are clearer on medication.  Yes / No 
8. By staying on medication, I can prevent getting sick.  Yes / No 
9. I feel weird, like a ‘zombie’, on medication.  Yes / No 
10. Medication makes me feel tired and sluggish.  Yes / No 
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Appendix E 
 
The Social Functioning Scale (SFS) and Quality of Life Enjoyment and Satisfaction 
Questionnaire (Q-LES-Q) Combined 
 
 
 
NAME: ______________________________________ 
 
 
This questionnaire helps us to learn how you have been getting on since you became ill, and is
 
designed to help assess the degree of enjoyment and satisfaction you have experienced during 
the past week.   
 
 
This questionnaire takes about 30 minutes to complete- before getting started could you 
please answer the following: 
 
1. Where do you live? 
 
Answer: __________________________________________________________ 
 
__________________________________________________________________
 
 
2. Who do you live with? 
 
Answer:
 __________________________________________________________ 
 
__________________________________________________________________ 
 
 
 
 
 
 
 
FOR INTERVIEWER’S USE ONLY: 
 
 Raw Score Scaled Score 
Withdrawal/Social Engagement (W)   
Interpersonal Communication (Inter)   
Independence-Performance (Ip)   
Independence-Competence (Ic)   
Recreation (R)   
Prosocial (P)   
Employment/Occupation (E/O)   
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1.  What time do you get up each day? 
 
Average weekday  _________ 
Average weekend 
(if different)           _________ 
 
 
2.   On average how many waking hours do you spend alone in one day? 
e.g.  alone in a room 
walking out alone 
 listening to radio or watching TV alone etc. 
 
Please tick one of the boxes: 
 
0-3 
hours 
Very little spent alone □ 
3-6 
hours 
Some of time □ 
6-9 
hours 
Quite a lot of the time □ 
9-12 
hours 
A great deal of time □ 
12 
hours 
Practically all the time □ 
 
 
3.  How often will you start a conversation at home? 
 
 
 
 
4.    How often do you leave the house (for any reason)? 
 
 
 
5.  
 How do you react to the presence of strangers/people that you don’t know? 
 
Avoid them □ 
Feel nervous □ 
Accept them □ 
Like them □ 
 
 
Almost never Rarely Sometimes Often 
□ □ □ □ 
Almost never Rarely Sometimes Often 
□ □ □ □ 
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1.    How many friends do you have at the moment? 
(people who you see regularly, do activities with etc.) 
   
 
 
 
2.    Do you have a partner? 
 
Yes  □ 
No □ 
 
 
 
3.    How often are you able to carry out a sensible or rational conversation? 
Please tick a box 
 
Almost never □ 
Rarely □ 
Sometimes □ 
Often □ 
 
 
 
4.    How easy or difficult do you find it talking to people at the moment? 
 
Very easy □ 
Quite easy □ 
Average □ 
Quite difficult □ 
Very difficult □ 
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During the past week how often have you:  
 
  
Never 
 
Rarely 
 
Sometimes 
Often or 
most of 
the time 
Frequently 
or all the 
time 
Enjoyed talking or being with friends or 
relatives 
 
□ □ □ □ □ 
Looked forward to getting together with 
friends or relatives 
 
□ □ □ □ □ 
Made social plans with friends or 
relatives 
 
□ □ □ □ □ 
Enjoyed talking with co-workers or 
neighbours 
 
□ □ □ □ □ 
Been patient with others when others 
were irritating in their actions or words 
 
□ □ □ □ □ 
Been interested in the problems of others □ □ □ □ □ 
Felt affection toward one or more people □ □ □ □ □ 
Gotten along well with other people □ □ □ □ □ 
Joked or laughed with other people 
 
□ □ □ □ □ 
Felt you met the needs of friends or 
relatives 
 
□ □ □ □ □ 
Felt your relationships with your friends 
or relatives were without major problems 
or conflicts 
□ □ □ □ □ 
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Please place a tick against each item to show how often you have done the following over the 
past month. 
 
 
 
 Never Rarely Sometimes Often 
Buying items from the shops 
(without help) 
 
□ □ □ □ 
Washing pots, tidying up etc. 
 
□ □ □ □ 
Regular washing, bathing etc. 
 
□ □ □ □ 
Washing own clothes 
 
□ □ □ □ 
Looking for a job/working 
 
□ □ □ □ 
Doing the food shopping 
 
□ □ □ □ 
Prepare and cook a meal 
 
□ □ □ □ 
Leaving the house alone 
 
□ □ □ □ 
Using buses, trains etc. 
 
□ □ □ □ 
Using money 
 
□ □ □ □ 
Budgeting 
 
□ □ □ □ 
Choosing and buying clothes 
for self 
 
□ □ □ □ 
Take care of personal 
appearance. 
□ □ □ □ 
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Please place a tick against each item to show how much of the time in the past week you 
have felt:  
 
                      
 Not 
at all 
Rarely Sometimes Often or 
most of the 
time 
Frequently 
or all the 
time 
Clearheaded 
 
□ □ □ □ □ 
Satisfied with your life 
 
□ □ □ □ □ 
Good about your appearance 
 
□ □ □ □ □ 
Happy or cheerful 
 
□ □ □ □ □ 
Independent 
 
□ □ □ □ □ 
Content 
 
□ □ □ □ □ 
Able to communicate with others 
 
□ □ □ □ □ 
Interested in taking care of your 
appearance (hair, clothing) and 
personal hygiene (bathing, dressing) 
 
□ □ □ □ □ 
Able to make decisions 
 
□ □ □ □ □ 
Relaxed 
 
□ □ □ □ □ 
Good about your life 
 
□ □ □ □ □ 
Able to travel about to get things 
done when needed (walk, use car, 
bus, train, or whatever is available as 
needed)? 
  
□ □ □ □ □ 
Able to deal with life’s problems 
 
□ □ □ □ □ 
Able to take care of yourself □ □ □ □ □ 
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Please place a tick in the appropriate column to indicate how often you have done any of the 
following activities over the past month. 
 
 
 
 Never Rarely Sometimes Often 
Playing musical instruments 
 
□ □ □ □ 
Sewing, knitting 
 
□ □ □ □ 
Gardening 
 
□ □ □ □ 
Reading things 
 
□ □ □ □ 
Watching television 
 
□ □ □ □ 
Listening to records or radio 
 
□ □ □ □ 
Cooking 
 
□ □ □ □ 
D.I.Y activities (e.g. putting up shelves) 
 
□ □ □ □ 
Fixing things (car, bike, household etc). 
 
□ □ □ □ 
Walking, rambling 
 
□ □ □ □ 
Driving\cycling 
(as a recreation) 
 
□ □ □ □ 
Swimming 
 
□ □ □ □ 
Hobby (e.g. collecting things) 
 
□ □ □ □ 
Shopping 
 
□ □ □ □ 
Artistic activity 
(painting, crafts etc.) 
□ □ □ □ 
 
 
 
 
 
 
 
 
 178 
Please place a tick in the appropriate column to indicate how often you have done any of the 
following activities over the past month.
 
 
 Never Rarely Sometimes Often 
Cinema 
 
□ □ □ □ 
Theatre\Concert 
 
□ □ □ □ 
Watching an indoor sport (squash, table-
tennis). 
 
□ □ □ □ 
Watching an outdoor sport (football, 
rugby). 
 
□ □ □ □ 
Art gallery\ museum. 
 
□ □ □ □ 
Exhibition. 
 
□ □ □ □ 
Visiting places of interest. 
 
□ □ □ □ 
Meetings, talks etc. 
 
□ □ □ □ 
Evening Class. 
 
□ □ □ □ 
Visiting relatives in their homes. 
  
□ □ □ □ 
Being visited by relatives. 
 
□ □ □ □ 
Visiting friends (including boy/girlfriends). 
 
□ □ □ □ 
Parties. 
 
□ □ □ □ 
Formal occasions. 
 
□ □ □ □ 
Disco etc. 
 
□ □ □ □ 
Nightclub\ Social club 
 
□ □ □ □ 
Playing an indoor sport. 
 
□ □ □ □ 
Playing an outdoor sport. 
 
□ □ □ □ 
Club\ Society. 
 
□ □ □ □ 
Pub. 
 
□ □ □ □ 
Eating Out. 
 
□ □ □ □ 
Church Activity. □ □ □ □ 
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In regards to the activities stated in the above two tables, in the past week: 
 
 Not at 
all or 
never 
Rarely Sometimes Often or 
most of 
the time 
Frequently 
or all the 
time 
When you had time, how often did 
you use that time for a leisure time 
activity? 
 
□ □ □ □ □ 
How often did you enjoy the leisure 
activities? 
 
□ □ □ □ □ 
How often did you look forward to 
the leisure activities before spending 
time on them? 
 
□ □ □ □ □ 
How often did you concentrate on the 
leisure activities and pay attention to 
them? 
 
□ □ □ □ □ 
If a problem arose in your leisure 
activities, how often did you solve it, 
or deal with it without undue stress? 
 
□ □ □ □ □ 
How often did the leisure activities 
sustain your interest? 
□ □ □ □ □ 
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Please place a tick against each item to show how able you are at doing or using the 
following. 
 
 
 Adequately Needs 
Help 
Unable  Don’t know 
Public transport 
 
□ □ □ □ 
Handling money. 
 
□ □ □ □ 
Budgeting. 
 
□ □ □ □ 
Cooking. 
 
□ □ □ □ 
Weekly shopping. 
 
□ □ □ □ 
Looking for a job/ in employment 
 
□ □ □ □ 
Washing own clothes. 
 
□ □ □ □ 
Personal hygiene. 
 
□ □ □ □ 
Washing, tidying etc. 
 
□ □ □ □ 
Purchasing from shops. 
 
□ □ □ □ 
Leaving the house alone. 
 
□ □ □ □ 
Choosing and buying clothes. 
 
□ □ □ □ 
Caring for personal appearance. □ □ □ □ 
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Are you in regular employment? 
(This includes industrial therapy, rehabilitation or retraining courses). 
 
Yes □ 
No □ 
 
 
1 IF YES:                       What sort of job                                                                             . 
                                               
                                        How many hours do You work per week?                                    .  
                                        
                                        How long have you had this job?                                                  . 
 
 
2 IF NO:                          When were you last in employment?                                           . 
  
                                         What sort of job was it?                                                               . 
 
                                         How many hours per week?                                                         . 
 
 
Do you perform volunteer work? 
 
Yes  □ 
No □ 
 
IF YES:
    What sort of work?        
     
    How many hours do you volunteer per week?    
 
    How long have you had this work?     
 
Are you registered disabled? 
 
Yes  □ 
No □ 
 
 
Do you attend hospital as a day patient?  
 
Yes  □ 
No □ 
 
 
If not employed (do not answer if working) 
 
Do you think you are capable of some sort of employment? 
 
Definitely yes Would have 
difficulty  
Definitely no 
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□ □ □ 
 
 
How often do you make attempts to find a new job? 
(e.g. go to the Job Centre, look in the newspaper.) 
 
Almost never Rarely Sometimes Often 
□ □ □ □ 
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If you have been working, please indicate how often, in the past week you have: 
 
 Not at 
all or 
never 
Rarely Sometimes Often or 
most of the 
time 
Frequently 
or all the 
time 
Enjoyed your work 
 
□ □ □ □ □ 
Solved work problems or dealt 
with them without undue stress 
 
□ □ □ □ □ 
Thought clearly about work 
 
□ □ □ □ □ 
Been decisive about work, or 
made decisions when needed 
 
□ □ □ □ □ 
Accomplished what you wanted 
to do 
 
□ □ □ □ □ 
Been pleased with your work 
accomplishments 
 
□ □ □ □ □ 
Worked well 
 
□ □ □ □ □ 
Been interested in your work 
 
□ □ □ □ □ 
Concentrated on work 
 
□ □ □ □ □ 
Worked carefully 
 
□ □ □ □ □ 
Kept up with expected work 
 
□ □ □ □ □ 
Taken care of work by yourself 
when it was necessary 
 
□ □ □ □ □ 
Communicated and interacted 
with ease with others while 
working 
□ □ □ □ □ 
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Have you been taking any courses,  going to class, or been involved in any type of course 
work, school, or TAFE or university studies during the past week?  
 
 YES    NO 
 
 
If YES, during the past week¸how much of the time have you: 
 
 Not at 
all or 
never 
Rarely Sometimes Often or 
most of 
the time 
Frequently 
or all the 
time 
Enjoyed the course/class work 
 
□ □ □ □ □ 
Looked forward to getting to 
work on the course/class work 
 
□ □ □ □ □ 
Dealt with the course/class 
work without undue stress 
 
□ □ □ □ □ 
Thought clearly about the 
course/class work 
 
□ □ □ □ □ 
Been decisive about the 
course/class work when 
needed 
 
□ □ □ □ □ 
Been pleased with your 
course/class work 
accomplishments 
 
□ □ □ □ □ 
Been interested in your 
course/class work 
 
□ □ □ □ □ 
Concentrated on the 
course/class work 
 
□ □ □ □ □ 
Felt good while doing your 
course/class work 
 
□ □ □ □ □ 
Communicated and interacted 
with ease with others at your 
course/class 
□ □ □ □ □ 
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Taking everything into consideration, during the past week, how satisfied have you been 
with your: 
 
 
                                                                 OVERALL LEVEL OF SATISFACTION 
 Very poor Poor Fair Good Very good 
Physical health 
 
□ □ □ □ □ 
Mood 
 
□ □ □ □ □ 
Work 
 
□ □ □ □ □ 
Household activities 
 
□ □ □ □ □ 
Social relationships 
 
□ □ □ □ □ 
Family relationships 
 
□ □ □ □ □ 
Leisure time activities 
 
□ □ □ □ □ 
Ability to function in daily life 
 
□ □ □ □ □ 
Sexual drive, interest and/or 
performance* 
 
□ □ □ □ □ 
Economic status 
 
□ □ □ □ □ 
Living/housing situation* 
 
□ □ □ □ □ 
Ability to get around physically 
without feeling dizzy or unsteady or 
falling?* 
 
□ □ □ □ □ 
Your vision in terms of ability to do 
work or hobbies?* 
 
□ □ □ □ □ 
Overall sense of well being 
 
□ □ □ □ □ 
Medication (if not taking any, check 
here        and leave item blank)  
 
□ □ □ □ □ 
How would you rate your overall life 
satisfaction and contentment during 
the past week? 
□ □ □ □ □ 
   
* If satisfaction is very poor, poor or fair on these items, please UNDERLINE the factor(s) 
associated with a lack of satisfaction. 
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Appendix F 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THE SOCIAL FUNCTIONING SCALE 
 
RELATIVES VERSION 
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NAME: ______________________________________ 
 
 
This questionnaire helps us to learn how the person you care for has been getting on since 
they became ill.   
 
 
This questionnaire takes about 20 minutes to complete- before getting started could you 
please answer the following: 
 
1. Does the person you care for still live with you? 
 
Answer: __________________________________________________________ 
__________________________________________________________________ 
 
2. If no, when did they move away? 
 
Answer:
 
__________________________________________________________ 
 
__________________________________________________________________ 
 
3.   Do you still have regular contact with the person you care for? 
     
Answer:_______________________________________________________ 
__________________________________________________________________ 
      
 
 
FOR INTERVIEWER’S USE ONLY: 
 
 Raw Score Scaled Score 
Withdrawal/Social Engagement (W)   
Interpersonal Communication (Inter)   
Independence-Performance (Ip)   
Independence-Competence (Ic)   
Recreation (R)   
Prosocial (P)   
Employment/Occupation (E/O)   
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1.    What time does he/she get up each day? 
 
Average weekday  _________  
      
Average weekend                           
(if different)           _________       
 
 
2.    On average how many hours does he/she spend alone in one day? 
e.g.  alone in a room 
  walking out alone 
  listening to radio or watching TV alone etc. 
 
Please tick one of the boxes: 
 
0-3 
hours 
Very little spent alone  
3-6 
hours 
Some of time  
6-9 
hours 
Quite a lot of the time  
9-12 
hours 
A great deal of time  
12 
hours 
Practically all the time  
 
 
3.    How often will he/she start a conversation at home? 
 
Almost never Rarely Sometimes Often 
    
 
 
4.    How often does he/she leave the house (for any reason)? 
 
Almost never Rarely Sometimes Often 
    
 
 
5.   How does he/she react to the presence of strangers/people they don’t know? 
 
Avoid them  
Feel nervous  
Accept them  
Like them  
 
 Score 
Before 9am       3 
9-11am             2 
11am-1pm        1 
AFTER 1pm      0 
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1.    How many friends does he/she have at the moment? 
(people he/she will see regularly, do activities with etc.) 
   
 
 
 
2.    Does he/she have a partner? 
 
Yes   
No  
 
 
3.    How often are you able to carry out a sensible or rational conversation                                                             
with him/her?  
Please tick a box 
 
Almost never  
Rarely  
Sometimes  
Often  
 
 
4.    How easy or difficult does he/she find it talking to people at the moment? 
 
Very easy  
Quite easy  
Average  
Quite difficult  
Very difficult  
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Please place a tick against each item to show how often she/he has done the following over 
the past month. 
 
 
 
 Never Rarely Sometimes Often 
Buying items from the shops 
(without help) 
    
Washing pots, tidying up etc.     
Regular washing, bathing etc.     
Washing own clothes     
Looking for a job/working     
Doing the food shopping     
Prepare and cook a meal     
Leaving the house alone     
Using buses, trains etc.     
Using money     
Budgeting     
Choosing and buying clothes 
for self 
    
Take care of personal 
appearance. 
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Please place a tick in the appropriate column to indicate how often he/she has done any of the 
following activities over the past month. 
 
 Never Rarely Sometimes Often 
Playing musical 
instruments 
    
Sewing, knitting     
Gardening     
Reading things     
Watching television     
Listening to records 
or radio 
    
Cooking     
D.I.Y activities (e.g. 
putting up shelves) 
    
Fixing things (car, 
bike, household etc). 
    
Walking, rambling     
Driving\cycling 
(as a recreation) 
    
Swimming     
Hobby (e.g. 
collecting things) 
    
Shopping     
Artistic activity 
(painting, crafts etc.) 
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Please place a tick in the appropriate column to indicate how often he/she has done any of the 
following activities over the past month. 
 
 Never Rarely Sometimes Often 
Cinema     
Theatre\Concert     
Watching an 
indoor sport 
(squash, table-
tennis). 
    
Watching an 
outdoor sport 
(football, 
rugby). 
    
Art gallery\ 
museum. 
    
Exhibition.     
Visiting places 
of interest. 
    
Meetings, talks 
etc. 
    
Evening Class.     
Visiting 
relatives in their 
homes.  
    
Being visited 
by relatives. 
    
Visiting friends 
(including 
boy/girlfriends). 
    
Parties.     
Formal 
occasions. 
    
Disco etc.     
Nightclub\ 
Social club 
    
Playing an 
indoor sport. 
    
Playing an 
outdoor sport. 
    
Club\ Society.     
Pub.     
Eating Out.     
Church 
Activity. 
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Please place a tick against each item to show how able he/she is at doing or using the 
following. 
 
 Adequately Needs Help Unable (needs) Not known 
Public transport     
Handling 
money. 
    
Budgeting.     
Cooking for 
shopping. 
    
Weekly 
shopping. 
    
Looking for a 
job/working. 
    
Washing own 
clothes. 
    
Personal 
hygiene. 
    
Washing, 
tidying etc. 
    
Purchasing 
from shops. 
    
Leaving the 
house alone. 
    
Choosing and 
buying clothes. 
    
Caring for 
personal 
appearance. 
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Appendix G 
 
Marlowe-Crowne 2(10) SDS 
 
 
Listed below are a number of statements concerning personal attitudes and traits. Read each 
item and decide whether the statement is true or false as it pertains to you personally. Please 
circle either True or False after each item. 
 
 
1. I never hesitate to go out of my way to help someone in trouble. (True / False) 
 
2. I have never intensely disliked anyone. (True / False) 
 
3. There have been times when I was quite jealous of the good fortune of others. (True / 
False) 
 
4. I would never think of letting someone else be punished for my wrong doings. (True / 
False) 
 
5. I sometimes feel resentful when I don’t get my way. (True / False) 
 
6. There have been times when I felt like rebelling against people in authority even though I 
knew they were right. (True / False) 
 
7. I am always courteous, even to people who are disagreeable. (True / False) 
 
8. When I don’t know something I don’t at all mind admitting it. (True / False) 
 
9. I can remember “playing sick” to get out of something. (True / False) 
 
10. I am sometimes irritated by people who ask favours of me. (True / False)
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Appendix H 
 
Qualitative Data Analysis – Post-treatment Interview Questions
 
 
Participant questions 
 
1. What were your expectations about the therapy? 
 
2. Tell me about your experiences of completing this therapy. 
 
3. What do you think you will remember most about the therapy? Which strategies, if 
any, will you continue to use? 
 
4. What did you find most helpful about the therapy? 
 
5. What did you find least helpful about the therapy? 
 
6. Have you noticed any changes in your thoughts about your (psychotic symptoms) over 
the past 4 months? If yes, what? 
 
7. Have you noticed any changes in your feelings about your (psychotic symptoms) over 
the past 4 months? If yes, what? 
 
8. Have you noticed any changes in the way you view yourself over the past 4 months? If 
yes, what? 
 
9. Have you noticed any changes in your behaviour as a result of taking part in this 
project? If yes, what? 
 
10. Do you think others have noticed changes in you? If yes, what? 
 
11. What areas in your life, if any, would you like to work on now? What kind of help 
might you need to work on these areas? 
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Qualitative Data Analysis – Post-treatment Interview Questions
 
 
Caregiver questions 
 
1. Have you noticed any changes in (participant name)’s thoughts about his/her 
(psychotic symptoms) over the last 4 months? If so, what? 
 
2. Have you noticed any changes in (participant name)’s feelings about his/her 
(psychotic symptoms) over the past 4 months? If so, what? 
 
3. Have you noticed any change in (participant name)’s view of him/herself over the past 
4 months? If so, what? 
 
4. Have you noticed any changes in (participant name)’s behaviour over the past 4 
months? 
 
5. What areas in (participant’s name)’s life, if any, do you think they would like to work 
on now? What kind of help do you think they might need to work on these areas? 
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Appendix I 
 
 
Table 1. 
 
Adjusted means and standard deviations of the SFS:P and C over baseline, pre-treatment 
and post-treatment. 
 
 
Area 
 
Measure 
 
Baseline 
 
  
Pre-treatment
 
  
Post-treatment
 
   
M 
 
 
SD 
  
M 
 
SD 
  
M 
 
SD 
W/E 
 
102.69 13.95  101.19 12.71  99.00 10.29 
Inter 
 
125.25 21.52  124.13 19.35  121.75 20.50 
IP 
 
106.25 16.90  100.19 19.50  103.69 16.36 
IC 
 
102.69 13.13  101.06 13.19  103.13 12.20 
R 
 
104.06 24.54  101.00 19.35  104.31 19.58 
P 
 
103.36 21.27  110.79 17.98  107.64 20.60 
Social 
Functioning 
Participant 
E/O 101.06 14.46  102.06 14.26  102.81 12.50 
 
W/E 
 
 
95.38 
 
10.21 
  
98.63 
 
10.32 
  
99.88 
 
7.95 
Inter 
 
112.63 17.61  111.50 16.15  119.75 21.51 
IP 
 
99.75 13.48  103.50 15.18  108.81 14.16 
IC 
 
103.06 6.95  105.88 16.16  111.38 12.01 
R 
 
106.94 15.39  109.19 16.20  112.31 14.86 
 
Social 
Functioning 
Caregiver 
P 
 
105.50 12.76  111.86 17.53  111.71 16.75 
 
